| Symbol | OGN |
|---|---|
| Name | ORGANON & CO. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 30 HUDSON STREET,FLOOR 33, JERSEY CITY, New Jersey, 07302, United States |
| Telephone | +1 551 430-6900 |
| Fax | — |
| — | |
| Website | https://www.organon.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001821825 |
| Description | Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within womens health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada. Additional info from NASDAQ: |
2026-06-15 20:41
Director Sharp Shalini 🟢 acquired 17.9K shares (1 derivative) of Organon & Co. (OGN) Transaction Date: Jun 12, 2026 | Filing ID: 043256
Read more
2026-06-15 20:40
Director Sequeira Ramona 🟢 acquired 17.9K shares (1 derivative) of Organon & Co. (OGN) Transaction Date: Jun 12, 2026 | Filing ID: 043249
Read more
2026-06-15 20:39
Director Patton Cynthia M 🟢 acquired 17.9K shares (1 derivative) of Organon & Co. (OGN) Transaction Date: Jun 12, 2026 | Filing ID: 043247
Read more
2026-06-15 20:38
Director Ozuah Philip 🟢 acquired 17.9K shares (1 derivative) of Organon & Co. (OGN) Transaction Date: Jun 12, 2026 | Filing ID: 043245
Read more
2026-06-15 20:37
Director Leone Deborah R 🟢 acquired 17.9K shares (1 derivative) of Organon & Co. (OGN) Transaction Date: Jun 12, 2026 | Filing ID: 043243
Read more
2026-06-15 20:36
Director LAZARUS ROCHELLE B 🟢 acquired 17.9K shares (1 derivative) of Organon & Co. (OGN) Transaction Date: Jun 12, 2026 | Filing ID: 043241
Read more
2026-06-15 20:34
Director Gayle Helene D 🟢 acquired 17.9K shares (1 derivative) of Organon & Co. (OGN) Transaction Date: Jun 12, 2026 | Filing ID: 043228
Read more
2026-06-15 20:33
Director Ezekowitz Alan 🟢 acquired 17.9K shares (1 derivative) of Organon & Co. (OGN) Transaction Date: Jun 12, 2026 | Filing ID: 043224
Read more
2026-06-15 20:32
Director ESSNER ROBERT 🟢 acquired 17.9K shares (1 derivative) of Organon & Co. (OGN) Transaction Date: Jun 12, 2026 | Filing ID: 043218
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07265479 | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participan… | Phase3 | Atopic Dermatitis | Recruiting | 2025-12-29 | 2028-01-01 | ClinicalTrials.gov |
| NCT06775626 | Body Composition and Sport Performance Among Young Female Soccer Players Using … | Early_Phase1 | Menstrual Symptoms | Suspended | 2025-04-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT06175832 | PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cros… | Phase4 | Ovarian Stimulation | Recruiting | 2025-01-27 | 2027-12-31 | ClinicalTrials.gov |
| NCT06561321 | Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplan… | Phase2 | Palmoplantar Keratoderma | Recruiting | 2024-10-30 | 2027-12-31 | ClinicalTrials.gov |
| NCT06378489 | The Use of Etonogestrel Contraceptive Implant as Treatment for Endometrial Hype… | — | Endometrial Hyperplasia Without Atypia | Unknown | 2024-06-01 | 2025-05-31 | ClinicalTrials.gov |
| NCT06134479 | Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation. | Phase3 | Fertility | Completed | 2023-12-12 | 2025-09-09 | ClinicalTrials.gov |
| NCT05761444 | Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin i… | Phase4 | Atherosclerotic Cardiovascular Disease | Completed | 2023-07-26 | 2024-10-15 | ClinicalTrials.gov |
| NCT05330130 | Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells | Phase1 | Ovarian Function Insufficiency | Completed | 2023-07-05 | 2024-06-30 | ClinicalTrials.gov |
| NCT05789576 | A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in P… | Phase4 | Psoriasis | Completed | 2023-03-13 | 2023-07-19 | ClinicalTrials.gov |
| NCT05504720 | Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HE… | Phase2 | Esophagogastric Adenocarcinoma | Active_Not_Recruiting | 2023-02-13 | 2027-12-01 | ClinicalTrials.gov |
| NCT05680740 | A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in In… | Phase4 | Psoriasis | Completed | 2022-12-27 | 2023-05-25 | ClinicalTrials.gov |
| NCT05632731 | Comparison of Clinical Outcomes in Fresh Cycle With Single Blastocyst Stage and… | Na | Infertility, Female | Unknown | 2022-12-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT05560646 | A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Comp… | Phase2 | Endometriosis | Completed | 2022-10-25 | 2025-05-28 | ClinicalTrials.gov |
| NCT05510063 | Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in … | Phase4 | Plaque Psoriasis | Completed | 2022-08-04 | 2023-05-04 | ClinicalTrials.gov |
| NCT05264506 | Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive | Phase3 | Contraception | Terminated | 2022-02-17 | 2024-01-26 | ClinicalTrials.gov |
| NCT05172726 | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2021-12-02 | 2026-10-01 | ClinicalTrials.gov |
| NCT05116371 | Control of Bleeding on Nexplanon in Latinx Patients | — | Contraception | Unknown | 2021-12-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT05186805 | Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive A… | Phase2 | Atopic Dermatitis | Completed | 2021-11-15 | 2022-08-24 | ClinicalTrials.gov |
| NCT05142774 | Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Derma… | Phase3 | Atopic Dermatitis | Completed | 2021-10-28 | 2024-03-07 | ClinicalTrials.gov |
| NCT05032859 | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-5… | Phase3 | Atopic Dermatitis | Completed | 2021-09-23 | 2023-02-08 | ClinicalTrials.gov |
| NCT05014568 | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults | Phase3 | Atopic Dermatitis | Completed | 2021-09-01 | 2023-04-07 | ClinicalTrials.gov |
| NCT05000489 | Perceptions of LARC Among AYA With Chronic Illness | — | Chronic Conditions, Multiple | Completed | 2021-04-16 | 2022-04-07 | ClinicalTrials.gov |
| NCT05013710 | Evaluating the Mobile Clinic Model as a Means of Increasing Access to Reproduct… | — | Healthcare Disparities | Unknown | 2021-01-01 | 2024-01-01 | ClinicalTrials.gov |
| NCT04626596 | A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Impla… | Phase3 | Contraception | Completed | 2020-11-19 | 2024-12-30 | ClinicalTrials.gov |
| NCT04047875 | Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant | Phase4 | Breakthrough Bleeding | Completed | 2020-09-15 | 2023-05-05 | ClinicalTrials.gov |
| NCT04053387 | Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) | Phase3 | Plaque Psoriasis | Completed | 2019-08-13 | 2021-04-06 | ClinicalTrials.gov |
| NCT04042103 | Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoria… | Phase2 | Plaque Psoriasis | Completed | 2019-07-23 | 2020-01-09 | ClinicalTrials.gov |
| NCT03983980 | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) | Phase3 | Plaque Psoriasis | Completed | 2019-06-06 | 2020-05-29 | ClinicalTrials.gov |
| NCT03768427 | Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholeste… | Phase3 | Hypercholesterolemia | Completed | 2019-05-27 | 2021-04-01 | ClinicalTrials.gov |
| NCT03956355 | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) | Phase3 | Plaque Psoriasis | Completed | 2019-05-21 | 2020-05-26 | ClinicalTrials.gov |
| NCT03019575 | Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human… | Phase3 | Hypogonadotropic Hypogonadism | Completed | 2017-02-02 | 2020-05-05 | ClinicalTrials.gov |
| NCT02741245 | A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hy… | Phase3 | Hypercholesterolemia | Completed | 2016-06-09 | 2017-01-18 | ClinicalTrials.gov |
| NCT02748057 | A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in… | Phase3 | Hypercholesterolemia | Completed | 2016-05-18 | 2017-12-11 | ClinicalTrials.gov |
| NCT02741271 | Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination Wit… | Phase3 | Asthma | Completed | 2016-05-11 | 2017-12-04 | ClinicalTrials.gov |
| NCT02668783 | Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in … | Phase3 | Moderate to Severe Primary Dysmenorrhea | Terminated | 2016-02-11 | 2016-09-07 | ClinicalTrials.gov |
| NCT02668822 | Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in … | Phase3 | Dysmenorrhea | Terminated | 2016-02-09 | 2016-09-12 | ClinicalTrials.gov |
| NCT02616146 | Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorges… | Phase3 | Contraception | Terminated | 2015-12-01 | 2016-10-06 | ClinicalTrials.gov |
| NCT02550288 | A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Part… | Phase3 | Hypercholesterolemia | Completed | 2015-09-29 | 2016-05-30 | ClinicalTrials.gov |
| NCT02524288 | Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Ri… | Phase3 | Contraception | Terminated | 2015-08-31 | 2016-09-16 | ClinicalTrials.gov |
| NCT02460159 | A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in… | Phase3 | Hypercholesterolemia | Completed | 2015-06-23 | 2016-12-22 | ClinicalTrials.gov |
| NCT02320396 | Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants W… | Phase3 | Seasonal Allergic Rhinitis | Completed | 2015-01-09 | 2015-04-27 | ClinicalTrials.gov |
| NCT02275546 | Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-… | Phase3 | Contraception: Optional Applicator for Insertion of Vaginal Ring | Completed | 2014-12-11 | 2015-04-10 | ClinicalTrials.gov |
| NCT01599494 | An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to R… | Phase3 | Infertility | Withdrawn | 2014-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02094235 | A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis | Phase1 | Atopic Dermatitis | Completed | 2014-01-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01980940 | The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoric… | Phase1 | Osteoarthritis Pain | Completed | 2013-12-23 | 2014-11-26 | ClinicalTrials.gov |
| NCT01916967 | An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participant… | Phase3 | Urticaria | Completed | 2013-08-27 | 2014-03-13 | ClinicalTrials.gov |
| NCT01916980 | Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants W… | Phase3 | Eczema | Completed | 2013-08-27 | 2014-03-22 | ClinicalTrials.gov |
| NCT01918033 | A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Parti… | Phase3 | Perennial Allergic Rhinitis | Completed | 2013-08-20 | 2014-01-26 | ClinicalTrials.gov |
| NCT01495741 | Post-Authorization Safety Surveillance Study of Asenapine in Participants With … | — | Bipolar Disorder | Completed | 2013-07-01 | 2017-12-18 | ClinicalTrials.gov |
| NCT01723579 | Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017) | Phase3 | Contraception | Withdrawn | 2013-07-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01857063 | Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants … | Phase3 | Seasonal Allergic Rhinitis | Completed | 2013-06-10 | 2013-09-01 | ClinicalTrials.gov |
| NCT01852812 | Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatm… | Phase3 | Perennial Allergic Rhinitis | Completed | 2013-06-07 | 2013-12-24 | ClinicalTrials.gov |
| NCT01498770 | An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08… | — | Bipolar Disorder | Completed | 2013-04-01 | 2017-12-21 | ClinicalTrials.gov |
| NCT01587235 | A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatmen… | Phase4 | Dyslipidemia | Withdrawn | 2013-03-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01709331 | A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combina… | Phase3 | Hypogonadism | Completed | 2013-02-11 | 2015-04-08 | ClinicalTrials.gov |
| NCT01670656 | A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmen… | Phase2 | Dysmenorrhea | Completed | 2013-01-21 | 2013-09-12 | ClinicalTrials.gov |
| NCT01615874 | Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Be… | Phase2 | Asthma | Withdrawn | 2013-01-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01709318 | A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next … | Phase2 | Contraception | Completed | 2012-12-12 | 2013-10-22 | ClinicalTrials.gov |
| NCT01617187 | A Study of the Efficacy and Safety of Asenapine in Participants With an Acute E… | Phase3 | Schizophrenia | Completed | 2012-12-04 | 2014-09-09 | ClinicalTrials.gov |
| NCT01656434 | Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Cont… | Phase3 | Contraception | Terminated | 2012-11-02 | 2014-02-12 | ClinicalTrials.gov |
| NCT01673620 | A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican… | Phase3 | Allergic Rhinitis | Completed | 2012-07-04 | 2012-10-10 | ClinicalTrials.gov |
| NCT01611883 | A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics Wi… | Phase4 | Hypercholesterolemia | Completed | 2012-07-02 | 2014-01-16 | ClinicalTrials.gov |
| NCT01572675 | A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148) | — | Osteoarthritis | Completed | 2012-06-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01026870 | Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Trea… | Phase3 | Asthma | Withdrawn | 2012-06-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00764478 | Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Ma… | Phase3 | Bipolar 1 Disorder | Completed | 2012-04-06 | 2014-05-28 | ClinicalTrials.gov |
| NCT01566149 | Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MD… | Phase3 | Asthma | Completed | 2012-03-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01554163 | Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Parti… | Phase3 | Osteoarthritis of the Knee | Completed | 2012-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01502371 | A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent … | Phase2 | Asthma | Completed | 2012-01-25 | 2015-01-29 | ClinicalTrials.gov |
| NCT01471340 | A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometa… | Phase4 | Asthma | Completed | 2012-01-09 | 2016-11-30 | ClinicalTrials.gov |
| NCT01490190 | Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Pra… | Phase4 | Contraception | Completed | 2011-12-26 | 2012-12-05 | ClinicalTrials.gov |
| NCT01461941 | A Phase 2 Study of E6005 in Patients With Atopic Dermatitis | Phase2 | Atopic Dermatitis | Completed | 2011-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01462370 | Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the T… | Phase3 | Dysmenorrhea | Completed | 2011-11-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01437111 | Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet… | Phase3 | Osteoporosis | Completed | 2011-10-26 | 2012-12-05 | ClinicalTrials.gov |
| NCT01429168 | A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Ana… | Phase4 | Osteoarthritis | Withdrawn | 2011-10-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01408615 | A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Cori… | — | Infertility, Female | Completed | 2011-09-20 | 2016-11-18 | ClinicalTrials.gov |
| NCT01277211 | A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Ch… | Phase3 | Contraception | Completed | 2011-09-19 | 2013-09-18 | ClinicalTrials.gov |
| NCT01370603 | A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Com… | Phase3 | Hypercholesterolemia | Completed | 2011-09-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01370590 | A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Com… | Phase3 | Hypercholesterolemia | Completed | 2011-09-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01333436 | A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Le… | Na | Dyslipidemia | Completed | 2011-07-20 | 2012-05-12 | ClinicalTrials.gov |
| NCT01350934 | A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX … | Phase4 | Osteoporosis, Postmenopausal | Completed | 2011-06-19 | 2013-01-10 | ClinicalTrials.gov |
| NCT01244815 | Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P061… | Phase3 | Bipolar Disorder, Pediatric | Completed | 2011-06-16 | 2013-09-17 | ClinicalTrials.gov |
| NCT01349907 | Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disor… | Phase3 | Bipolar Disorder | Completed | 2011-06-16 | 2014-09-05 | ClinicalTrials.gov |
| NCT01386125 | A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS… | Phase3 | Nasal Polyps | Completed | 2011-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01277822 | Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment… | Phase4 | Hypertension | Completed | 2011-05-30 | 2013-04-22 | ClinicalTrials.gov |
| NCT01244828 | Long-term Study of Asenapine in Participants With Residual Subtype, Receiving M… | Phase3 | Schizophrenia | Completed | 2011-04-05 | 2014-08-21 | ClinicalTrials.gov |
| NCT01307046 | MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Contro… | Phase3 | Hypertension | Completed | 2011-03-29 | 2012-02-07 | ClinicalTrials.gov |
| NCT01307033 | A Long-term Study of the Safety of MK-0954A in Patients With Essential Hyperten… | Phase3 | Hypertension | Completed | 2011-03-29 | 2012-12-04 | ClinicalTrials.gov |
| NCT01327638 | Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankyl… | — | Spondylarthropathies; Spondylitis, Ankylosing | Completed | 2011-02-15 | 2018-12-06 | ClinicalTrials.gov |
| NCT01236430 | A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Prod… | Phase1 | Hyperlipidemia | Completed | 2011-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01258803 | A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination… | Phase2 | Asthma | Completed | 2010-12-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01294696 | Survey of Osteoarthritis Real World Therapies (MK-0663-140) | — | Osteoarthritis | Completed | 2010-10-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01181778 | Evaluation of Participant Responses to Educational Counseling About Different C… | — | Contraception | Completed | 2010-10-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01190267 | Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizop… | Phase3 | Schizophrenia, Paranoid | Completed | 2010-09-28 | 2013-10-07 | ClinicalTrials.gov |
| NCT01190254 | Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizoph… | Phase3 | Schizophrenia, Paranoid | Completed | 2010-09-28 | 2013-04-01 | ClinicalTrials.gov |
| NCT01208207 | A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis … | Phase3 | Spondylitis, Ankylosing | Completed | 2010-09-27 | 2014-11-12 | ClinicalTrials.gov |
| NCT01208181 | A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis… | Phase3 | Arthritis, Rheumatoid | Completed | 2010-09-27 | 2014-07-29 | ClinicalTrials.gov |
| NCT01179880 | A Study of E6005 in Japanese Patients With Atopic Dermatitis | Phase1 | Atopic Dermatitis | Completed | 2010-09-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01206517 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual… | Phase1 | Schizophrenia | Completed | 2010-07-18 | 2011-08-04 | ClinicalTrials.gov |
| NCT01154036 | MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Stud… | Phase3 | Hypercholesterolemia | Completed | 2010-07-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01146418 | Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031) | Phase3 | Infertility | Completed | 2010-06-02 | 2014-04-29 | ClinicalTrials.gov |
| NCT01144416 | Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recF… | Phase3 | Infertility | Completed | 2010-06-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01135134 | Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone F… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2010-06-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01142596 | Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P0… | Phase3 | Schizophrenia | Completed | 2010-05-25 | 2015-04-22 | ClinicalTrials.gov |
| NCT01098110 | 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Par… | Phase3 | Schizophrenia | Completed | 2010-05-25 | 2014-04-14 | ClinicalTrials.gov |
| NCT01165424 | A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediat… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2010-04-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01077817 | Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Med… | — | Esophageal Cancer | Completed | 2010-02-26 | 2012-02-16 | ClinicalTrials.gov |
| NCT01041807 | Cozaar XQ Re-examination Study (MK-0954-349) | — | Hypertension | Completed | 2010-02-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01004263 | A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Tr… | Phase3 | Acute Migraine With or Without Aura in Adolescents | Completed | 2009-12-01 | 2011-04-18 | ClinicalTrials.gov |
| NCT01001234 | A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment … | Phase3 | Migraine, Acute | Completed | 2009-11-30 | 2011-04-21 | ClinicalTrials.gov |
| NCT01345786 | Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial … | Phase1 | Healthy Postmenopausal Females | Completed | 2009-11-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00967746 | An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding … | Phase2 | Contraception | Completed | 2009-11-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01077843 | Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Thera… | — | Ankylosing Spondylitis | Completed | 2009-08-17 | 2015-07-01 | ClinicalTrials.gov |
| NCT00671528 | Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (St… | Phase4 | Dermatitis, Atopic | Terminated | 2009-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00894556 | A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment … | Phase3 | Acute Migraine | Completed | 2009-06-10 | 2010-01-12 | ClinicalTrials.gov |
| NCT00867165 | Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in… | Phase3 | Primary Hypercholesterolemia | Completed | 2009-05-21 | 2012-04-13 | ClinicalTrials.gov |
| NCT01381679 | Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Le… | — | Hypercholesterolemia | Completed | 2009-05-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00862251 | Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dos… | Phase3 | Cardiovascular Disorder | Completed | 2009-04-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00812006 | A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topir… | Phase3 | Migraine | Completed | 2009-03-24 | 2009-10-22 | ClinicalTrials.gov |
| NCT00756938 | Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337) | Phase3 | Hypertension | Completed | 2009-03-01 | 2012-08-14 | ClinicalTrials.gov |
| NCT00871351 | Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin o… | Phase4 | Primary Hypercholesterolemia | Completed | 2009-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00819377 | Milrinone Inhaled in Cardiac Surgery | Phase2 | Valvular Stenosis | Completed | 2009-02-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00820027 | Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK… | Phase3 | Pain, Postoperative | Completed | 2008-12-15 | 2010-12-14 | ClinicalTrials.gov |
| NCT01436253 | Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179) | — | Dyslipidemia | Completed | 2008-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01414192 | A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204) | — | Dyslipidemia | Completed | 2008-11-15 | 2014-09-15 | ClinicalTrials.gov |
| NCT01368185 | Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366) | — | Hypertension | Completed | 2008-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00783263 | A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastat… | Phase3 | Hypercholesterolemia | Completed | 2008-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00782184 | Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Ri… | Phase3 | Hypercholesterolemia | Completed | 2008-11-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00903721 | Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (St… | — | Allergic Rhinitis | Completed | 2008-11-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00788710 | A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663… | Phase3 | Acute Pain Following a Total Abdominal Hysterectomy | Completed | 2008-10-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01390415 | A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabet… | — | Hypertension | Completed | 2008-09-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00732381 | Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Al… | Phase3 | Allergic Rhinitis | Completed | 2008-08-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00728416 | Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Al… | Phase3 | Allergic Rhinitis | Completed | 2008-08-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT01098071 | Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P… | Phase4 | Adenoids | Completed | 2008-08-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00739297 | The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic A… | Phase1 | Chronic Asthma | Completed | 2008-07-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00733005 | Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Al… | Phase3 | Allergic Rhinitis | Completed | 2008-07-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00635570 | Acceptability of the NuvaRing Among Students | Phase4 | Birth Control Compliance | Completed | 2008-07-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00684450 | Cardiac Surgery: In Vivo Titration of Protamine | Na | Bleeding | Completed | 2008-06-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00692913 | A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal… | Phase3 | Osteoporosis | Completed | 2008-06-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00710606 | Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obes… | Na | Pharmacokinetics | Completed | 2008-06-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00694369 | A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postope… | Phase3 | Postoperative Dental Pain | Completed | 2008-06-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00702338 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical… | — | Pregnancy | Completed | 2008-05-15 | 2008-12-15 | ClinicalTrials.gov |
| NCT00779532 | Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 231… | Phase1 | Contraception | Completed | 2008-05-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00599027 | An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent … | Phase3 | Allergic Rhinitis | Completed | 2008-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00666679 | Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticos… | Phase2 | Asthma | Completed | 2008-05-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00729651 | Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteop… | Phase4 | Osteoporosis Postmenopausal | Completed | 2008-03-20 | 2009-04-10 | ClinicalTrials.gov |
| NCT00651807 | A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) … | Phase2 | Benign Prostatic Hyperplasia (BPH) | Terminated | 2008-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00761527 | Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup i… | — | Rhinitis, Allergic, Seasonal | Completed | 2008-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00739674 | SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335) | Phase3 | Hypertension | Completed | 2008-02-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00635882 | Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoa… | Phase2 | Asthma | Completed | 2008-02-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00496834 | LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED) | Phase4 | Hypertension | Completed | 2008-02-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00534976 | The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatri… | Phase4 | Exercise-induced Bronchoconstriction (EIB) | Completed | 2008-02-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00700076 | Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitiv… | Phase1 | Healthy | Completed | 2008-01-22 | 2009-03-09 | ClinicalTrials.gov |
| NCT00723723 | Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED) | — | Coronary Heart Disease | Completed | 2008-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00730132 | Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients… | — | Coronary Heart Disease | Completed | 2008-01-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00604812 | Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1) | Phase1 | Migraine Disorders | Completed | 2007-12-17 | 2010-09-17 | ClinicalTrials.gov |
| NCT00653523 | Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercho… | Phase3 | Hypercholesterolemia | Completed | 2007-12-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00654095 | Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hyperch… | Phase3 | Hypercholesterolemia | Completed | 2007-12-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00757627 | Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(… | Phase4 | Pain | Completed | 2007-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00723736 | Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic R… | — | Rhinitis | Completed | 2007-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00535405 | A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Comb… | Phase3 | Hypercholesterolemia | Completed | 2007-11-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00540839 | A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Partici… | Phase3 | Asthma, Bronchial | Withdrawn | 2007-11-01 | — | ClinicalTrials.gov |
| NCT00516737 | Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081) | Phase3 | Migraine | Completed | 2007-10-03 | 2008-04-08 | ClinicalTrials.gov |
| NCT00724477 | Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their L… | — | Primary Hypercholesterolemia | Completed | 2007-10-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00875095 | Impact of Sperm DNA Integrity on Artificial Reproductive Treatment (ART) | — | Sperm DNA Impact on ART Outcomes | Terminated | 2007-10-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01140048 | Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374) | — | Respiratory Syncytial Virus Bronchiolitis | Completed | 2007-10-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00739050 | Effect of Simvastatin on Endothelial Function in Premenopausal Women With Syste… | Phase4 | Systemic Lupus Erythematosus | Terminated | 2007-09-19 | 2008-02-01 | ClinicalTrials.gov |
| NCT00524771 | Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC) | — | Contraception | Completed | 2007-09-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00536380 | Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERI… | Phase4 | Chronic Idiopathic Urticaria | Completed | 2007-09-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT01431508 | A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hyp… | Phase4 | Hypertension | Completed | 2007-08-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00636207 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled M… | Phase1 | Asthma | Completed | 2007-08-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00552032 | Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid … | Phase3 | Adenoids Hypertrophy | Completed | 2007-08-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00654628 | Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytor… | Phase4 | Hypercholesterolemia | Completed | 2007-08-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00920634 | Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPL… | — | Anovulation | Completed | 2007-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00496730 | A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Effi… | Phase3 | Hypercholesterolemia | Completed | 2007-07-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00552110 | Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Tog… | Phase2 | Seasonal Allergic Rhinitis | Completed | 2007-07-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00442117 | A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI … | Phase3 | Asthma | Completed | 2007-06-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00705211 | A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficac… | — | Hypercholesterolemia | Completed | 2007-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00704444 | A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficac… | — | Hypercholesterolemia | Completed | 2007-06-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00568178 | An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Ped… | Phase3 | Proteinuria | Completed | 2007-06-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00447603 | A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypert… | Phase3 | Hypertension | Terminated | 2007-05-24 | 2007-10-22 | ClinicalTrials.gov |
| NCT00697255 | A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a … | Phase2 | Ovulation Induction | Terminated | 2007-05-15 | 2008-05-15 | ClinicalTrials.gov |
| NCT00664937 | Exercise Induced Bronchoconstriction (0476-359) | Phase1 | Asthma, Exercise-induced | Completed | 2007-05-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00546754 | BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Ver… | Phase3 | Hypertension | Completed | 2007-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00711607 | A Trial to Assess the Pharmacokinetic Profile (e.g., Uptake, Distribution and E… | Phase1 | Healthy | Completed | 2007-05-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00652431 | Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P049… | Phase1 | Hypercholesterolemia | Completed | 2007-05-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00725491 | A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment … | Phase3 | Controlled Ovarian Stimulation | Completed | 2007-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00521599 | A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two… | Phase4 | Asthma | Completed | 2007-05-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00726856 | Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition… | — | Dyslipidemia | Completed | 2007-05-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00702624 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical… | — | Pregnancy | Completed | 2007-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00424008 | Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subje… | Phase3 | Asthma | Completed | 2007-04-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00802789 | Montelukast in Chronic Asthma | — | Asthma | Completed | 2007-04-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00545844 | Singulair(R) In Asthma And Allergic Rhinitis (0476-383) | Phase4 | Asthma | Completed | 2007-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00453063 | Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once … | Phase3 | Seasonal Allergic Rhinitis | Completed | 2007-03-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00468312 | Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in… | Phase3 | Seasonal Allergic Rhinitis | Completed | 2007-03-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00620035 | A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque… | Phase3 | Contraception | Completed | 2007-03-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00462748 | A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Level… | Phase3 | Hypercholesterolemia | Completed | 2007-03-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00442338 | Study of MK-0476 in Adult Patients With Acute Asthma (0476-334) | Phase3 | Asthma | Completed | 2007-03-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00702234 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical… | — | Pregnancy | Completed | 2007-02-15 | 2010-01-15 | ClinicalTrials.gov |
| NCT00491504 | This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasa… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2007-02-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00479713 | A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin C… | Phase3 | Hypercholesterolemia | Completed | 2007-02-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00409773 | Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED) | Phase3 | Hypercholesterolemia | Completed | 2007-01-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00418834 | Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at Hig… | Phase3 | Hypercholesterolemia | Completed | 2007-01-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00702845 | To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovari… | Phase3 | Infertility | Completed | 2006-12-28 | 2007-11-15 | ClinicalTrials.gov |
| NCT00702546 | Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From … | — | In Vitro Fertilization | Completed | 2006-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00423176 | The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associat… | Phase3 | Sinusitis | Terminated | 2006-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00423995 | Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Expo… | Phase3 | Seasonal Allergic Rhinitis | Completed | 2006-11-01 | 2007-03-10 | ClinicalTrials.gov |
| NCT00909389 | Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin… | — | Hypercholesterolemia | Completed | 2006-11-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00687531 | Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of L… | Phase4 | Asthma | Terminated | 2006-11-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00778999 | Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU R… | Phase4 | Infertility | Completed | 2006-10-01 | 2008-07-24 | ClinicalTrials.gov |
| NCT00511433 | Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compare… | Phase3 | Contraception | Completed | 2006-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00511355 | Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Funct… | Phase3 | Contraception | Completed | 2006-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00337675 | Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLET… | Phase3 | Asthma | Completed | 2006-10-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00696878 | Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Sti… | Phase3 | In Vitro Fertilization | Completed | 2006-09-26 | 2009-05-15 | ClinicalTrials.gov |
| NCT00442351 | Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Vers… | Phase4 | Asthma | Terminated | 2006-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00395603 | Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122) | Phase3 | Cardiovascular Diseases | Terminated | 2006-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00442897 | Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients … | Phase4 | Hypercholesterolemia | Completed | 2006-09-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00394355 | Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and M… | Phase4 | Asthma | Completed | 2006-09-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00405964 | Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Stu… | Phase3 | Allergic Rhinitis | Completed | 2006-09-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00511342 | Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-… | Phase3 | Contraception | Completed | 2006-09-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00406783 | Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (S… | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2006-08-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00943852 | The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Bloo… | Phase1 | Hypertension | Completed | 2006-08-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00703014 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical… | — | Pregnancy | Completed | 2006-07-13 | 2009-03-15 | ClinicalTrials.gov |
| NCT00378378 | Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Betwe… | Phase3 | Nasal Polyps | Completed | 2006-07-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00423579 | The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High … | Phase4 | Hypercholesterolemia | Completed | 2006-07-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT01685424 | Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care … | — | Osteoarthritis | Completed | 2006-06-30 | 2015-03-01 | ClinicalTrials.gov |
| NCT00696800 | A Study to Investigate the Efficacy and Safety of a Single Injection of Corifol… | Phase3 | In Vitro Fertilization | Completed | 2006-06-27 | 2008-01-15 | ClinicalTrials.gov |
| NCT00755794 | The Singulair® add-on Study Effectiveness of Adding Montelukast to Inhaled Cort… | Phase3 | Asthma | Completed | 2006-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00832455 | Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Monteluka… | Phase4 | Asthma | Completed | 2006-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00413062 | Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared … | Phase3 | Contraception | Completed | 2006-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00461032 | Montelukast Back to School Asthma Study (0476-340) | Phase3 | Asthma | Completed | 2006-06-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00379288 | Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol i… | Phase3 | Asthma | Completed | 2006-06-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00374972 | Combined Hormonal Versus Progestin Only Contraception During Lactation | — | Lactation | Withdrawn | 2006-06-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00359216 | The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered… | Phase4 | Perennial Allergic Rhinitis | Completed | 2006-05-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00803790 | A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Com… | Phase1 | Osteoporosis | Completed | 2006-05-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00284856 | Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED) | Phase3 | Asthma | Completed | 2006-05-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00358527 | Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhi… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2006-05-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00511199 | Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared … | Phase3 | Contraception | Completed | 2006-05-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00475553 | Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing® | Na | Breakthrough Bleeding | Completed | 2006-05-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00553891 | Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoi… | Phase4 | Nasal Obstruction | Withdrawn | 2006-05-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00702273 | Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreser… | — | In Vitro Fertilization | Completed | 2006-04-19 | 2009-05-31 | ClinicalTrials.gov |
| NCT00413972 | Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia… | Phase3 | Hypercholesterolemia | Completed | 2006-04-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00702520 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical… | — | Pregnancy | Completed | 2006-04-01 | 2008-01-15 | ClinicalTrials.gov |
| NCT00449111 | An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR P… | Phase3 | Hypertension | Terminated | 2006-03-13 | 2006-09-30 | ClinicalTrials.gov |
| NCT00250458 | Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea | Phase3 | Migraine | Completed | 2006-03-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00289874 | Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED) | Phase3 | Asthma | Completed | 2006-03-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT01065779 | FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267) | — | Osteoporosis | Completed | 2006-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00704535 | Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Po… | — | Primary Hypercholesterolemia | Completed | 2006-03-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00319995 | Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients Wi… | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2006-03-01 | 2006-06-28 | ClinicalTrials.gov |
| NCT00359138 | The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Test… | Phase4 | Hypersensitivity | Completed | 2006-02-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00276484 | To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With Hi… | Phase3 | Hypercholesterolemia | Completed | 2006-02-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00276458 | To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With Hi… | Phase3 | Hypercholesterolemia | Completed | 2006-02-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00281320 | Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717) | Phase3 | Psychosis | Completed | 2006-02-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00289887 | Obese Hypertension Study (0954-315) | Phase3 | Hypertension | Completed | 2006-02-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT01219387 | Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Wo… | — | AMH Levels | Completed | 2006-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00705081 | Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administra… | — | Hypercholesterolemia | Completed | 2006-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00264147 | Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED) | Phase2 | Rheumatoid Arthritis | Completed | 2006-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00276016 | The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine… | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2006-01-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00702351 | A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follic… | Phase2 | In Vitro Fertilization | Completed | 2005-12-09 | 2007-07-11 | ClinicalTrials.gov |
| NCT00652327 | Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dos… | Phase4 | Hypercholesterolemia | Completed | 2005-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00271817 | To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patie… | Phase3 | Hypercholesterolemia | Completed | 2005-12-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00127166 | Two Investigational Drugs in the Prevention of Airway Constriction Brought on b… | Phase3 | Exercise Induced Asthma | Completed | 2005-12-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00265343 | 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patien… | Phase3 | Schizophrenia | Completed | 2005-12-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00245570 | Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchocon… | Phase3 | Asthma, Exercise-Induced | Completed | 2005-12-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00101439 | A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Fol… | Phase3 | Hypercholesterolemia | Completed | 2005-11-10 | 2006-11-08 | ClinicalTrials.gov |
| NCT00166530 | EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hy… | Phase4 | Atherosclerosis | Completed | 2005-11-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00920361 | Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPL… | — | Fertilization in Vitro | Completed | 2005-11-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00445107 | SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363) | Phase3 | Asthma | Completed | 2005-11-01 | 2006-05-17 | ClinicalTrials.gov |
| NCT00157924 | Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic… | Phase4 | Hypercholesterolemia | Completed | 2005-11-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00651560 | Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148) | Phase3 | Hyperlipidemia | Completed | 2005-11-01 | 2005-12-23 | ClinicalTrials.gov |
| NCT00202878 | IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytori… | Phase3 | Hypercholesterolemia | Completed | 2005-10-17 | 2014-09-18 | ClinicalTrials.gov |
| NCT00166504 | Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092… | Phase4 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00724698 | Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis… | — | Rhinitis | Completed | 2005-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00783224 | A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionat… | Phase3 | Perennial Allergic Rhinitis | Completed | 2005-09-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00229970 | MK0476 Study in Adult Patients With Acute Asthma (0476-322) | Phase3 | Asthma | Completed | 2005-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00546052 | A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Pla… | Phase3 | Hypertension | Completed | 2005-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00156065 | Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Cont… | Phase3 | Schizophrenia | Completed | 2005-09-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00779116 | Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg R… | Phase4 | Allergies | Completed | 2005-09-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00400218 | Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients Wit… | Phase3 | Hypertension | Completed | 2005-09-01 | 2006-07-19 | ClinicalTrials.gov |
| NCT00380627 | Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094) | Phase4 | Pain | Completed | 2005-09-01 | 2006-01-31 | ClinicalTrials.gov |
| NCT00319449 | Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With… | Phase4 | Hypercholesterolemia | Completed | 2005-09-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00145509 | 40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproa… | Phase3 | Bipolar Disorder | Completed | 2005-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00398151 | To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated W… | Phase3 | Asthma | Completed | 2005-08-01 | 2006-01-18 | ClinicalTrials.gov |
| NCT00780403 | Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg R… | Phase4 | Allergies | Completed | 2005-08-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00129402 | Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (… | Phase3 | Hypercholesterolemia | Completed | 2005-08-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00423488 | Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Ty… | Phase3 | Hypercholesterolemia | Completed | 2005-07-12 | 2007-02-16 | ClinicalTrials.gov |
| NCT00174265 | 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patie… | Phase3 | Schizophrenia | Completed | 2005-07-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00156104 | Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(C… | Phase3 | Schizophrenia | Completed | 2005-07-01 | 2006-09-16 | ClinicalTrials.gov |
| NCT01070966 | Vytorin Reexamination Study (0653A-174) | — | Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) | Completed | 2005-07-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00159783 | 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501… | Phase3 | Bipolar Disorder | Completed | 2005-07-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00117338 | A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-30… | Phase3 | Asthma | Completed | 2005-07-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00878462 | An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenap… | Phase2 | Psychosis | Completed | 2005-06-29 | 2005-10-15 | ClinicalTrials.gov |
| NCT00145470 | 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproa… | Phase3 | Bipolar Disorder | Completed | 2005-06-02 | 2007-03-22 | ClinicalTrials.gov |
| NCT00269620 | PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra | Phase4 | Contraception | Completed | 2005-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00111722 | Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072) | Phase3 | Migraine | Completed | 2005-05-27 | 2006-02-23 | ClinicalTrials.gov |
| NCT00111709 | Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) | Phase3 | Migraine | Completed | 2005-05-27 | 2006-02-26 | ClinicalTrials.gov |
| NCT00156117 | Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933) | Phase3 | Schizophrenia | Completed | 2005-05-12 | 2006-05-30 | ClinicalTrials.gov |
| NCT00652847 | Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A … | Phase4 | Hypercholesterolemia | Completed | 2005-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT01005056 | Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVE… | — | Contraception | Completed | 2005-05-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00704769 | Response of Desloratadine Syrup in the Relief of Symptoms Associated With Peren… | — | Rhinitis | Completed | 2005-05-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00202904 | Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With Hi… | Phase4 | Hypercholesterolemia | Completed | 2005-05-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00732368 | A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhi… | Phase3 | Perennial Allergic Rhinitis | Completed | 2005-05-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00620464 | A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720) | Phase3 | Contraception | Completed | 2005-05-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00110435 | A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Markete… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2005-05-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00398294 | To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet … | Phase4 | Hypercholesterolemia | Completed | 2005-05-01 | 2006-04-04 | ClinicalTrials.gov |
| NCT00212836 | Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Pers… | Phase3 | Schizophrenia | Completed | 2005-04-21 | 2007-08-02 | ClinicalTrials.gov |
| NCT00150176 | To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patien… | Phase3 | Schizophrenia | Completed | 2005-04-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00816972 | Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis a… | Phase2 | Post-nasal Drip | Completed | 2005-04-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00380523 | Analgesic Treatment Mediated by Arcoxia (0663-093) | Phase4 | Pain | Completed | 2005-04-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00156091 | Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Contr… | Phase3 | Schizophrenia | Completed | 2005-04-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00457275 | Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070) | Phase3 | Hypercholesterolemia | Completed | 2005-04-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00380705 | Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365) | Phase4 | Asthma | Completed | 2005-03-18 | 2005-07-29 | ClinicalTrials.gov |
| NCT00311844 | A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-indu… | Phase4 | Conjunctivitis, Allergic | Completed | 2005-03-01 | 2005-05-28 | ClinicalTrials.gov |
| NCT00395473 | Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED) | Phase3 | Hypercholesterolemia | Completed | 2005-03-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00398541 | Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function o… | Phase3 | Hypertension | Completed | 2005-03-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00151424 | Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947) | Phase3 | Schizophrenia | Completed | 2005-02-15 | 2006-02-06 | ClinicalTrials.gov |
| NCT00157963 | Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (09… | Phase4 | Essential Hypertension | Completed | 2005-02-05 | 2006-02-08 | ClinicalTrials.gov |
| NCT00652717 | Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins I… | Phase4 | Cardiovascular Disorder | Completed | 2005-02-01 | 2005-08-04 | ClinicalTrials.gov |
| NCT00779740 | Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study … | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-02-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT01304511 | Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix… | — | Fertilization in Vitro | Completed | 2005-02-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00541697 | Eze/Simva Switch Study in Diabetics (0653A-807) | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2005-01-19 | 2005-10-14 | ClinicalTrials.gov |
| NCT00143182 | 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P0700… | Phase3 | Bipolar Disorder | Completed | 2005-01-07 | 2006-06-28 | ClinicalTrials.gov |
| NCT00442559 | Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367) | Phase4 | Asthma | Completed | 2005-01-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00142558 | A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment o… | Phase4 | Acute Gout | Completed | 2005-01-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT01070953 | EZETROL® Re-examination Study (MK0653-175)(COMPLETED) | — | Hypercholesterolemia | Completed | 2005-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00132717 | A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possibl… | Phase3 | Hypercholesterolemia | Completed | 2005-01-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00159796 | 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mani… | Phase3 | Bipolar Disorder | Completed | 2004-12-14 | 2006-04-28 | ClinicalTrials.gov |
| NCT00140972 | A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoar… | Phase4 | Osteoarthritis | Completed | 2004-12-03 | 2005-06-27 | ClinicalTrials.gov |
| NCT00394160 | Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297) | Phase2 | Bronchiolitis | Completed | 2004-12-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00145496 | Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Pers… | Phase3 | Schizophrenia | Completed | 2004-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00783458 | Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal … | Phase4 | Allergic Rhinitis | Completed | 2004-12-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00307060 | MK0954A-264 Filter Study (0954A-264)(COMPLETED) | Phase3 | Mild to Severe Hypertension | Completed | 2004-12-01 | 2005-06-02 | ClinicalTrials.gov |
| NCT00092053 | Study of Investigational Drug in Osteoporosis (MK-0217-908) | Phase3 | Postmenopausal Osteoporosis | Completed | 2004-12-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00817050 | Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal … | Phase4 | Allergic Rhinitis | Completed | 2004-12-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00159744 | 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mani… | Phase3 | Bipolar Disorder | Completed | 2004-11-30 | 2006-04-29 | ClinicalTrials.gov |
| NCT00794794 | Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826) | Phase3 | Allergic Rhinitis | Completed | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00095017 | Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment … | Phase2 | Bone Neoplasms | Withdrawn | 2004-11-01 | — | ClinicalTrials.gov |
| NCT00127647 | An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327) | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2004-11-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00093899 | A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidem… | Phase3 | Hyperlipidemia | Completed | 2004-11-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00089895 | EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segme… | Phase3 | Myocardial Ischemia | Completed | 2004-11-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00794378 | Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829… | Phase3 | Allergic Rhinitis | Completed | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00095004 | Study to Test an Approved Product in the Early Treatment of Migraine (0462-066) | Phase3 | Migraine | Completed | 2004-10-21 | 2005-04-04 | ClinicalTrials.gov |
| NCT00092898 | An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated… | Phase3 | Lipid Metabolism, Inborn Errors | Completed | 2004-10-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00771160 | MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMP… | Phase3 | Rhinitis, Allergic | Completed | 2004-09-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00212771 | Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schiz… | Phase3 | Schizophrenia | Completed | 2004-09-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00651963 | Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Sta… | Phase4 | Lipid Metabolism Disorder | Completed | 2004-09-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00651378 | Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubli… | Phase4 | Hypercholesterolemia | Terminated | 2004-09-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00092963 | Study to Test an Approved Product in the Early Treatment of Migraine (0462-065) | Phase3 | Migraine | Completed | 2004-08-17 | 2005-01-14 | ClinicalTrials.gov |
| NCT00783211 | Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for T… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00349258 | The Use of GnRH Agonist Trigger in the Prevention of OHSS | Phase4 | Ovarian Hyperstimulation Syndrome | Completed | 2004-08-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00783146 | Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for T… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00092989 | Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, … | Phase3 | Asthma | Completed | 2004-07-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00328523 | TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060) | Phase3 | Hypercholesterolaemia | Completed | 2004-06-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00090181 | Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED) | Phase4 | Chronic Low Back Pain | Completed | 2004-06-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00650819 | Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone … | Phase3 | Hypercholesterolemia | Completed | 2004-06-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00751218 | A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once… | Phase4 | Urticaria | Completed | 2004-05-06 | 2005-05-24 | ClinicalTrials.gov |
| NCT00090142 | Montelukast in Exercise-Induced Bronchospasm - 2004 (0476-275) | Phase3 | Asthma, Exercise-Induced | Completed | 2004-05-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00641771 | 4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on … | Phase1 | Osteoporosis | Completed | 2004-05-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00779545 | A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study… | Phase2 | Rhinitis, Allergic, Perennial | Completed | 2004-04-08 | 2004-08-06 | ClinicalTrials.gov |
| NCT00135148 | Decrease of Libido of Post-Operative Male-Female Transsexuals and a Healthy Fem… | — | Transsexualism | Completed | 2004-04-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00090298 | Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Pat… | Phase3 | Hypercholesterolemia | Completed | 2004-04-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00953680 | Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet an… | Phase1 | Hypertension | Completed | 2004-04-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00413764 | Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally… | Phase3 | Sexual Dysfunction | Completed | 2004-03-23 | 2005-11-15 | ClinicalTrials.gov |
| NCT01044056 | A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl E… | Phase4 | Contraception | Completed | 2004-03-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00092781 | A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663… | Phase3 | Osteoarthritis | Completed | 2004-03-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00092768 | A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663… | Phase3 | Osteoarthritis | Completed | 2004-03-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00751166 | A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once … | Phase4 | Urticaria | Terminated | 2004-03-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00653913 | Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and … | Phase1 | Hypercholesterolemia | Completed | 2004-03-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00092144 | Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED) | Phase3 | Asthma | Completed | 2004-02-26 | 2004-06-15 | ClinicalTrials.gov |
| NCT00446186 | MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378) | Phase2 | Rhinitis Allergic | Completed | 2004-02-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00090168 | Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholest… | Phase3 | Hypercholesterolemia | Completed | 2004-01-27 | 2004-11-10 | ClinicalTrials.gov |
| NCT00651404 | Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary … | Phase3 | Hypercholesterolemia | Completed | 2004-01-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00127179 | A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906… | Phase3 | Benign Prostatic Hyperplasia | Completed | 2004-01-01 | 2005-07-25 | ClinicalTrials.gov |
| NCT00651014 | Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterol… | Phase4 | Hypercholesterolemia | Terminated | 2004-01-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00461422 | Early Follicular Supplementation of Ganirelix in IVF 2004 | Phase4 | Infertility | Completed | 2004-01-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00783237 | Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P… | Phase4 | Allergic Rhinitis | Completed | 2003-12-01 | 2004-02-21 | ClinicalTrials.gov |
| NCT00751075 | Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus A… | Phase3 | Acute Rhinosinusitis | Completed | 2003-12-01 | 2004-06-22 | ClinicalTrials.gov |
| NCT00789152 | The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P036… | Phase3 | Allergic Rhinitis | Completed | 2003-12-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00492882 | Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome | — | Anovulation | Completed | 2003-11-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00653276 | MD Ezetimibe Cyclosporine Interaction (0653-057) | Phase1 | Cholesterol | Completed | 2003-11-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00651391 | Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactiv… | Phase3 | Hypercholesterolemia | Terminated | 2003-10-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00403793 | Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057) | Phase2 | Contraception | Completed | 2003-10-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00650663 | Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subject… | Phase4 | Hypercholesterolemia | Completed | 2003-10-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00092118 | The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhiniti… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2003-10-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00702988 | Pregnancy & Neonatal Follow-up of Ongoing Pregnancies Established During Clinic… | — | Pregnancy | Completed | 2003-10-01 | 2005-02-28 | ClinicalTrials.gov |
| NCT00446056 | Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379) | Phase4 | Asthma | Completed | 2003-09-25 | 2004-06-16 | ClinicalTrials.gov |
| NCT00092066 | A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigationa… | Phase3 | Osteoporosis | Completed | 2003-09-24 | 2004-05-01 | ClinicalTrials.gov |
| NCT00212784 | Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schiz… | Phase3 | Schizophrenia | Completed | 2003-09-04 | 2006-03-15 | ClinicalTrials.gov |
| NCT00653835 | Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High C… | Phase4 | Hypercholesterolaemia | Completed | 2003-09-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00731185 | Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (… | Phase3 | Nasal Polyps | Completed | 2003-09-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00652444 | Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Popul… | Phase4 | Hypercholesterolemia | Completed | 2003-09-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00834119 | Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Co… | Phase4 | Rhinitis, Allergic | Completed | 2003-09-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00653796 | Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High… | Phase4 | Hypercholesterolemia | Completed | 2003-09-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00076973 | An Investigational Drug Study to Treat Respiratory Symptoms Associated With Res… | Phase3 | Bronchiolitis | Completed | 2003-08-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00394069 | PK Study in 3- to 6- Month-Old Children (0476-268)(COMPLETED) | Phase2 | Bronchiolitis | Completed | 2003-07-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00779636 | Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Dise… | Phase4 | Allergic Airway Disease | Completed | 2003-07-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00652301 | A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together… | Phase3 | Cholesterol | Completed | 2003-07-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00795522 | An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the … | Phase4 | Urticaria | Completed | 2003-07-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00117000 | The Effects of Testosterone and Nutritional Supplementation in the Undernourish… | Phase3 | Malnutrition | Unknown | 2003-07-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00092690 | MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin)… | Phase3 | Hypercholesterolemia | Completed | 2003-06-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00756418 | Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled … | Phase4 | Asthma | Completed | 2003-06-01 | 2004-08-28 | ClinicalTrials.gov |
| NCT00092131 | Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270) | Phase3 | Asthma, Exercise-Induced | Completed | 2003-06-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00598208 | A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Inje… | Phase2 | Fertilization | Completed | 2003-05-19 | 2004-03-15 | ClinicalTrials.gov |
| NCT00092612 | Co-administration Study in Patients With Elevated Cholesterol and Coronary Hear… | Phase3 | Hypercholesterolemia | Completed | 2003-05-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00650689 | Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Prim… | Phase3 | Hypercholesterolemia | Completed | 2003-05-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00805584 | Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated Wit… | Phase4 | Rhinitis, Allergic, Seasonal | Completed | 2003-05-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00092638 | An Investigational Drug Study in Patients With Elevated Cholesterol and Coronar… | Phase3 | Hypercholesterolemia | Completed | 2003-05-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00805662 | Nasal Oxcytocin During IUI | Na | Idiopathic Infertility | Completed | 2003-05-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00806416 | A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Com… | Phase1 | Osteoporosis | Completed | 2003-05-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00805324 | Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Childr… | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2003-05-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00092755 | An Investigational Drug in Patients With Osteoarthritis (0663-073) | Phase3 | Osteoarthritis | Completed | 2003-04-09 | 2003-11-13 | ClinicalTrials.gov |
| NCT00070707 | Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (… | Phase4 | Rhinitis, Allergic, Seasonal | Completed | 2003-04-03 | 2003-11-26 | ClinicalTrials.gov |
| NCT00651274 | Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastati… | Phase4 | Atherosclerosis | Completed | 2003-04-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00783354 | A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiop… | Phase4 | Urticaria | Completed | 2003-04-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00139815 | Michelangelo - Oasis 5 | Phase3 | Thromboembolism | Completed | 2003-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00230984 | IRAD2 : Patients With Respiratory Failure at Home | Phase3 | Chronic Respiratory Failure | Completed | 2003-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00385437 | Sedating Antidepressant Improves Driving Safety in Patients With Major Depressi… | Phase2 | Depression | Completed | 2003-04-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00357526 | Oral Contraceptive Pills Compared to Vaginal Rings | Na | Pregnancy | Completed | 2003-04-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00092573 | Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-… | Phase3 | Hypercholesterolemia | Completed | 2003-04-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00092027 | A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219) | Phase3 | Postmenopausal Osteoporosis | Completed | 2003-03-19 | 2004-03-15 | ClinicalTrials.gov |
| NCT00092040 | A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmen… | Phase3 | Osteoporosis, Postmenopausal | Completed | 2003-03-18 | 2005-09-28 | ClinicalTrials.gov |
| NCT00817076 | Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Childr… | Phase3 | Dermatitis, Atopic | Completed | 2003-03-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00651144 | Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healt… | Phase1 | Hypercholesterolemia | Completed | 2003-03-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00092625 | Co-administration Study in Patients With Elevated Cholesterol and Coronary Hear… | Phase3 | Hypercholesterolemia | Completed | 2003-03-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00092885 | An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Pa… | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2003-03-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00269191 | A Study to Assess the Safety and Efficacy of an Investigational Drug in Patient… | Phase3 | Osteoarthritis | Completed | 2003-02-05 | 2003-11-21 | ClinicalTrials.gov |
| NCT00988260 | Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED) | Phase2 | Controlled Ovarian Stimulation | Completed | 2003-02-03 | 2004-04-12 | ClinicalTrials.gov |
| NCT00294463 | Effects of Tibolone Treatment on the Endometrium | Phase4 | Postmenopause | Completed | 2003-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00157937 | A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild … | Phase4 | Asthma | Completed | 2003-02-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00092742 | Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthri… | Phase3 | Rheumatoid Arthritis | Completed | 2003-02-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00140959 | Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLET… | Phase4 | Hypertension | Completed | 2003-02-01 | 2004-06-30 | ClinicalTrials.gov |
| NCT00092599 | Investigational Drug Study in Patients With Elevated Cholesterol and Coronary H… | Phase3 | Hypercholesterolemia | Completed | 2003-02-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00763529 | Elocon vs Fluticasone in Localized Psoriasis (P03197) | Phase4 | Psoriasis | Completed | 2003-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00092664 | An Extension Study of An Investigational Drug in Patients With Hypercholesterol… | Phase3 | Hypercholesterolemia | Completed | 2003-01-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00250445 | A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patie… | Phase3 | Rheumatoid Arthritis,Osteoarthritis | Completed | 2003-01-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00750750 | Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus A… | Phase2 | Acute Rhinosinusitis | Completed | 2003-01-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00725374 | A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Po… | Phase3 | Breast Cancer | Completed | 2002-12-15 | 2005-04-15 | ClinicalTrials.gov |
| NCT00794846 | Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2002-12-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00092560 | Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036) | Phase3 | Hypercholesterolemia | Completed | 2002-12-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00794495 | Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2002-12-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00794599 | Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2002-12-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00157911 | A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterole… | Phase3 | Hypercholerolemia | Completed | 2002-12-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00795158 | How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With C… | Phase3 | Urticaria | Completed | 2002-11-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00431093 | Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-… | Phase4 | Menopause | Completed | 2002-11-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00794248 | Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal A… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2002-11-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00945035 | Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (… | Phase1 | Pain | Completed | 2002-11-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00794768 | Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Al… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2002-11-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00757562 | Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives,… | Phase3 | Chronic Idiopathic Urticaria | Completed | 2002-11-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00783133 | Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal A… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2002-11-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00835094 | A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DP… | Phase4 | Asthma | Completed | 2002-10-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00092092 | Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma… | Phase4 | Asthma, Bronchial | Completed | 2002-10-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT01101464 | A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 … | Phase2 | Schizophrenia | Completed | 2002-10-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00817817 | A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhal… | Phase3 | Asthma | Completed | 2002-10-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00092586 | Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol L… | Phase3 | Hypercholesterolemia | Completed | 2002-09-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00092014 | A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Den… | Phase3 | Postmenopausal Osteoporosis | Completed | 2002-09-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00092651 | A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholestero… | Phase3 | Hypercholesterolemia | Completed | 2002-09-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00545324 | First Step With Singulair® Therapy (0476-323) | Phase4 | Asthma | Completed | 2002-09-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00092833 | Investigational Drug in Patients With Hypercholesterolemia or in Patients With … | Phase3 | Hypercholesterolemia, Familial | Terminated | 2002-07-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00092703 | Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0… | Phase3 | Osteoarthritis | Completed | 2002-06-27 | 2003-11-01 | ClinicalTrials.gov |
| NCT00092729 | An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-06… | Phase3 | Dysmenorrhea | Completed | 2002-06-07 | 2002-12-06 | ClinicalTrials.gov |
| NCT00552097 | Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosi… | Phase3 | Atherosclerosis | Completed | 2002-06-01 | 2006-04-25 | ClinicalTrials.gov |
| NCT00092716 | Comparing an Investigational Medication Versus an Approved Medication in Reduci… | Phase3 | Hypercholesterolemia | Completed | 2002-05-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00408863 | Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerabil… | Phase3 | Breast Cancer | Completed | 2002-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00092157 | Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224) | Phase3 | Hypercholesterolemia | Completed | 2002-05-01 | 2003-03-04 | ClinicalTrials.gov |
| NCT00092105 | Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms U… | Phase3 | Asthma, Bronchial | Completed | 2002-04-01 | 2003-01-28 | ClinicalTrials.gov |
| NCT00092209 | Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients Wit… | Phase3 | Hypertension | Completed | 2002-04-01 | 2002-11-01 | ClinicalTrials.gov |
| NCT00542087 | Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED) | Phase3 | Osteoarthritis | Completed | 2002-03-22 | 2002-12-20 | ClinicalTrials.gov |
| NCT00867191 | Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal S… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2002-02-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00551447 | A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patien… | Phase3 | Coronary Disease | Completed | 2002-01-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00702195 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phas… | — | Pregnancy | Completed | 2002-01-01 | 2003-09-15 | ClinicalTrials.gov |
| NCT00090259 | Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Ev… | Phase3 | Heart Failure | Completed | 2001-12-19 | 2009-05-13 | ClinicalTrials.gov |
| NCT00551876 | Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Sim… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2001-12-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00725413 | A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Eto… | Phase4 | Contraception | Completed | 2001-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00974571 | Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246) | Phase3 | Perennial Allergic Rhinitis | Completed | 2001-11-01 | 2002-05-01 | ClinicalTrials.gov |
| NCT00489346 | A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With M… | Phase3 | Asthma, Bronchial | Completed | 2001-10-01 | 2002-06-01 | ClinicalTrials.gov |
| NCT00745108 | Tibolone Endometrium Study (Study 32972)(P06470) | Phase3 | Postmenopausal Women | Completed | 2001-10-01 | 2005-07-21 | ClinicalTrials.gov |
| NCT00480662 | A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's B… | Phase3 | Paget's Disease of Bone | Completed | 2001-10-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00480805 | HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED) | Phase3 | Type 2 Diabetes Mellitus | Completed | 2001-08-08 | 2002-10-16 | ClinicalTrials.gov |
| NCT00963469 | Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240) | Phase3 | Seasonal Allergic Rhinitis | Completed | 2001-08-01 | 2001-11-01 | ClinicalTrials.gov |
| NCT00702585 | Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovu… | Phase2 | Infertility | Completed | 2001-08-01 | 2002-10-15 | ClinicalTrials.gov |
| NCT00389896 | A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Le… | Phase3 | HDL Cholesterol | Completed | 2001-07-26 | 2002-10-04 | ClinicalTrials.gov |
| NCT00541684 | Health Assessment Study (0954-946) | Phase3 | Hypertension | Completed | 2001-07-11 | 2003-01-23 | ClinicalTrials.gov |
| NCT00702806 | Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Contr… | Phase2 | Infertility | Completed | 2001-07-01 | 2002-10-15 | ClinicalTrials.gov |
| NCT00480766 | A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent … | Phase3 | Osteoporosis | Completed | 2001-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00519857 | Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468) | Phase3 | Osteoporosis | Completed | 2001-07-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00239590 | Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD) | Phase2 | Coronary Heart Disease | Completed | 2001-06-01 | 2004-04-24 | ClinicalTrials.gov |
| NCT00389740 | A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With… | Phase3 | Osteoporosis, Postmenopausal | Completed | 2001-04-02 | 2003-01-16 | ClinicalTrials.gov |
| NCT00943397 | Extended Safety Study of Montelukast in Infants and Young Children With Chronic… | Phase3 | Asthma | Completed | 2001-04-01 | 2001-11-01 | ClinicalTrials.gov |
| NCT00972738 | Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235) | Phase3 | Seasonal Allergic Rhinitis | Completed | 2001-04-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00968149 | A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic R… | Phase3 | Seasonal Allergic Rhinitis | Completed | 2001-03-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00092820 | Sitosterolemia Extension Study (0653-004)(COMPLETED) | Phase3 | Lipid Metabolism, Inborn Errors | Completed | 2001-02-12 | 2004-11-30 | ClinicalTrials.gov |
| NCT00092807 | Sitosterolemia Extension Study (0653-003)(COMPLETED) | Phase3 | Lipid Metabolism, Inborn Errors | Completed | 2001-02-12 | 2004-11-30 | ClinicalTrials.gov |
| NCT03882892 | Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovas… | Phase3 | Hypercholesterolemia | Completed | 2001-02-02 | 2002-08-08 | ClinicalTrials.gov |
| NCT03882905 | A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in… | Phase3 | Primary Hypercholesterolemia | Completed | 2001-01-31 | 2001-07-27 | ClinicalTrials.gov |
| NCT00700661 | A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907) | Phase3 | Asthma | Completed | 2001-01-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00092677 | An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (… | Phase3 | Aortic Stenosis | Completed | 2001-01-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00724789 | Monitor the Incidence of Congenital Malformations in Infants of Women Who Have … | — | Pregnancy | Completed | 2000-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT03885921 | Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastat… | Phase3 | Hypercholesterolemia | Completed | 2000-10-25 | 2003-07-08 | ClinicalTrials.gov |
| NCT03882996 | A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Par… | Phase3 | Hypercholesterolemia | Completed | 2000-10-06 | 2003-02-04 | ClinicalTrials.gov |
| NCT00960141 | A Study Investigating the Effect of Montelukast in Patients With Seasonal Aller… | Phase3 | Seasonal Allergic Rhinitis | Completed | 2000-08-01 | 2000-11-01 | ClinicalTrials.gov |
| NCT00943683 | Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study… | Na | Asthma | Completed | 2000-08-01 | 2001-02-01 | ClinicalTrials.gov |
| NCT00431431 | Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Pos… | Phase4 | Osteopenia | Completed | 2000-07-31 | 2005-02-15 | ClinicalTrials.gov |
| NCT00140881 | A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in… | Phase4 | Asthma | Completed | 2000-06-01 | 2003-02-14 | ClinicalTrials.gov |
| NCT00647933 | An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodyna… | Phase1 | Infertility | Completed | 2000-06-01 | 2000-12-01 | ClinicalTrials.gov |
| NCT00395408 | Linear Growth Study (0476-097)(COMPLETED) | Phase4 | Asthma | Completed | 2000-06-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT03884452 | Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Particip… | Phase3 | Familial Hypercholesterolemia | Completed | 2000-05-03 | 2001-05-24 | ClinicalTrials.gov |
| NCT03867318 | Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Ator… | Phase3 | Hypercholesterolemia | Completed | 2000-04-24 | 2001-11-16 | ClinicalTrials.gov |
| NCT00393211 | Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042) | Phase3 | Recurrent Low Back Pain | Completed | 2000-04-01 | 2000-11-01 | ClinicalTrials.gov |
| NCT00393354 | Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041) | Phase3 | Recurrent Low Back Pain | Completed | 2000-04-01 | 2000-11-01 | ClinicalTrials.gov |
| NCT00140907 | ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-2… | Phase4 | High Blood Pressure | Completed | 2000-03-14 | 2005-01-01 | ClinicalTrials.gov |
| NCT03867110 | An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to A… | Phase3 | Hypercholesterolemia | Completed | 2000-03-06 | 2001-07-27 | ClinicalTrials.gov |
| NCT00979901 | Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK… | Phase3 | Seasonal Allergic Rhinitis | Completed | 2000-03-01 | 2000-05-01 | ClinicalTrials.gov |
| NCT00140985 | Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Pr… | Phase4 | Renal Disorder | Completed | 2000-02-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT01062867 | First Administration to Man Of Org 25435 a New Intravenous Anesthetic | Phase1 | Anaesthesia | Completed | 2000-01-01 | 2000-03-01 | ClinicalTrials.gov |
| NCT00251576 | Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who… | Phase3 | Acute Coronary Syndrome | Completed | 1999-11-01 | 2004-03-23 | ClinicalTrials.gov |
| NCT00963599 | Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117) | Phase3 | Seasonal Allergic Rhinitis | Completed | 1999-09-01 | 1999-11-01 | ClinicalTrials.gov |
| NCT00242489 | Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007) | Phase2 | Osteoarthritis | Completed | 1998-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00396175 | Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) | Phase3 | Androgenetic Alopecia | Completed | 1998-03-01 | — | ClinicalTrials.gov |
| NCT00140946 | A Study to Assess the Effect of Montelukast Sodium With Concomitant Administrat… | Phase4 | Asthma | Completed | 1998-03-01 | 2000-10-01 | ClinicalTrials.gov |
| NCT00398931 | FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051) | Phase3 | Osteoporosis, Postmenopausal | Completed | 1998-02-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00968201 | Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 ) | Phase3 | Asthma | Completed | 1997-12-01 | 2001-03-01 | ClinicalTrials.gov |
| NCT00308347 | A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan … | Phase3 | Type 2 Diabetes | Completed | 1996-05-01 | 2001-04-01 | ClinicalTrials.gov |
| NCT03879772 | Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in th… | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 1996-03-12 | 1996-07-01 | ClinicalTrials.gov |
| NCT00898677 | Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0… | Phase3 | Migraine Headache | Completed | 1995-09-01 | 1996-09-01 | ClinicalTrials.gov |
| NCT00897104 | MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029) | Phase3 | Migraine Headache | Completed | 1995-08-01 | 1996-09-01 | ClinicalTrials.gov |
| NCT00338260 | Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954… | Phase3 | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | Completed | 1995-06-01 | 2001-11-01 | ClinicalTrials.gov |
| NCT00398606 | A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calc… | Phase3 | Osteoporosis, Postmenopausal | Completed | 1995-04-01 | — | ClinicalTrials.gov |
| NCT00899379 | Treatment of Multiple Attacks of Acute Migraine (0462-025) | Phase3 | Migraine Headache | Completed | 1995-04-01 | 1996-04-01 | ClinicalTrials.gov |
| NCT03855228 | Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Lora… | Phase3 | Rhinitis, Allergic | Completed | 1995-03-01 | 1995-08-07 | ClinicalTrials.gov |
| NCT00897949 | MK0462 in Treatment of Migraine With Recurrence (MK0462-022) | Phase3 | Migraine Headache | Completed | 1995-03-01 | 1996-07-01 | ClinicalTrials.gov |
| NCT01286207 | Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extensio… | Phase3 | Migraine Disorders | Completed | 1995-03-01 | 1997-05-01 | ClinicalTrials.gov |
| NCT00911547 | The Clinical Effect of MK0476 With Concomitant Administration of and Removal of… | Phase3 | Asthma | Completed | 1995-03-01 | 1996-05-01 | ClinicalTrials.gov |
| NCT03882047 | Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLON… | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 1994-08-11 | 1994-09-16 | ClinicalTrials.gov |
| NCT03861559 | Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared… | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 1994-03-30 | 1994-07-07 | ClinicalTrials.gov |
| NCT03855189 | Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Diprop… | Phase3 | Seasonal Allergic Rhinitis | Completed | 1993-08-23 | 1993-10-22 | ClinicalTrials.gov |
Total clinical trials: 534
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| usual administration of exogenous recombinant FSH | Other | Preclinical | Anovulation | COMPLETED | NCT00492882 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| usual administration of exogenous recombinant FSH | Other | Preclinical | Anovulation | COMPLETED | NCT00492882 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| usual administration of exogenous recombinant FSH | Other | Preclinical | Anovulation | COMPLETED | NCT00492882 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| usual administration of exogenous recombinant FSH | Other | Preclinical | Anovulation | COMPLETED | NCT00492882 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| usual administration of exogenous recombinant FSH | Other | Preclinical | Anovulation | COMPLETED | NCT00492882 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| usual administration of exogenous recombinant FSH | Other | Preclinical | Anovulation | COMPLETED | NCT00492882 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| usual administration of exogenous recombinant FSH | Other | Preclinical | Anovulation | COMPLETED | NCT00492882 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| usual administration of exogenous recombinant FSH | Other | Preclinical | Anovulation | COMPLETED | NCT00492882 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| OG-6219 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| OG-6219 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| OG-6219 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| OG-6219 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| Comparator: Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00250458 |
| Comparator: Rizatriptan | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00250458 |
| Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks | Drug | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00242489 |
| MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks) | Drug | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00242489 |
| Comparator: Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00250458 |
| Comparator: Rizatriptan | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00250458 |
| Comparator: Placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00092118 |
| Montelukast | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00092118 |
| Comparator: Placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00092118 |
| Montelukast | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00092118 |
| Nuvaring ™ (etonorgestrel/ethinylestradiol) | Other | Phase PHASE4 | Contraception | COMPLETED | NCT01044056 |
| norelgestrominum and ethinylestradiol patch oral contraceptive patch | Other | Phase PHASE4 | Contraception | COMPLETED | NCT01044056 |
| Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets | Other | Phase PHASE4 | Contraception | COMPLETED | NCT01044056 |
| Nuvaring ™ (etonorgestrel/ethinylestradiol) | Other | Phase PHASE4 | Contraception | COMPLETED | NCT01044056 |
| norelgestrominum and ethinylestradiol patch oral contraceptive patch | Other | Phase PHASE4 | Contraception | COMPLETED | NCT01044056 |
| Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets | Other | Phase PHASE4 | Contraception | COMPLETED | NCT01044056 |
| Ethinylestradiol + Desogestrel | Other | Preclinical | Contraception | COMPLETED | NCT01005056 |
| Ethinylestradiol + Desogestrel | Other | Preclinical | Contraception | COMPLETED | NCT01005056 |
| Follitropin beta | Other | Preclinical | Anovulation | COMPLETED | NCT00920634 |
| Follitropin beta | Other | Preclinical | Anovulation | COMPLETED | NCT00920634 |
| Follitropin beta | Other | Preclinical | Fertilization in Vitro | COMPLETED | NCT00920361 |
| Follitropin beta | Other | Preclinical | Fertilization in Vitro | COMPLETED | NCT00920361 |
| Follitropin beta | Other | Preclinical | Fertilization in Vitro | COMPLETED | NCT00920361 |
| Marvelon | Other | Phase PHASE4 | Infertility | COMPLETED | NCT00778999 |
| Marvelon | Other | Phase PHASE4 | Infertility | COMPLETED | NCT00778999 |
| etonogestrel implant (Implanon) | Other | Phase PHASE4 | Contraception | COMPLETED | NCT00725413 |
| placebo nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03861559 |
| mometasone furoate nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03861559 |
| Placebo tablet | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Placebo nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Loratadine | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Placebo tablet | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Placebo nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Loratadine | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT03855189 |
| Beclomethasone Dipropionate (BDP) | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT03855189 |
| Mometasone Furoate (MF) | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT03855189 |
| Vytorin (R) (Ezetimibe + Simvastatin) | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00909389 |
| Oxycodone | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Morphine | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Matching Placebo for Ibuprofen | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Matching Placebo for Etoricoxib 90 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Matching Placebo for Etoricoxib 120 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Ibuprofen 600 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Etoricoxib 120 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Etoricoxib 90 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Oxycodone | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Morphine | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Matching Placebo for Ibuprofen | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Matching Placebo for Etoricoxib 90 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Matching Placebo for Etoricoxib 120 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Ibuprofen 600 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Etoricoxib 120 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Etoricoxib 90 mg | Other | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| etoricoxib (MK0663) 90 mg | Other | Phase PHASE3 | Acute Pain Following a Total Abdominal Hysterectomy | COMPLETED | NCT00788710 |
| Comparator: Placebo | Other | Phase PHASE3 | Acute Pain Following a Total Abdominal Hysterectomy | COMPLETED | NCT00788710 |
| etoricoxib (MK0663) 120 mg | Other | Phase PHASE3 | Acute Pain Following a Total Abdominal Hysterectomy | COMPLETED | NCT00788710 |
| etoricoxib (MK0663) 90 mg | Other | Phase PHASE3 | Acute Pain Following a Total Abdominal Hysterectomy | COMPLETED | NCT00788710 |
| Comparator: Placebo | Other | Phase PHASE3 | Acute Pain Following a Total Abdominal Hysterectomy | COMPLETED | NCT00788710 |
| etoricoxib (MK0663) 120 mg | Other | Phase PHASE3 | Acute Pain Following a Total Abdominal Hysterectomy | COMPLETED | NCT00788710 |
| Fluticasone | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Mometasone | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Placebo for FP | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Placebo for MF | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Fluticasone | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Mometasone | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Placebo for FP | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Placebo for MF | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Zyrtec® (cetirizine) | Other | Phase PHASE4 | Allergies | COMPLETED | NCT00780403 |
| Desloratadine | Other | Phase PHASE4 | Allergies | COMPLETED | NCT00780403 |
| Zyrtec® (cetirizine) | Other | Phase PHASE4 | Allergies | COMPLETED | NCT00780403 |
| Desloratadine | Other | Phase PHASE4 | Allergies | COMPLETED | NCT00780403 |
| Zyrtec® (cetirizine) | Other | Phase PHASE4 | Allergies | COMPLETED | NCT00779116 |
| Desloratadine | Other | Phase PHASE4 | Allergies | COMPLETED | NCT00779116 |
| Zyrtec® (cetirizine) | Other | Phase PHASE4 | Allergies | COMPLETED | NCT00779116 |
| Desloratadine | Other | Phase PHASE4 | Allergies | COMPLETED | NCT00779116 |
| Desloratadine Syrup | Other | Preclinical | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00761527 |
| Desloratadine Syrup | Other | Preclinical | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00761527 |
| etoricoxib | Other | Phase PHASE4 | Pain | COMPLETED | NCT00757627 |
| Statin | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT00730132 |
| Ezetimibe | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT00730132 |
| Statin | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT00730132 |
| Ezetimibe | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT00730132 |
| Statin | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT00730132 |
| Ezetimibe | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT00730132 |
| Matching placebo nasal spray | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00728416 |
| Mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00728416 |
| Matching placebo nasal spray | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00728416 |
| Mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00728416 |
| Desloratadine | Other | Preclinical | Rhinitis | COMPLETED | NCT00724698 |
| INEGY | Other | Preclinical | Primary Hypercholesterolemia | COMPLETED | NCT00724477 |
| INEGY | Other | Preclinical | Primary Hypercholesterolemia | COMPLETED | NCT00724477 |
| INEGY | Other | Preclinical | Primary Hypercholesterolemia | COMPLETED | NCT00724477 |
| Desloratadine | Other | Preclinical | Rhinitis | COMPLETED | NCT00723736 |
| statin | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705081 |
| ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705081 |
| statin | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705081 |
| ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705081 |
| Desloratadine (assigned by investigator as part of normal practice) | Other | Preclinical | Rhinitis | COMPLETED | NCT00704769 |
| Ezetimibe | Other | Preclinical | Primary Hypercholesterolemia | COMPLETED | NCT00704535 |
| Ezetimibe | Other | Preclinical | Primary Hypercholesterolemia | COMPLETED | NCT00704535 |
| Comparator: placebo | Other | Phase PHASE3 | Postoperative Dental Pain | COMPLETED | NCT00694369 |
| Comparator: acetaminophen + codeine | Other | Phase PHASE3 | Postoperative Dental Pain | COMPLETED | NCT00694369 |
| Comparator: ibuprofen | Other | Phase PHASE3 | Postoperative Dental Pain | COMPLETED | NCT00694369 |
| Comparator: etoricoxib | Other | Phase PHASE3 | Postoperative Dental Pain | COMPLETED | NCT00694369 |
| Cream (betamethasone diproprionate) | Other | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate and gentamicin) | Other | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate) | Other | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate) | Other | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate and gentamicin) | Other | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate) | Other | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate) | Other | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate and gentamicin) | Other | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate) | Other | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Double Statin (simvastatin, atorvastatin, or pravastatin) | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin) | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| Double Statin (simvastatin, atorvastatin, or pravastatin) | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin) | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| Double Statin (simvastatin, atorvastatin, or pravastatin) | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin) | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| Double Statin (simvastatin, atorvastatin, or pravastatin) | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin) | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| Rescue medication: Prednisone/Prednisolone | Drug | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Rescue medication: short-acting beta-2 agonist (SABA) MDI | Drug | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Montelukast tablets 5 mg (4 mg for children 5 years of age) | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| BDP hydrofluoroalkane (HFA) 80 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F MDI 100/5 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F MDI 50/5 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F Metered Dose Inhaler (MDI) 25/5 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Rescue medication: Prednisone/Prednisolone | Drug | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Rescue medication: short-acting beta-2 agonist (SABA) MDI | Drug | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Montelukast tablets 5 mg (4 mg for children 5 years of age) | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| BDP hydrofluoroalkane (HFA) 80 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F MDI 100/5 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F MDI 50/5 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F Metered Dose Inhaler (MDI) 25/5 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Rescue medication: Prednisone/Prednisolone | Drug | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Rescue medication: short-acting beta-2 agonist (SABA) MDI | Drug | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Montelukast tablets 5 mg (4 mg for children 5 years of age) | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| BDP hydrofluoroalkane (HFA) 80 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F MDI 100/5 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F MDI 50/5 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F Metered Dose Inhaler (MDI) 25/5 mcg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Ezetimibe/atorvastatin 10mg/80mg FDC | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Atorvastatin 80mg | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Atorvastatin 10mg | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Ezetimibe/atorvastatin 10mg/10mg FDC | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Ezetimibe | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Ezetimibe/atorvastatin 10mg/80mg FDC | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Atorvastatin 80mg | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Atorvastatin 10mg | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Ezetimibe/atorvastatin 10mg/10mg FDC | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Ezetimibe | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Ezetimibe/atorvastatin 10mg/80mg FDC | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Atorvastatin 80mg | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Atorvastatin 10mg | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Ezetimibe/atorvastatin 10mg/10mg FDC | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Ezetimibe | Other | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Placebo metered-dose inhaler BID | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT01026870 |
| SCH 32088 mometasone furoate (MF) metered-dose inhaler | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT01026870 |
| mometasone furoate | Other | Preclinical | Allergic Rhinitis | COMPLETED | NCT00903721 |
| mometasone furoate | Other | Preclinical | Allergic Rhinitis | COMPLETED | NCT00903721 |
| desloratadine | Other | Phase PHASE3 | Dermatitis, Atopic | COMPLETED | NCT00817076 |
| desloratadine | Other | Phase PHASE3 | Dermatitis, Atopic | COMPLETED | NCT00817076 |
| desloratadine | Other | Phase PHASE3 | Dermatitis, Atopic | COMPLETED | NCT00817076 |
| Placebo for Oxybutynin 2.5 mg | Other | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Placebo for Desloratadine 2.5 mg | Other | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Oxybutynin 2.5 mg | Other | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Desloratadine 2.5 mg | Other | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Placebo for Oxybutynin 2.5 mg | Other | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Placebo for Desloratadine 2.5 mg | Other | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Oxybutynin 2.5 mg | Other | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Desloratadine 2.5 mg | Other | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Desloratadine | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00805324 |
| Desloratadine | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00805324 |
| Cetirizine (Zyrtec) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00794794 |
| Desloratadine (Clarinex) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00794794 |
| Cetirizine (Zyrtec) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00794794 |
| Desloratadine (Clarinex) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00794794 |
| Cetirizine (Zyrtec) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00794378 |
| Desloratadine (Clarinex) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00794378 |
| Cetirizine (Zyrtec) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00794378 |
| Desloratadine (Clarinex) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00794378 |
| NOMAC-E2 placebo | Other | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| Moxifloxacin placebo | Other | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| NOMAC-E2 (Org 10486-0 + Org 2317) | Other | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| Moxifloxacin | Other | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| NOMAC-E2 placebo | Other | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| Moxifloxacin placebo | Other | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| NOMAC-E2 (Org 10486-0 + Org 2317) | Other | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| Moxifloxacin | Other | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| Comparator: Diclofenac sodium | Other | Phase PHASE3 | Rheumatoid Arthritis,Osteoarthritis | COMPLETED | NCT00250445 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Rheumatoid Arthritis,Osteoarthritis | COMPLETED | NCT00250445 |
| Comparator: Diclofenac sodium | Other | Phase PHASE3 | Rheumatoid Arthritis,Osteoarthritis | COMPLETED | NCT00250445 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Rheumatoid Arthritis,Osteoarthritis | COMPLETED | NCT00250445 |
| Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks | Drug | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00242489 |
| MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks) | Drug | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00242489 |
| Ganirelix | Other | Phase PHASE2 | Controlled Ovarian Stimulation | COMPLETED | NCT00988260 |
| Ganirelix | Other | Phase PHASE2 | Controlled Ovarian Stimulation | COMPLETED | NCT00988260 |
| Asenapine WHITE UNFLAVORED (Treatment C) | Drug | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine RED raspberry flavor (Treatment B) | Drug | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine WHITE raspberry flavor (Treatment A) | Drug | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine WHITE UNFLAVORED (Treatment C) | Drug | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine RED raspberry flavor (Treatment B) | Drug | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine WHITE raspberry flavor (Treatment A) | Drug | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine WHITE UNFLAVORED (Treatment C) | Drug | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine RED raspberry flavor (Treatment B) | Drug | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine WHITE raspberry flavor (Treatment A) | Drug | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Desloratadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00867191 |
| Placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00867191 |
| Desloratadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00867191 |
| Placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00867191 |
| Mometasone furoate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00835094 |
| Mometasone furoate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00835094 |
| Mometasone furoate | Other | Phase PHASE4 | Rhinitis, Allergic | COMPLETED | NCT00834119 |
| Mometasone furoate | Other | Phase PHASE4 | Rhinitis, Allergic | COMPLETED | NCT00834119 |
| Mometasone furoate | Other | Phase PHASE4 | Rhinitis, Allergic | COMPLETED | NCT00834119 |
| fluticasone nasal spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00817050 |
| Mometasone Furoate Nasal Spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00817050 |
| fluticasone nasal spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00817050 |
| Mometasone Furoate Nasal Spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00817050 |
| levocetirizine | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00789152 |
| desloratadine | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00789152 |
| fluticasone nasal spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00783458 |
| Mometasone Furoate Nasal Spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00783458 |
| fluticasone nasal spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00783458 |
| Mometasone Furoate Nasal Spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00783458 |
| fluticasone nasal spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00783458 |
| Mometasone Furoate Nasal Spray | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00783458 |
| desloratadine | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00783354 |
| desloratadine | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00783354 |
| Placebo | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00783237 |
| Mometasone | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00783237 |
| placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783211 |
| fexofenadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783211 |
| desloratadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783211 |
| placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783211 |
| fexofenadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783211 |
| desloratadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783211 |
| placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783211 |
| fexofenadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783211 |
| desloratadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783211 |
| placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783146 |
| fexofenadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783146 |
| desloratadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783146 |
| fexofenadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783133 |
| Desloratadine 5 mg | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783133 |
| fexofenadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783133 |
| Desloratadine 5 mg | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00783133 |
| mometasone furoate | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00779740 |
| mometasone furoate | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00779740 |
| Placebo | Other | Phase PHASE4 | Allergic Airway Disease | COMPLETED | NCT00779636 |
| Desloratadine | Other | Phase PHASE4 | Allergic Airway Disease | COMPLETED | NCT00779636 |
| Placebo | Other | Phase PHASE4 | Allergic Airway Disease | COMPLETED | NCT00779636 |
| Desloratadine | Other | Phase PHASE4 | Allergic Airway Disease | COMPLETED | NCT00779636 |
| Mometasone furoate | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00779545 |
| Placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00779545 |
| Mometasone furoate | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00779545 |
| Placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00779545 |
| Mometasone furoate | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00779545 |
| Placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00779545 |
| montelukast sodium | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT00771160 |
| montelukast sodium | Other | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT00771160 |
| Fluticasone | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00763529 |
| Mometasone | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00763529 |
| Fluticasone | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00763529 |
| Mometasone | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00763529 |
| Placebo | Other | Phase PHASE3 | Chronic Idiopathic Urticaria | COMPLETED | NCT00757562 |
| desloratadine | Other | Phase PHASE3 | Chronic Idiopathic Urticaria | COMPLETED | NCT00757562 |
| nsNSAIDs | Other | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| Other COX-2 inhibitor | Other | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| etoricoxib | Other | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| nsNSAIDs | Other | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| Other COX-2 inhibitor | Other | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| etoricoxib | Other | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| nsNSAIDs | Other | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| Other COX-2 inhibitor | Other | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| etoricoxib | Other | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02748057 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02748057 |
| Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02748057 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02748057 |
| Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02748057 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02748057 |
| LNG-EE 150 μg/30 μg COC | Other | Phase PHASE3 | Contraception | TERMINATED | NCT02616146 |
| ENG-E2 125 μg/300 μg vaginal ring | Other | Phase PHASE3 | Contraception | TERMINATED | NCT02616146 |
| Losartan 50 mg / HCTZ 12.5 mg | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01431508 |
| Rescue medication | Drug | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT01349907 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT01349907 |
| Rescue medication | Drug | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT01349907 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT01349907 |
| hCG | Other | Phase PHASE3 | Hypogonadotropic Hypogonadism | COMPLETED | NCT03019575 |
| Corifollitropin alfa | Other | Phase PHASE3 | Hypogonadotropic Hypogonadism | COMPLETED | NCT03019575 |
| Prednisone/prednisolone | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Albuterol 90 mcg /salbutamol 100 mcg HFA MDI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate MDI 200 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate MDI 100 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate/Formoterol MDI 200/5 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate/Formoterol MDI 100/5 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Prednisone/prednisolone | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Albuterol 90 mcg /salbutamol 100 mcg HFA MDI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate MDI 200 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate MDI 100 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate/Formoterol MDI 200/5 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate/Formoterol MDI 100/5 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Ibuprofen | Other | Phase PHASE3 | Dysmenorrhea | TERMINATED | NCT02668822 |
| Placebo vaginal ring | Other | Phase PHASE3 | Dysmenorrhea | TERMINATED | NCT02668822 |
| ENG 125 μg + E2 300 μg vaginal ring (MK-8342B) | Other | Phase PHASE3 | Dysmenorrhea | TERMINATED | NCT02668822 |
| Ibuprofen | Other | Phase PHASE3 | Dysmenorrhea | TERMINATED | NCT02668822 |
| Placebo vaginal ring | Other | Phase PHASE3 | Dysmenorrhea | TERMINATED | NCT02668822 |
| ENG 125 μg + E2 300 μg vaginal ring (MK-8342B) | Other | Phase PHASE3 | Dysmenorrhea | TERMINATED | NCT02668822 |
| Ibuprofen | Other | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| Placebo vaginal ring | Other | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring | Other | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| Ibuprofen | Other | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| Placebo vaginal ring | Other | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring | Other | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| Ibuprofen | Other | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| Placebo vaginal ring | Other | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring | Other | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| ferrous fumarate | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| ethinylestradiol (EE) | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| Placebo | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| NETA-EE | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| ferrous fumarate | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| ethinylestradiol (EE) | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| Placebo | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| NETA-EE | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| Calcium 500 mg | Other | Phase PHASE4 | Osteoporosis, Postmenopausal | COMPLETED | NCT01350934 |
| Calcitriol | Other | Phase PHASE4 | Osteoporosis, Postmenopausal | COMPLETED | NCT01350934 |
| alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus) | Other | Phase PHASE4 | Osteoporosis, Postmenopausal | COMPLETED | NCT01350934 |
| Placebo to match amlodipine | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Amlodipine camsylate | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Placebo to match losartan/amlodipine tablets | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Losartan (+) amlodipine | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Placebo to match amlodipine | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Amlodipine camsylate | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Placebo to match losartan/amlodipine tablets | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Losartan (+) amlodipine | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| DRSP 3 mg + EE 30 µg | Other | Phase PHASE3 | Contraception | COMPLETED | NCT01277211 |
| ENG 120 µg + EE 15 µg intravaginal ring | Other | Phase PHASE3 | Contraception | COMPLETED | NCT01277211 |
| Alendronate placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Risendronate placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Vitamin D | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Elemental Calcium | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Risedronate 35 mg | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Alendronate | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks | Drug | Phase PHASE3 | HDL Cholesterol | COMPLETED | NCT00389896 |
| MK0733 / Duration of Treatment: 18 Weeks | Drug | Phase PHASE3 | HDL Cholesterol | COMPLETED | NCT00389896 |
| Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks | Drug | Phase PHASE3 | HDL Cholesterol | COMPLETED | NCT00389896 |
| MK0733 / Duration of Treatment: 18 Weeks | Drug | Phase PHASE3 | HDL Cholesterol | COMPLETED | NCT00389896 |
| MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00380705 |
| MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00380705 |
| MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days | Drug | Phase PHASE4 | Pain | COMPLETED | NCT00380627 |
| Duration of Treatment: 3 months | Drug | Phase PHASE3 | Hypercholesterolaemia | COMPLETED | NCT00328523 |
| MK-0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolaemia | COMPLETED | NCT00328523 |
| Duration of Treatment: 3 months | Drug | Phase PHASE3 | Hypercholesterolaemia | COMPLETED | NCT00328523 |
| MK-0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolaemia | COMPLETED | NCT00328523 |
| loratadine; montelukast | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00319995 |
| desloratadine | Other | Phase PHASE4 | Conjunctivitis, Allergic | COMPLETED | NCT00311844 |
| losartan / Duration of Treatment: 6 weeks | Drug | Phase PHASE3 | Mild to Severe Hypertension | COMPLETED | NCT00307060 |
| MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks | Drug | Phase PHASE3 | Mild to Severe Hypertension | COMPLETED | NCT00307060 |
| losartan / Duration of Treatment: 6 weeks | Drug | Phase PHASE3 | Mild to Severe Hypertension | COMPLETED | NCT00307060 |
| MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks | Drug | Phase PHASE3 | Mild to Severe Hypertension | COMPLETED | NCT00307060 |
| Placebo or Ibuprofen / Duration of Treatment 12 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00269191 |
| MK0663, etoricoxib / Duration of Treatment 12 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00269191 |
| Placebo or Ibuprofen / Duration of Treatment 12 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00269191 |
| MK0663, etoricoxib / Duration of Treatment 12 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00269191 |
| Placebo or Ibuprofen / Duration of Treatment 12 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00269191 |
| MK0663, etoricoxib / Duration of Treatment 12 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00269191 |
| Duration of Treatment: Z-Phase, 2 years. | Drug | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours | Drug | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Comparator: A-Phase: low molecular weight heparin, unfractionated heparin | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years | Drug | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| A-Phase: tirofiban; Z-Phase simvastatin | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Duration of Treatment: Z-Phase, 2 years. | Drug | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours | Drug | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Comparator: A-Phase: low molecular weight heparin, unfractionated heparin | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years | Drug | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| A-Phase: tirofiban; Z-Phase simvastatin | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212836 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212836 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212836 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212836 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212784 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212784 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212784 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212784 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212784 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212784 |
| atorvastatin | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00166530 |
| simvastatin | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00166530 |
| ezetimibe (+) simvastatin | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00166530 |
| atorvastatin | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00166530 |
| simvastatin | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00166530 |
| ezetimibe (+) simvastatin | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00166530 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159796 |
| Olanzapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159796 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159796 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159796 |
| Olanzapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159796 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159796 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159744 |
| Olanzapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159744 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159744 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159744 |
| Olanzapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159744 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159744 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159744 |
| Olanzapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159744 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159744 |
| MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks | Drug | Phase PHASE4 | Essential Hypertension | COMPLETED | NCT00157963 |
| MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks | Drug | Phase PHASE4 | Essential Hypertension | COMPLETED | NCT00157963 |
| Comparator: theophylline ER/Duration of Treatment: 16 weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00157937 |
| MK0476; montelukast sodium/Duration of Treatment: 16 weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00157937 |
| Comparator: theophylline ER/Duration of Treatment: 16 weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00157937 |
| MK0476; montelukast sodium/Duration of Treatment: 16 weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00157937 |
| Comparator: simvastatin / Duration of Treatment: 12 weeks | Drug | Phase PHASE3 | Hypercholerolemia | COMPLETED | NCT00157911 |
| MK0653; ezetimibe / Duration of Treatment: 12 weeks | Drug | Phase PHASE3 | Hypercholerolemia | COMPLETED | NCT00157911 |
| Comparator: simvastatin / Duration of Treatment: 12 weeks | Drug | Phase PHASE3 | Hypercholerolemia | COMPLETED | NCT00157911 |
| MK0653; ezetimibe / Duration of Treatment: 12 weeks | Drug | Phase PHASE3 | Hypercholerolemia | COMPLETED | NCT00157911 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156117 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156117 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156117 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156117 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156117 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156117 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156117 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156117 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156117 |
| Placebo arm | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156104 |
| Haloperidol | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156104 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156104 |
| Placebo arm | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156104 |
| Haloperidol | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156104 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156104 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00151424 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00151424 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00151424 |
| Olanzapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00143182 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00143182 |
| Olanzapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00143182 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00143182 |
| Olanzapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00143182 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00143182 |
| Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days | Drug | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| MK0663; etoricoxib / Duration of Treatment: 5 Days | Drug | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days | Drug | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| MK0663; etoricoxib / Duration of Treatment: 5 Days | Drug | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days | Drug | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| MK0663; etoricoxib / Duration of Treatment: 5 Days | Drug | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days | Drug | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| MK0663; etoricoxib / Duration of Treatment: 5 Days | Drug | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks | Drug | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT00140972 |
| MK0663; etoricoxib / Duration of Treatment:4 Weeks | Drug | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT00140972 |
| Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks | Drug | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT00140972 |
| MK0663; etoricoxib / Duration of Treatment:4 Weeks | Drug | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT00140972 |
| Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks | Drug | Phase PHASE4 | Hypertension | COMPLETED | NCT00140959 |
| MK0954, losartan potassium/Duration of Treatment: 18 weeks | Drug | Phase PHASE4 | Hypertension | COMPLETED | NCT00140959 |
| Comparator: Placebo | Other | Phase PHASE4 | High Blood Pressure | COMPLETED | NCT00140907 |
| losartan potassium | Other | Phase PHASE4 | High Blood Pressure | COMPLETED | NCT00140907 |
| Comparator: simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: pravastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: lovastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: fluvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| MK0653A (ezetimibe [+] simvastatin) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: pravastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: lovastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: fluvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| MK0653A (ezetimibe [+] simvastatin) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: pranlukast | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00127647 |
| montelukast sodium | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00127647 |
| Comparator: pranlukast | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00127647 |
| montelukast sodium | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00127647 |
| Comparator: placebo / Duration of Treatment: 48 weeks | Drug | Phase PHASE3 | Benign Prostatic Hyperplasia | COMPLETED | NCT00127179 |
| MK0906, finasteride / Duration of Treatment: 48 weeks | Drug | Phase PHASE3 | Benign Prostatic Hyperplasia | COMPLETED | NCT00127179 |
| Tapinarof cream, 1% | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05186805 |
| oxytocin, placebo | Other | Approved | Idiopathic Infertility | COMPLETED | NCT00805662 |
| oxytocin, placebo | Other | Approved | Idiopathic Infertility | COMPLETED | NCT00805662 |
| ORG25435 | Other | Phase PHASE1 | Anaesthesia | COMPLETED | NCT01062867 |
| ORG25435 | Other | Phase PHASE1 | Anaesthesia | COMPLETED | NCT01062867 |
| 150 mcg levonorgestrel/30 mcg ethinyl estradiol | Other | Preclinical | Contraception | UNKNOWN | NCT05116371 |
| Org 36286 (corifollitropin alfa) | Other | Phase PHASE2 | In Vitro Fertilization | COMPLETED | NCT00702351 |
| Comparator: Placebo (unspecified) | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00641771 |
| alendronate sodium (+) cholecalciferol | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00641771 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00461032 |
| montelukast | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00461032 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00461032 |
| montelukast | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00461032 |
| aminophylline hydrate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00442338 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00442338 |
| aminophylline hydrate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00442338 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00442338 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00289874 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00289874 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00289874 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00289874 |
| Comparator: Placebo (salmeterol) | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Placebo (montelukast) | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Salmeterol | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Montelukast | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Placebo (salmeterol) | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Placebo (montelukast) | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Salmeterol | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Montelukast | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00229970 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00229970 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00229970 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00229970 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00229970 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00229970 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00229970 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00229970 |
| Comparator: placebo / Duration of Treatment: 16 weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00140946 |
| MK0476; montelukast sodium/Duration of Treatment: 16 weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00140946 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00092131 |
| Comparator: Montelukast | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00092131 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00092131 |
| Comparator: Montelukast | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00092131 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00092131 |
| Comparator: Montelukast | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00092131 |
| ibandronate | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092053 |
| Placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092053 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00090142 |
| Comparator: Montelukast | Other | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00090142 |
| Progesterone | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| human Chorionic Gonadotropin (hCG) | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| Ganirelix | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| recFSH | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| MK-8962 | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| Progesterone | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| human Chorionic Gonadotropin (hCG) | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| Ganirelix | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| recFSH | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| MK-8962 | Other | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| corifollitropin alfa | Other | Preclinical | Infertility, Female | COMPLETED | NCT01408615 |
| corifollitropin alfa | Other | Preclinical | Infertility, Female | COMPLETED | NCT01408615 |
| corifollitropin alfa | Other | Preclinical | Infertility, Female | COMPLETED | NCT01408615 |
| Standard Care | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT01286207 |
| Rizatriptan 10 mg | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT01286207 |
| Rizatriptan 5 mg | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT01286207 |
| Standard Care | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT01286207 |
| Rizatriptan 10 mg | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT01286207 |
| Rizatriptan 5 mg | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT01286207 |
| Placebo for recFSH | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| Placebo for SCH 900962 | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| RecFSH / follitropin beta | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| SCH 900962 / Corifollitropin alfa / Org 36286 | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| Placebo for recFSH | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| Placebo for SCH 900962 | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| RecFSH / follitropin beta | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| SCH 900962 / Corifollitropin alfa / Org 36286 | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| Raloxifene | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Risedronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Ibandronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Etidronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Alendronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Raloxifene | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Risedronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Ibandronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Etidronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Alendronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Raloxifene | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Risedronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Ibandronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Etidronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Alendronate | Other | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| FOSAMAX PLUS D | Other | Preclinical | Osteoporosis | COMPLETED | NCT01065779 |
| FOSAMAX PLUS | Other | Preclinical | Osteoporosis | COMPLETED | NCT01065779 |
| FOSAMAX PLUS D | Other | Preclinical | Osteoporosis | COMPLETED | NCT01065779 |
| FOSAMAX PLUS | Other | Preclinical | Osteoporosis | COMPLETED | NCT01065779 |
| Comparator: placebo | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00974571 |
| Comparator: cetirizine | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00974571 |
| montelukast sodium | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00974571 |
| Comparator: placebo | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00974571 |
| Comparator: cetirizine | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00974571 |
| montelukast sodium | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00974571 |
| Comparator: Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| Comparator: Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| Comparator: Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00968201 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00968201 |
| Comparator: Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00968149 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00968149 |
| Comparator: Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00968149 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00968149 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963469 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963469 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963469 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963469 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963469 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963469 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963469 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963469 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963469 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00960141 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00960141 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00960141 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00960141 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00960141 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00960141 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00960141 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00960141 |
| montelukast sodium | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00960141 |
| Comparator: Placebo | Other | Approved | Asthma | COMPLETED | NCT00943683 |
| montelukast sodium | Other | Approved | Asthma | COMPLETED | NCT00943683 |
| Comparator: Placebo | Other | Approved | Asthma | COMPLETED | NCT00943683 |
| montelukast sodium | Other | Approved | Asthma | COMPLETED | NCT00943683 |
| Comparator: Usual Care | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00943397 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00943397 |
| Comparator: Usual Care | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00943397 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00943397 |
| placebo tablet | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| Placebo inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| beclomethasone | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| placebo tablet | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| Placebo inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| beclomethasone | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| placebo tablet | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| Placebo inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| beclomethasone | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| Comparator: Placebo | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00899379 |
| rizatriptan benzoate | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00899379 |
| Comparator: Placebo | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00899379 |
| rizatriptan benzoate | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00899379 |
| Comparator: Placebo | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| Comparator: sumatriptan | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| rizatriptan benzoate | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| Comparator: Placebo | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| Comparator: sumatriptan | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| rizatriptan benzoate | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| Comparator: Placebo | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| Comparator: sumatriptan | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| rizatriptan benzoate | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| Comparator: placebo | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00897949 |
| rizatriptan benzoate (MK0462) | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00897949 |
| Comparator: placebo | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00897949 |
| rizatriptan benzoate (MK0462) | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00897949 |
| Comparator: Placebo | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00897104 |
| Comparator: sumatriptan | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00897104 |
| rizatriptan benzoate (MK0462) | Other | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00897104 |
| Comparator: Vitamin D | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| Comparator: alendronate | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| alendronate sodium+vitamin D combination | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| Comparator: Vitamin D | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| Comparator: alendronate | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| alendronate sodium+vitamin D combination | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| Comparator: Vitamin D | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| Comparator: alendronate | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| alendronate sodium+vitamin D combination | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| CE/MPA | Other | Phase PHASE3 | Postmenopausal Women | COMPLETED | NCT00745108 |
| Tibolone 2.5 mg | Other | Phase PHASE3 | Postmenopausal Women | COMPLETED | NCT00745108 |
| tibolone | Other | Phase PHASE3 | Postmenopausal Women | COMPLETED | NCT00745108 |
| CE/MPA | Other | Phase PHASE3 | Postmenopausal Women | COMPLETED | NCT00745108 |
| Tibolone 2.5 mg | Other | Phase PHASE3 | Postmenopausal Women | COMPLETED | NCT00745108 |
| tibolone | Other | Phase PHASE3 | Postmenopausal Women | COMPLETED | NCT00745108 |
| triptorelin | Other | Phase PHASE3 | Controlled Ovarian Stimulation | COMPLETED | NCT00725491 |
| ganirelix | Other | Phase PHASE3 | Controlled Ovarian Stimulation | COMPLETED | NCT00725491 |
| triptorelin | Other | Phase PHASE3 | Controlled Ovarian Stimulation | COMPLETED | NCT00725491 |
| ganirelix | Other | Phase PHASE3 | Controlled Ovarian Stimulation | COMPLETED | NCT00725491 |
| triptorelin | Other | Phase PHASE3 | Controlled Ovarian Stimulation | COMPLETED | NCT00725491 |
| ganirelix | Other | Phase PHASE3 | Controlled Ovarian Stimulation | COMPLETED | NCT00725491 |
| GnRH agonist | Other | Preclinical | Pregnancy | COMPLETED | NCT00724789 |
| ganirelix | Other | Preclinical | Pregnancy | COMPLETED | NCT00724789 |
| GnRH agonist | Other | Preclinical | Pregnancy | COMPLETED | NCT00724789 |
| ganirelix | Other | Preclinical | Pregnancy | COMPLETED | NCT00724789 |
| GnRH agonist | Other | Preclinical | Pregnancy | COMPLETED | NCT00724789 |
| ganirelix | Other | Preclinical | Pregnancy | COMPLETED | NCT00724789 |
| nomegestrol acetate and estradiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00711607 |
| recFSH | Other | Preclinical | Pregnancy | COMPLETED | NCT00702988 |
| Org 36286 | Other | Preclinical | Pregnancy | COMPLETED | NCT00702988 |
| recFSH | Other | Preclinical | Pregnancy | COMPLETED | NCT00702988 |
| Org 36286 | Other | Preclinical | Pregnancy | COMPLETED | NCT00702988 |
| recFSH | Other | Preclinical | Pregnancy | COMPLETED | NCT00702988 |
| Org 36286 | Other | Preclinical | Pregnancy | COMPLETED | NCT00702988 |
| recFSH | Other | Preclinical | Pregnancy | COMPLETED | NCT00702988 |
| Org 36286 | Other | Preclinical | Pregnancy | COMPLETED | NCT00702988 |
| open-label recFSH (follitropin beta) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| placebo-corifollitropin alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| placebo-recFSH (follitropin beta) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| progesterone | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| human chorion gonadotropin (hCG) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| gonadatropin releasing hormone (GnRH) antagonist ganirelix | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| recFSH (follitropin beta) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| Corifollitropin alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| open-label recFSH (follitropin beta) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| placebo-corifollitropin alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| placebo-recFSH (follitropin beta) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| progesterone | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| human chorion gonadotropin (hCG) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| gonadatropin releasing hormone (GnRH) antagonist ganirelix | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| recFSH (follitropin beta) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| Corifollitropin alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| open-label recFSH | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| placebo-corifollitropin alfa | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| placebo-recFSH (follitropin alfa) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| progesterone | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| human chorion gonadatropin (hCG) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| gonadatropin releasing hormone (GnRH) antagonist ganirelix | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| recFSH (follitropin alfa) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| corifollitropin alfa | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| open-label recFSH | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| placebo-corifollitropin alfa | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| placebo-recFSH (follitropin alfa) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| progesterone | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| human chorion gonadatropin (hCG) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| gonadatropin releasing hormone (GnRH) antagonist ganirelix | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| recFSH (follitropin alfa) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| corifollitropin alfa | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| Lyndiol® | Other | Phase PHASE1 | Infertility | COMPLETED | NCT00647933 |
| Org 36286 | Other | Phase PHASE1 | Infertility | COMPLETED | NCT00647933 |
| Lyndiol® | Other | Phase PHASE1 | Infertility | COMPLETED | NCT00647933 |
| Org 36286 | Other | Phase PHASE1 | Infertility | COMPLETED | NCT00647933 |
| Placebo | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00519857 |
| Tibolone | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00519857 |
| Placebo | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00519857 |
| Tibolone | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00519857 |
| low-dose estradiol/noresterone | Other | Phase PHASE4 | Menopause | COMPLETED | NCT00431093 |
| tibolone | Other | Phase PHASE4 | Menopause | COMPLETED | NCT00431093 |
| low-dose estradiol/noresterone | Other | Phase PHASE4 | Menopause | COMPLETED | NCT00431093 |
| tibolone | Other | Phase PHASE4 | Menopause | COMPLETED | NCT00431093 |
| Comparator : placebo (unspecified) /Duration of Treatment : 5 Years | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398931 |
| MK0217, alendronate sodium / Duration of Treatment : 5 Years | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398931 |
| Comparator : placebo (unspecified) /Duration of Treatment : 5 Years | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398931 |
| MK0217, alendronate sodium / Duration of Treatment : 5 Years | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398931 |
| Comparator : calcium carbonate /Duration of Treatment : 2 Years | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398606 |
| MK0217, alendronate sodium / Duration of Treatment : 2 Years | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398606 |
| Comparator : calcium carbonate /Duration of Treatment : 2 Years | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398606 |
| MK0217, alendronate sodium / Duration of Treatment : 2 Years | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398606 |
| Zotepine | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Sertindole | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Amisulpride | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Clozapine | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Lurasidone | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Paliperidone | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Iloperidone | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Ziprasidone | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Olanzapine | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Risperidone | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Quetiapine | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Aripiprazole | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Asenapine | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| etonogestrel implant (Implanon) | Other | Phase PHASE4 | Contraception | COMPLETED | NCT00725413 |
| etonogestrel implant (Implanon) | Other | Phase PHASE4 | Contraception | COMPLETED | NCT00725413 |
| etonogestrel implant (Implanon) | Other | Phase PHASE4 | Contraception | COMPLETED | NCT00725413 |
| Implanon (etonogestrel implant) | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00620464 |
| Radiopaque Implanon | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00620464 |
| Radiopaque Etonogestrel Implant | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00620035 |
| Radiopaque Etonogestrel Implant | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00620035 |
| estradiol-norethisterone | Other | Phase PHASE3 | Sexual Dysfunction | COMPLETED | NCT00413764 |
| tibolone | Other | Phase PHASE3 | Sexual Dysfunction | COMPLETED | NCT00413764 |
| estradiol-norethisterone | Other | Phase PHASE3 | Sexual Dysfunction | COMPLETED | NCT00413764 |
| tibolone | Other | Phase PHASE3 | Sexual Dysfunction | COMPLETED | NCT00413764 |
| placebo | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00408863 |
| tibolone | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00408863 |
| Placebo | Other | Phase PHASE2 | Contraception | COMPLETED | NCT00403793 |
| etonogestrel with testosterone undecanoate | Other | Phase PHASE2 | Contraception | COMPLETED | NCT00403793 |
| Placebo | Other | Phase PHASE2 | Contraception | COMPLETED | NCT00403793 |
| etonogestrel with testosterone undecanoate | Other | Phase PHASE2 | Contraception | COMPLETED | NCT00403793 |
| Placebo | Other | Phase PHASE2 | Contraception | COMPLETED | NCT00403793 |
| etonogestrel with testosterone undecanoate | Other | Phase PHASE2 | Contraception | COMPLETED | NCT00403793 |
| Comparator: cholecalciferol (Vitamin D) | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00806416 |
| Comparator: alendronate | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00806416 |
| alendronate sodium (+) cholecalciferol | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00806416 |
| Comparator: cholecalciferol (Vitamin D) | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00806416 |
| Comparator: alendronate | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00806416 |
| alendronate sodium (+) cholecalciferol | Other | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00806416 |
| Placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00358527 |
| Mometasone Furoate Nasal Spray (MFNS) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00358527 |
| Placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00358527 |
| Mometasone Furoate Nasal Spray (MFNS) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00358527 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156065 |
| Haloperidol | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156065 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156065 |
| Haloperidol | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156065 |
| Asenapine - Double Blind | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00150176 |
| Placebo - Double Blind | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00150176 |
| Asenapine - Open Label | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00150176 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00145509 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00145509 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00145496 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00145496 |
| simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00129402 |
| ezetimibe with simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00129402 |
| simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00129402 |
| ezetimibe with simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00129402 |
| Fluticasone propionate placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Mometasone furoate placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Fluticasone propionate | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Mometasone furoate | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Fluticasone propionate placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Mometasone furoate placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Fluticasone propionate | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Mometasone furoate | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Fluticasone propionate placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Mometasone furoate placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Fluticasone propionate | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Mometasone furoate | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Chlorpheniramine maleate syrup | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Placebo nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Beclomethasone dipropionate nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Mometasone furoate nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Chlorpheniramine maleate syrup | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Placebo nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Beclomethasone dipropionate nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Mometasone furoate nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| placebo nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03861559 |
| mometasone furoate nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03861559 |
| celecoxib | Other | Preclinical | Osteoarthritis | COMPLETED | NCT01572675 |
| etorocoxib | Other | Preclinical | Osteoarthritis | COMPLETED | NCT01572675 |
| Celecoxib 200 mg | Other | Phase PHASE3 | Osteoarthritis of the Knee | COMPLETED | NCT01554163 |
| Etoricoxib 30 mg | Other | Phase PHASE3 | Osteoarthritis of the Knee | COMPLETED | NCT01554163 |
| Celecoxib 200 mg | Other | Phase PHASE3 | Osteoarthritis of the Knee | COMPLETED | NCT01554163 |
| Etoricoxib 30 mg | Other | Phase PHASE3 | Osteoarthritis of the Knee | COMPLETED | NCT01554163 |
| Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Placebo to ibuprofen | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Placebo to etoricoxib | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Ibuprofen | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Etoricoxib | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Placebo to ibuprofen | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Placebo to etoricoxib | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Ibuprofen | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Etoricoxib | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Hypolipemics | Other | Preclinical | Dyslipidemia | COMPLETED | NCT01436253 |
| Lifestyle Changes | Other | Preclinical | Dyslipidemia | COMPLETED | NCT01436253 |
| Hypolipemics | Other | Preclinical | Dyslipidemia | COMPLETED | NCT01436253 |
| Lifestyle Changes | Other | Preclinical | Dyslipidemia | COMPLETED | NCT01436253 |
| Ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT01381679 |
| Ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT01381679 |
| Ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT01381679 |
| Placebo to ezetimibe/atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Placebo to ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Placebo to atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Ezetimibe/atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Placebo to ezetimibe/atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Placebo to ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Placebo to atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Ezetimibe/atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Placebo to ezetimibe/atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Placebo to ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Placebo to atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Ezetimibe/atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Placebo to ezetimibe/atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Placebo to ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Placebo to atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Ezetimibe/atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370590 |
| Phase 3 NOMAC-E2 "Batch B" | Other | Phase PHASE1 | Healthy Postmenopausal Females | COMPLETED | NCT01345786 |
| Phase 3 NOMAC-E2 "Batch A" | Other | Phase PHASE1 | Healthy Postmenopausal Females | COMPLETED | NCT01345786 |
| Commercial NOMAC-E2 | Other | Phase PHASE1 | Healthy Postmenopausal Females | COMPLETED | NCT01345786 |
| Phase 3 NOMAC-E2 "Batch B" | Other | Phase PHASE1 | Healthy Postmenopausal Females | COMPLETED | NCT01345786 |
| Phase 3 NOMAC-E2 "Batch A" | Other | Phase PHASE1 | Healthy Postmenopausal Females | COMPLETED | NCT01345786 |
| Commercial NOMAC-E2 | Other | Phase PHASE1 | Healthy Postmenopausal Females | COMPLETED | NCT01345786 |
| Comparator: rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01154036 |
| atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01154036 |
| ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01154036 |
| Asenapine 1x15mg followed by 3x5mg | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT01101464 |
| Asenapine 3x5mg followed by 1x15mg | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT01101464 |
| Asenapine 1x15mg followed by 3x5mg | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT01101464 |
| Asenapine 3x5mg followed by 1x15mg | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT01101464 |
| Asenapine 1x15mg followed by 3x5mg | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT01101464 |
| Asenapine 3x5mg followed by 1x15mg | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT01101464 |
| Comparator: montelukast/loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: montelukast | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: montelukast/loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: montelukast | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: montelukast/loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: montelukast | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963599 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963599 |
| Comparator: montelukast | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963599 |
| Comparator: montelukast/loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963599 |
| Comparator: placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963599 |
| Comparator: loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963599 |
| Comparator: montelukast | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963599 |
| Comparator: montelukast/loratadine | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00963599 |
| hydrochlorothiazide (HCTZ) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00953680 |
| losartan potassium | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00953680 |
| losartan potassium (+) hydrochlorothiazide (HCTZ) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00953680 |
| hydrochlorothiazide (HCTZ) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00953680 |
| losartan potassium | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00953680 |
| losartan potassium (+) hydrochlorothiazide (HCTZ) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00953680 |
| Comparator: etoricoxib | Other | Phase PHASE1 | Pain | COMPLETED | NCT00945035 |
| etoricoxib | Other | Phase PHASE1 | Pain | COMPLETED | NCT00945035 |
| Comparator: etoricoxib | Other | Phase PHASE1 | Pain | COMPLETED | NCT00945035 |
| etoricoxib | Other | Phase PHASE1 | Pain | COMPLETED | NCT00945035 |
| Comparator: etoricoxib | Other | Phase PHASE1 | Pain | COMPLETED | NCT00945035 |
| etoricoxib | Other | Phase PHASE1 | Pain | COMPLETED | NCT00945035 |
| Comparator: Placebo | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: losartan + ISMN | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: isosorbide mononitrate (ISMN) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| losartan potassium | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: Placebo | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: losartan + ISMN | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: isosorbide mononitrate (ISMN) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| losartan potassium | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: Placebo | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: losartan + ISMN | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: isosorbide mononitrate (ISMN) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| losartan potassium | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| DRSP-EE | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511433 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511433 |
| DRSP-EE | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511433 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511433 |
| Levonorgestrel and Ethinyl Estradiol | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511355 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511355 |
| Levonorgestrel and Ethinyl Estradiol | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511355 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511355 |
| LNG-EE | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511342 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511342 |
| DRSP-EE | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511199 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511199 |
| DRSP-EE | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511199 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00511199 |
| Placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00491504 |
| Mometasone Furoate Nasal Spray | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00491504 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00468312 |
| Mometasone furoate nasal spray | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00468312 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00468312 |
| Mometasone furoate nasal spray | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00468312 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00468312 |
| Mometasone furoate nasal spray | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00468312 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00453063 |
| mometasone furoate | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00453063 |
| Placebo for Asmanex twisthaler | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00442351 |
| Asmanex twisthaler | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00442351 |
| Placebo for Asmanex twisthaler | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00442351 |
| Asmanex twisthaler | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00442351 |
| Placebo for Asmanex twisthaler | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00442351 |
| Asmanex twisthaler | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00442351 |
| Simvastatin Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00423488 |
| Ezetimibe Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00423488 |
| Simvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00423488 |
| Ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00423488 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00413972 |
| Ezetimibe with Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00413972 |
| ezetimibe with simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00413972 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00413972 |
| Ezetimibe with Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00413972 |
| ezetimibe with simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00413972 |
| DRSP-EE | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00413062 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00413062 |
| DRSP-EE | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00413062 |
| NOMAC-E2 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT00413062 |
| Levocetirizine placebo capsule | Other | Phase PHASE4 | Hypersensitivity | COMPLETED | NCT00359138 |
| Desloratadine placebo tablet | Other | Phase PHASE4 | Hypersensitivity | COMPLETED | NCT00359138 |
| levocetirizine | Other | Phase PHASE4 | Hypersensitivity | COMPLETED | NCT00359138 |
| desloratadine | Other | Phase PHASE4 | Hypersensitivity | COMPLETED | NCT00359138 |
| Atorvastatin 10 mg | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00319449 |
| Placebo | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00319449 |
| Ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00319449 |
| Atorvastatin 10 mg | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00319449 |
| Placebo | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00319449 |
| Ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00319449 |
| Comparator: Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00289887 |
| Comparator: losartan +/- HCTZ | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00289887 |
| Comparator: Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00289887 |
| Comparator: losartan +/- HCTZ | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00289887 |
| Comparator: Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00289887 |
| Comparator: losartan +/- HCTZ | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00289887 |
| Asenapine | Other | Phase PHASE3 | Psychosis | COMPLETED | NCT00281320 |
| placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00276016 |
| pseudoephedrine | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00276016 |
| phenylephrine | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00276016 |
| placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00276016 |
| pseudoephedrine | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00276016 |
| phenylephrine | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00276016 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00265343 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00265343 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00265343 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00265343 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00265343 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00265343 |
| Comparator: diclofenac | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00264147 |
| Comparator: placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00264147 |
| etoricoxib | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00264147 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00174265 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00174265 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00174265 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00174265 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00174265 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00174265 |
| Olanzapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159783 |
| asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00159783 |
| Placebo to fluticasone | Other | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Fluticasone propionate | Other | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Placebo to montelukast | Other | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Montelukast sodium | Other | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Placebo to fluticasone | Other | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Fluticasone propionate | Other | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Placebo to montelukast | Other | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Montelukast sodium | Other | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| amlodipine/losartan | Other | Preclinical | Hypertension | COMPLETED | NCT01041807 |
| Comparator : atenolol /Duration of Treatment : 5 Years | Drug | Phase PHASE3 | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | COMPLETED | NCT00338260 |
| MK0954, /Duration of Treatment : 5 Years | Drug | Phase PHASE3 | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | COMPLETED | NCT00338260 |
| Comparator : atenolol /Duration of Treatment : 5 Years | Drug | Phase PHASE3 | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | COMPLETED | NCT00338260 |
| MK0954, /Duration of Treatment : 5 Years | Drug | Phase PHASE3 | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | COMPLETED | NCT00338260 |
| Placebo / Duration of Treatment: mean 3.4 years | Drug | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT00308347 |
| MK0954, losartan / Duration of Treatment: mean 3.4 years | Drug | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT00308347 |
| Comparator: placebo, losartan, hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00092209 |
| MK0954A, hydrochlorothiazide (+) losartan potassium | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00092209 |
| Comparator: placebo, losartan, hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00092209 |
| MK0954A, hydrochlorothiazide (+) losartan potassium | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00092209 |
| Comparator: diclofenac / Duration of Treatment: 4 weeks | Drug | Phase PHASE4 | Chronic Low Back Pain | COMPLETED | NCT00090181 |
| MK0663, etoricoxib / Duration of Treatment: 4 weeks | Drug | Phase PHASE4 | Chronic Low Back Pain | COMPLETED | NCT00090181 |
| Comparator: diclofenac / Duration of Treatment: 4 weeks | Drug | Phase PHASE4 | Chronic Low Back Pain | COMPLETED | NCT00090181 |
| MK0663, etoricoxib / Duration of Treatment: 4 weeks | Drug | Phase PHASE4 | Chronic Low Back Pain | COMPLETED | NCT00090181 |
| Estradiol (E2) | Other | Phase PHASE3 | Contraception | WITHDRAWN | NCT01723579 |
| Nomegestrol acetate (NOMAC) | Other | Phase PHASE3 | Contraception | WITHDRAWN | NCT01723579 |
| Estradiol (E2) | Other | Phase PHASE3 | Contraception | WITHDRAWN | NCT01723579 |
| Nomegestrol acetate (NOMAC) | Other | Phase PHASE3 | Contraception | WITHDRAWN | NCT01723579 |
| Estradiol (E2) | Other | Phase PHASE3 | Contraception | WITHDRAWN | NCT01723579 |
| Nomegestrol acetate (NOMAC) | Other | Phase PHASE3 | Contraception | WITHDRAWN | NCT01723579 |
| Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate | Other | Preclinical | Dyslipidemia | COMPLETED | NCT00726856 |
| Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate | Other | Preclinical | Dyslipidemia | COMPLETED | NCT00726856 |
| Statin | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT00723723 |
| Statin | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT00723723 |
| Ezetimibe + other lipid-lowering medication(s) | Drug | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705211 |
| Ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705211 |
| Ezetimibe + other lipid-lowering medication(s) | Drug | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705211 |
| Ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705211 |
| Ezetimibe + other lipid-lowering medication(s) | Drug | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705211 |
| Ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705211 |
| Ezetimibe + other lipid-lowering medication(s) | Drug | Preclinical | Hypercholesterolemia | COMPLETED | NCT00704444 |
| Ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00704444 |
| Ezetimibe + other lipid-lowering medication(s) | Drug | Preclinical | Hypercholesterolemia | COMPLETED | NCT00704444 |
| Ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00704444 |
| Ezetimibe + other lipid-lowering medication(s) | Drug | Preclinical | Hypercholesterolemia | COMPLETED | NCT00704444 |
| Ezetimibe | Other | Preclinical | Hypercholesterolemia | COMPLETED | NCT00704444 |
| pitavastatin | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00653913 |
| SCH 58235 | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00653913 |
| pitavastatin | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00653913 |
| SCH 58235 | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00653913 |
| Niaspan | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00652431 |
| Vytorin | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00652431 |
| Vytorin + Niaspan | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00652431 |
| Niaspan | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00652431 |
| Vytorin | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00652431 |
| Vytorin + Niaspan | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00652431 |
| MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days | Drug | Phase PHASE4 | Pain | COMPLETED | NCT00380523 |
| MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days | Drug | Phase PHASE4 | Pain | COMPLETED | NCT00380523 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212771 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212771 |
| olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212771 |
| asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00212771 |
| placebo | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00202904 |
| ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00202904 |
| placebo | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00202904 |
| ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00202904 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156091 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156091 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156091 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156091 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156091 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156091 |
| Comparator: amlodipine / Duration of Treatment: 20 weeks | Drug | Phase PHASE4 | Renal Disorder | COMPLETED | NCT00140985 |
| MK0954, losartan potassium/Duration of Treatment: 20 weeks | Drug | Phase PHASE4 | Renal Disorder | COMPLETED | NCT00140985 |
| Comparator: amlodipine / Duration of Treatment: 20 weeks | Drug | Phase PHASE4 | Renal Disorder | COMPLETED | NCT00140985 |
| MK0954, losartan potassium/Duration of Treatment: 20 weeks | Drug | Phase PHASE4 | Renal Disorder | COMPLETED | NCT00140985 |
| Comparator: amlodipine / Duration of Treatment: 20 weeks | Drug | Phase PHASE4 | Renal Disorder | COMPLETED | NCT00140985 |
| MK0954, losartan potassium/Duration of Treatment: 20 weeks | Drug | Phase PHASE4 | Renal Disorder | COMPLETED | NCT00140985 |
| MK0663, etoricoxib / Duration of Treatment: 4 weeks | Drug | Phase PHASE2 | Bone Neoplasms | WITHDRAWN | NCT00095017 |
| MK0663, etoricoxib / Duration of Treatment: 4 weeks | Drug | Phase PHASE2 | Bone Neoplasms | WITHDRAWN | NCT00095017 |
| Comparator: Diclofenac sodium | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00092742 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00092742 |
| Comparator: Diclofenac sodium | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00092742 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00092742 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882996 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882996 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882996 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882996 |
| desloratadine | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00805584 |
| desloratadine | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00805584 |
| desloratadine | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00805584 |
| Desloratadine | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00795522 |
| Desloratadine | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00795522 |
| Desloratadine | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00795522 |
| desloratadine | Other | Phase PHASE3 | Urticaria | COMPLETED | NCT00795158 |
| desloratadine | Other | Phase PHASE3 | Urticaria | COMPLETED | NCT00795158 |
| Cetirizine (Zyrtec) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794846 |
| Desloratadine 5 mg (Clarinex) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794846 |
| fexofenadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794768 |
| desloratadine 5 mg | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794768 |
| Cetirizine (Zyrtec) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794599 |
| Desloratadine 5 mg (Clarinex) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794599 |
| Cetirizine (Zyrtec) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794599 |
| Desloratadine 5 mg (Clarinex) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794599 |
| Cetirizine (Zyrtec) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794495 |
| Desloratadine 5 mg (Clarinex) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794495 |
| Cetirizine (Zyrtec) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794495 |
| Desloratadine 5 mg (Clarinex) | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794495 |
| fexofenadine | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794248 |
| desloratadine 5 mg | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794248 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00651404 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00651404 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00651404 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00651404 |
| Ezetimibe | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00651144 |
| Placebo | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00651144 |
| Rosuvastatin | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00651144 |
| Ezetimibe + Rosuvastatin | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00651144 |
| Placebo | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651014 |
| Ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651014 |
| Placebo | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651014 |
| Ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651014 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650689 |
| Ezetimibe + Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650689 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650689 |
| Ezetimibe + Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650689 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650689 |
| Ezetimibe + Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650689 |
| Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | Drug | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT00396175 |
| MK0906, finasteride / Duration of Treatment : 48 Weeks | Drug | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT00396175 |
| Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | Drug | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT00396175 |
| MK0906, finasteride / Duration of Treatment : 48 Weeks | Drug | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT00396175 |
| Etoricoxib | Other | Preclinical | Osteoarthritis | COMPLETED | NCT01685424 |
| Etoricoxib | Other | Preclinical | Osteoarthritis | COMPLETED | NCT01685424 |
| Etoricoxib | Other | Preclinical | Osteoarthritis | COMPLETED | NCT01685424 |
| Other Statin | Other | Phase PHASE4 | Dyslipidemia | WITHDRAWN | NCT01587235 |
| Ezetimibe/simvastatin | Other | Phase PHASE4 | Dyslipidemia | WITHDRAWN | NCT01587235 |
| Other Statin | Other | Phase PHASE4 | Dyslipidemia | WITHDRAWN | NCT01587235 |
| Ezetimibe/simvastatin | Other | Phase PHASE4 | Dyslipidemia | WITHDRAWN | NCT01587235 |
| Other Statin | Other | Phase PHASE4 | Dyslipidemia | WITHDRAWN | NCT01587235 |
| Ezetimibe/simvastatin | Other | Phase PHASE4 | Dyslipidemia | WITHDRAWN | NCT01587235 |
| Placebo for etoricoxib | Other | Phase PHASE4 | Osteoarthritis | WITHDRAWN | NCT01429168 |
| Etoricoxib | Other | Phase PHASE4 | Osteoarthritis | WITHDRAWN | NCT01429168 |
| No anti-inflammatory treatment | Drug | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Other Non-selective NSAIDs | Other | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Other Cox-2 inhibitors | Other | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Etoricoxib | Other | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| No anti-inflammatory treatment | Drug | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Other Non-selective NSAIDs | Other | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Other Cox-2 inhibitors | Other | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Etoricoxib | Other | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Placebo (Unspecified) | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652444 |
| simvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652444 |
| ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652444 |
| placebo nasal spray | Other | Phase PHASE4 | Nasal Obstruction | WITHDRAWN | NCT00553891 |
| mometasone furoate nasal spray | Other | Phase PHASE4 | Nasal Obstruction | WITHDRAWN | NCT00553891 |
| placebo nasal spray | Other | Phase PHASE4 | Nasal Obstruction | WITHDRAWN | NCT00553891 |
| mometasone furoate nasal spray | Other | Phase PHASE4 | Nasal Obstruction | WITHDRAWN | NCT00553891 |
| placebo nasal spray | Other | Phase PHASE4 | Nasal Obstruction | WITHDRAWN | NCT00553891 |
| mometasone furoate nasal spray | Other | Phase PHASE4 | Nasal Obstruction | WITHDRAWN | NCT00553891 |
| Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks | Drug | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393354 |
| MK0663, Etoricoxib / Duration of Treatment : 12 Weeks | Drug | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393354 |
| Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks | Drug | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393211 |
| MK0663, Etoricoxib / Duration of Treatment : 12 Weeks | Drug | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393211 |
| Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks | Drug | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393211 |
| MK0663, Etoricoxib / Duration of Treatment : 12 Weeks | Drug | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393211 |
| Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks | Drug | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393211 |
| MK0663, Etoricoxib / Duration of Treatment : 12 Weeks | Drug | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393211 |
| double cleavage-stage or single blastocyst stage embryos transfer | Other | Approved | Infertility, Female | UNKNOWN | NCT05632731 |
| SB5 (Adalimumab Biosimilar) | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT05510063 |
| Humira (Adalimumab) | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT05510063 |
| SB5 (Adalimumab Biosimilar) | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT05510063 |
| Humira (Adalimumab) | Other | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT05510063 |
| Complete Clinical Interaction | Other | Preclinical | Healthcare Disparities | UNKNOWN | NCT05013710 |
| Orgalutran | Other | Preclinical | Fertilization in Vitro | COMPLETED | NCT01304511 |
| Orgalutran | Other | Preclinical | Fertilization in Vitro | COMPLETED | NCT01304511 |
| Rizatriptan 10 mg Placebo | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| Rizatriptan 5 mg Placebo | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| rizatriptan benzoate (10 mg) | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| rizatriptan benzoate (5 mg) | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| Rizatriptan 10 mg Placebo | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| Rizatriptan 5 mg Placebo | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| rizatriptan benzoate (10 mg) | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| rizatriptan benzoate (5 mg) | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| Etonogestrel implant | Other | Preclinical | Endometrial Hyperplasia Without Atypia | UNKNOWN | NCT06378489 |
| MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT01437111 |
| MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT01437111 |
| rizatriptan benzoate | Other | Phase PHASE3 | Acute Migraine With or Without Aura in Adolescents | COMPLETED | NCT01004263 |
| rizatriptan benzoate | Other | Phase PHASE3 | Acute Migraine With or Without Aura in Adolescents | COMPLETED | NCT01004263 |
| Comparator: Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00516737 |
| Comparator: rizatriptan benzoate | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00516737 |
| Comparator: Calcium | Other | Phase PHASE4 | Osteoporosis Postmenopausal | COMPLETED | NCT00729651 |
| Comparator: Alendronate sodium (Fosamax) | Other | Phase PHASE4 | Osteoporosis Postmenopausal | COMPLETED | NCT00729651 |
| alendronate sodium (+) cholecalciferol | Other | Phase PHASE4 | Osteoporosis Postmenopausal | COMPLETED | NCT00729651 |
| Comparator: Calcium | Other | Phase PHASE4 | Osteoporosis Postmenopausal | COMPLETED | NCT00729651 |
| Comparator: Alendronate sodium (Fosamax) | Other | Phase PHASE4 | Osteoporosis Postmenopausal | COMPLETED | NCT00729651 |
| alendronate sodium (+) cholecalciferol | Other | Phase PHASE4 | Osteoporosis Postmenopausal | COMPLETED | NCT00729651 |
| placebo | Other | Phase PHASE3 | Migraine, Acute | COMPLETED | NCT01001234 |
| rizatriptan | Other | Phase PHASE3 | Migraine, Acute | COMPLETED | NCT01001234 |
| placebo | Other | Phase PHASE3 | Migraine, Acute | COMPLETED | NCT01001234 |
| rizatriptan | Other | Phase PHASE3 | Migraine, Acute | COMPLETED | NCT01001234 |
| Comparator: placebo | Other | Phase PHASE1 | Chronic Asthma | COMPLETED | NCT00739297 |
| Comparator: montelukast | Other | Phase PHASE1 | Chronic Asthma | COMPLETED | NCT00739297 |
| Comparator: placebo | Other | Phase PHASE1 | Chronic Asthma | COMPLETED | NCT00739297 |
| Comparator: montelukast | Other | Phase PHASE1 | Chronic Asthma | COMPLETED | NCT00739297 |
| Referred-Care Model | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00692913 |
| Calcium Supplement 500 mg | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00692913 |
| FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol) | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00692913 |
| Referred-Care Model | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00692913 |
| Calcium Supplement 500 mg | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00692913 |
| FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol) | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00692913 |
| Comparator: placebo (unspecified) | Other | Phase PHASE1 | Asthma, Exercise-induced | COMPLETED | NCT00664937 |
| montelukast sodium | Other | Phase PHASE1 | Asthma, Exercise-induced | COMPLETED | NCT00664937 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00636207 |
| Montelukast | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00636207 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00636207 |
| Montelukast | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00636207 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00636207 |
| Montelukast | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00636207 |
| Placebo for Ezetimibe | Other | Phase PHASE3 | Familial Hypercholesterolemia | COMPLETED | NCT03884452 |
| Ezetimibe | Other | Phase PHASE3 | Familial Hypercholesterolemia | COMPLETED | NCT03884452 |
| Simvastatin | Other | Phase PHASE3 | Familial Hypercholesterolemia | COMPLETED | NCT03884452 |
| Atorvastatin | Other | Phase PHASE3 | Familial Hypercholesterolemia | COMPLETED | NCT03884452 |
| Statin | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT03882905 |
| Simivastatin | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT03882905 |
| Placebo | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT03882905 |
| Ezetimibe | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT03882905 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882892 |
| Atovastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882892 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882892 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882892 |
| Atovastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882892 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882892 |
| Placebo for Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Placebo for Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Placebo for Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Placebo for Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Placebo for Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Placebo for Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Atorvastatin 80 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Atorvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Atorvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Atorvastatin 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Atorvastatin 80 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Atorvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Atorvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Atorvastatin 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Comparator: Sumatriptan | Other | Phase PHASE3 | Acute Migraine | COMPLETED | NCT00894556 |
| Comparator: Placebo | Other | Phase PHASE3 | Acute Migraine | COMPLETED | NCT00894556 |
| rizatriptan | Other | Phase PHASE3 | Acute Migraine | COMPLETED | NCT00894556 |
| Comparator: Sumatriptan | Other | Phase PHASE3 | Acute Migraine | COMPLETED | NCT00894556 |
| Comparator: Placebo | Other | Phase PHASE3 | Acute Migraine | COMPLETED | NCT00894556 |
| rizatriptan | Other | Phase PHASE3 | Acute Migraine | COMPLETED | NCT00894556 |
| Comparator: placebo (unspecified) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00666679 |
| Comparator: montelukast | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00666679 |
| Comparator: mometasone | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00666679 |
| MK0653, ezetimibe / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00395473 |
| MK0653, ezetimibe / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00395473 |
| MK0653, ezetimibe / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00395473 |
| Comparator: Placebo (unspecified) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00337675 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00337675 |
| Comparator: Placebo (unspecified) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00337675 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00337675 |
| Comparator: fluticasone | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00284856 |
| Comparator: Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00284856 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00284856 |
| Salmeterol matching placebo | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Montelukast matching placebo | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Fluticasone propionate | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Salmeterol xinafoate | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Montelukast sodium | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Salmeterol matching placebo | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Montelukast matching placebo | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Fluticasone propionate | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Salmeterol xinafoate | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Montelukast sodium | Other | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Comparator: placebo (unspecified) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00117338 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00117338 |
| Comparator: placebo (unspecified) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00117338 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00117338 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092690 |
| MK0653A, ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092690 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092690 |
| MK0653A, ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092690 |
| Test Meal | Other | Approved | Dyslipidemia | COMPLETED | NCT01333436 |
| Test Meal | Other | Approved | Dyslipidemia | COMPLETED | NCT01333436 |
| montelukast sodium | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00832455 |
| montelukast sodium | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00832455 |
| Comparator: Comparator: placebo (unspecified) | Other | Phase PHASE4 | Exercise-induced Bronchoconstriction (EIB) | COMPLETED | NCT00534976 |
| Comparator: montelukast sodium | Other | Phase PHASE4 | Exercise-induced Bronchoconstriction (EIB) | COMPLETED | NCT00534976 |
| Comparator: Comparator: placebo (unspecified) | Other | Phase PHASE4 | Exercise-induced Bronchoconstriction (EIB) | COMPLETED | NCT00534976 |
| Comparator: montelukast sodium | Other | Phase PHASE4 | Exercise-induced Bronchoconstriction (EIB) | COMPLETED | NCT00534976 |
| Comparator: Comparator: placebo (unspecified) | Other | Phase PHASE4 | Exercise-induced Bronchoconstriction (EIB) | COMPLETED | NCT00534976 |
| Comparator: montelukast sodium | Other | Phase PHASE4 | Exercise-induced Bronchoconstriction (EIB) | COMPLETED | NCT00534976 |
| inhaled corticosteroid | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00442559 |
| montelukast sodium | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00442559 |
| inhaled corticosteroid | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00442559 |
| montelukast sodium | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00442559 |
| Comparator: Placebo. | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| Comparator: ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| Comparator: Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| Comparator: Placebo. | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| Comparator: ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| Comparator: Placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| Comparator: rosuvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 10 mg + ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 5 mg + ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 10 mg + ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 5 mg + ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| MF MDI 200 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| MF DPI 200 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| mometasone furoate/formoterol 400/10 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| mometasone furoate/formoterol 200/10 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| mometasone furoate/formoterol 100/10 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| MF MDI 200 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| MF DPI 200 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| mometasone furoate/formoterol 400/10 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| mometasone furoate/formoterol 200/10 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| mometasone furoate/formoterol 100/10 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| Placebo | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00552110 |
| oxymetazoline nasal spray (OXY) twice daily | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00552110 |
| mometasone furoate nasal spray (MFNS) once daily | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00552110 |
| OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY) | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00552110 |
| Placebo (unspecified) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00418834 |
| atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00418834 |
| ezetimibe and atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00418834 |
| ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276484 |
| atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276484 |
| ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276484 |
| atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276484 |
| ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276484 |
| atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276484 |
| Placebo for atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03768427 |
| Placebo for FDC EZ/Ator | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03768427 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03768427 |
| EZ 10 mg/Ator 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03768427 |
| EZ 10 mg/Ator 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03768427 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| Albuterol/Salbutamol PRN | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF MDI 100 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF/F MDI 100/10 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF MDI 100 mcg BID (Open Label) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| Albuterol/Salbutamol PRN | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF MDI 100 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF/F MDI 100/10 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF MDI 100 mcg BID (Open Label) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| Albuterol/Salbutamol PRN | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF MDI 100 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF/F MDI 100/10 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF MDI 100 mcg BID (Open Label) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| Placebo for Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| Placebo for Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| Rosuvastatin 2.5 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| Ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| Placebo for Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| Placebo for Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| Rosuvastatin 2.5 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| Ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| Diet control/Daily Exercise | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02550288 |
| Placebo for Atorvastatin 10 mg capsule | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02550288 |
| Placebo for Ezetimibe 10 mg tablet | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02550288 |
| Atorvastatin 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02550288 |
| Ezetimibe 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02550288 |
| EZ 10 mg/Atorva 10 mg FDC | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02460159 |
| EZ 10 mg/Atorva 20 mg FDC | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02460159 |
| atorvastatin 10 mg or simvastatin 20 mg | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| Rosuvastatin | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| simvastatin 40 mg or atorvastatin 20 mg | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| atorvastatin 10 mg or simvastatin 20 mg | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| Rosuvastatin | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| simvastatin 40 mg or atorvastatin 20 mg | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| atorvastatin 10 mg or simvastatin 20 mg | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| Rosuvastatin | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| simvastatin 40 mg or atorvastatin 20 mg | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| atorvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00782184 |
| atorvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00782184 |
| ezetimibe/simvastatin 10/40 | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00782184 |
| atorvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00782184 |
| atorvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00782184 |
| ezetimibe/simvastatin 10/40 | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00782184 |
| Low Salt Diet | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00739674 |
| losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB]) | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00739674 |
| Low Salt Diet | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00739674 |
| losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB]) | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00739674 |
| Comparator: Valsartan (+) Hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00546754 |
| losartan potassium (+) hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00546754 |
| Comparator: Valsartan (+) Hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00546754 |
| losartan potassium (+) hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00546754 |
| losartan potassium (+) hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00546052 |
| losartan potassium (+) hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00546052 |
| Atorvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Ezetimibe 10 mg/simvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Atorvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Ezetimibe 10 mg/simvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Atorvastatin 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Atorvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Ezetimibe 10 mg/simvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Atorvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Ezetimibe 10 mg/simvastatin 20 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Atorvastatin 10 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00496730 |
| simvastatin (+) ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00496730 |
| Comparator: Placebo (unspecified) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00479713 |
| Comparator : rosuvastatin calcium | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00479713 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00479713 |
| Comparator: rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00462748 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00462748 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00462748 |
| Comparator: rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00462748 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00462748 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00462748 |
| Comparator: rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00462748 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00462748 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00462748 |
| Comparator: Placebo (unspecified) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| Comparator: atorvastatin calcium | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| Comparator: Placebo (unspecified) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| Comparator: atorvastatin calcium | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| Comparator: Placebo (unspecified) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| Comparator: atorvastatin calcium | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| Comparator: Placebo to niacin (ER) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: ezetimibe and simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: ezetimibe/simvastatin and niacin (ER) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: Placebo to Niacin (ER) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: niacin (ER) tablet | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: Placebo to ezetimibe/simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: ezetimibe/simvastatin + niacin (ER) | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: Placebo | Other | Phase PHASE3 | Aortic Stenosis | COMPLETED | NCT00092677 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Aortic Stenosis | COMPLETED | NCT00092677 |
| Comparator: Placebo | Other | Phase PHASE3 | Aortic Stenosis | COMPLETED | NCT00092677 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Aortic Stenosis | COMPLETED | NCT00092677 |
| Losartan 150 mg | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00090259 |
| Losartan 50 mg | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00090259 |
| Losartan 150 mg | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00090259 |
| Losartan 50 mg | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00090259 |
| Losartan 150 mg | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00090259 |
| Losartan 50 mg | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00090259 |
| LNG-EE 150 μg/30 μg COC | Other | Phase PHASE3 | Contraception | TERMINATED | NCT02616146 |
| ENG-E2 125 μg/300 μg vaginal ring | Other | Phase PHASE3 | Contraception | TERMINATED | NCT02616146 |
| ENG-E2 125 μg/300 μg vaginal ring | Other | Phase PHASE3 | Contraception | TERMINATED | NCT02524288 |
| ENG-E2 125 μg/300 μg vaginal ring | Other | Phase PHASE3 | Contraception | TERMINATED | NCT02524288 |
| ENG-E2 125 μg/300 μg vaginal ring | Other | Phase PHASE3 | Contraception | TERMINATED | NCT02524288 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT02320396 |
| Desloratadine 5 mg | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT02320396 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT02320396 |
| Desloratadine 5 mg | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT02320396 |
| Single-use, non-sterile applicator | Other | Phase PHASE3 | Contraception: Optional Applicator for Insertion of Vaginal Ring | COMPLETED | NCT02275546 |
| Placebo vaginal ring | Other | Phase PHASE3 | Contraception: Optional Applicator for Insertion of Vaginal Ring | COMPLETED | NCT02275546 |
| Single-use, non-sterile applicator | Other | Phase PHASE3 | Contraception: Optional Applicator for Insertion of Vaginal Ring | COMPLETED | NCT02275546 |
| Placebo vaginal ring | Other | Phase PHASE3 | Contraception: Optional Applicator for Insertion of Vaginal Ring | COMPLETED | NCT02275546 |
| Placebo to losartan 50 mg | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| Placebo to losartan 100 mg | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| Placebo to MK-0954A | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| Losartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| MK-0954A | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| Placebo to MK-954H | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| Placebo to MK-0954A | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| MK-954H | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| MK-0954A | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| Placebo to MK-954H | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| Placebo to MK-0954A | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| MK-954H | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| MK-0954A | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| Placebo to MK-954H | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| Placebo to MK-0954A | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| MK-954H | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| MK-0954A | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| Placebo | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00089895 |
| Eptifibatide (Integrilin) | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00089895 |
| Placebo | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00089895 |
| Eptifibatide (Integrilin) | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00089895 |
| Placebo | Other | Phase PHASE3 | Adenoids Hypertrophy | COMPLETED | NCT00552032 |
| Mometasone Furoate nasal spray | Other | Phase PHASE3 | Adenoids Hypertrophy | COMPLETED | NCT00552032 |
| Placebo | Other | Phase PHASE3 | Adenoids Hypertrophy | COMPLETED | NCT00552032 |
| Mometasone Furoate nasal spray | Other | Phase PHASE3 | Adenoids Hypertrophy | COMPLETED | NCT00552032 |
| Budesonide DPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00442117 |
| mometasone furoate dry powder inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00442117 |
| Budesonide DPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00442117 |
| mometasone furoate dry powder inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00442117 |
| Fluticasone propionate/salmeterol (F/SC) DPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00424008 |
| Mometasone furoate/formoterol (MF/F) MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00424008 |
| Fluticasone propionate/salmeterol (F/SC) DPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00424008 |
| Mometasone furoate/formoterol (MF/F) MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00424008 |
| Matching Placebo nasal spray plus antibiotic | Other | Phase PHASE3 | Sinusitis | TERMINATED | NCT00423176 |
| MFNS and antibiotic | Other | Phase PHASE3 | Sinusitis | TERMINATED | NCT00423176 |
| Matching Placebo nasal spray plus antibiotic | Other | Phase PHASE3 | Sinusitis | TERMINATED | NCT00423176 |
| MFNS and antibiotic | Other | Phase PHASE3 | Sinusitis | TERMINATED | NCT00423176 |
| Placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00406783 |
| 5-mg Desloratadine | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00406783 |
| Placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00406783 |
| 5-mg Desloratadine | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00406783 |
| Placebo tablet | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00405964 |
| 5-mg Desloratadine | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00405964 |
| Placebo tablet | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00405964 |
| 5-mg Desloratadine | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00405964 |
| Fluticasone/Salmeterol 500/50 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| Fluticasone/Salmeterol 250/50 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| mometasone furoate combination MDI 400/10 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| mometasone furoate combination MDI 200/10 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| Fluticasone/Salmeterol 500/50 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| Fluticasone/Salmeterol 250/50 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| mometasone furoate combination MDI 400/10 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| mometasone furoate combination MDI 200/10 mcg BID | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| Placebo nasal spray | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT00378378 |
| Mometasone Furoate Nasal Spray (MFNS) | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT00378378 |
| Placebo nasal spray | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT00378378 |
| Mometasone Furoate Nasal Spray (MFNS) | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT00378378 |
| Placebo for MFNS | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT01386125 |
| Mometasone Furoate Nasal Spray (MFNS) | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT01386125 |
| Placebo for MFNS | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT01386125 |
| Mometasone Furoate Nasal Spray (MFNS) | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT01386125 |
| Placebo for MFNS | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT01386125 |
| Mometasone Furoate Nasal Spray (MFNS) | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT01386125 |
| placebo | Other | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190254 |
| asenapine 5.0 mg | Other | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190254 |
| asenapine 2.5 mg | Other | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190254 |
| placebo | Other | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190254 |
| asenapine 5.0 mg | Other | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190254 |
| asenapine 2.5 mg | Other | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190254 |
| Placebo | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT00867165 |
| ezetimibe | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT00867165 |
| Placebo | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT00867165 |
| ezetimibe | Other | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT00867165 |
| Matching placebo nasal spray | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00733005 |
| Mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00733005 |
| Matching placebo nasal spray | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00733005 |
| Mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00733005 |
| Matching placebo nasal spray | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00732381 |
| Mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00732381 |
| atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00654095 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00654095 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00653523 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00653523 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00653523 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00653523 |
| Placebo nasal spray | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00599027 |
| Mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00599027 |
| Placebo nasal spray | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00599027 |
| Mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00599027 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00145470 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00145470 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00145470 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00145470 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00145470 |
| Asenapine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00145470 |
| asenapine | Other | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190267 |
| ezetimibe (+) simvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00654628 |
| ezetimibe (+) simvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00654628 |
| Comparator: carvedilol (+) hydrochlorothiazide | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| Comparator: losartan (+) hydrochlorothiazide (HCTZ) | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| Comparator: carvedilol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| losartan potassium | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| Comparator: carvedilol (+) hydrochlorothiazide | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| Comparator: losartan (+) hydrochlorothiazide (HCTZ) | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| Comparator: carvedilol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| losartan potassium | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| Comparator: atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00442897 |
| simvastatin (+) ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00442897 |
| Comparator: atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00442897 |
| simvastatin (+) ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00442897 |
| simvastatin 40 mg | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00423579 |
| Ezetimibe/Simvastatin 10/20 mg | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00423579 |
| simvastatin 40 mg | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00423579 |
| Ezetimibe/Simvastatin 10/20 mg | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00423579 |
| montelukast | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00394355 |
| fluticasone propionate hydrofluoroalkane (HFA) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00394355 |
| mometasone furoate dry powder inhaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00394355 |
| atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00166504 |
| ezetimibe (+) simvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00166504 |
| atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00166504 |
| ezetimibe (+) simvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00166504 |
| Mometasone Furoate DPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Placebo MDI without spacer | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Placebo MDI with spacer | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Formoterol Fumarate DPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Mometasone Furoate DPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Placebo MDI without spacer | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Placebo MDI with spacer | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Formoterol Fumarate DPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Asenapine 10 mg | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01206517 |
| Asenapine 5 mg | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01206517 |
| Asenapine 2.5 mg | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01206517 |
| Asenapine 10 mg | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01206517 |
| Asenapine 5 mg | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01206517 |
| Asenapine 2.5 mg | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01206517 |
| Rosuvastatin | Other | Phase PHASE4 | Primary Hypercholesterolemia | COMPLETED | NCT00871351 |
| Atorvastatin | Other | Phase PHASE4 | Primary Hypercholesterolemia | COMPLETED | NCT00871351 |
| Ezetimibe | Other | Phase PHASE4 | Primary Hypercholesterolemia | COMPLETED | NCT00871351 |
| Rosuvastatin | Other | Phase PHASE4 | Primary Hypercholesterolemia | COMPLETED | NCT00871351 |
| Atorvastatin | Other | Phase PHASE4 | Primary Hypercholesterolemia | COMPLETED | NCT00871351 |
| Ezetimibe | Other | Phase PHASE4 | Primary Hypercholesterolemia | COMPLETED | NCT00871351 |
| Comparator: placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00812006 |
| rizatriptan benzoate | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00812006 |
| Comparator: placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00812006 |
| rizatriptan benzoate | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00812006 |
| Comparator: Placebo | Other | Phase PHASE4 | Systemic Lupus Erythematosus | TERMINATED | NCT00739050 |
| simvastatin | Other | Phase PHASE4 | Systemic Lupus Erythematosus | TERMINATED | NCT00739050 |
| Enalapril Maleate | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Placebo (Losartan) | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Comparator: Placebo (amlodipine besylate) | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Comparator: amlodipine besylate | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Comparator: Placebo (Losartan) | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Losartan Potassium | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Enalapril Maleate | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Placebo (Losartan) | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Comparator: Placebo (amlodipine besylate) | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Comparator: amlodipine besylate | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Comparator: Placebo (Losartan) | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Losartan Potassium | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| montelukast sodium | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00545844 |
| montelukast sodium | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00545844 |
| 20-mg Desloratadine | Other | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| 10-mg Desloratadine | Other | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| 5-mg Desloratadine | Other | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| 20-mg Desloratadine | Other | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| 10-mg Desloratadine | Other | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| 5-mg Desloratadine | Other | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| 20-mg Desloratadine | Other | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| 10-mg Desloratadine | Other | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| 5-mg Desloratadine | Other | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| Placebo | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00521599 |
| Mometasone furoate dry powder inhaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00521599 |
| Placebo | Other | Phase PHASE4 | Perennial Allergic Rhinitis | COMPLETED | NCT00359216 |
| Mometasone furoate nasal spray | Other | Phase PHASE4 | Perennial Allergic Rhinitis | COMPLETED | NCT00359216 |
| hCG | Other | Phase PHASE3 | Hypogonadism | COMPLETED | NCT01709331 |
| Corifollitropin alfa | Other | Phase PHASE3 | Hypogonadism | COMPLETED | NCT01709331 |
| hCG | Other | Phase PHASE3 | Hypogonadism | COMPLETED | NCT01709331 |
| Corifollitropin alfa | Other | Phase PHASE3 | Hypogonadism | COMPLETED | NCT01709331 |
| hCG | Other | Phase PHASE3 | Hypogonadism | COMPLETED | NCT01709331 |
| Corifollitropin alfa | Other | Phase PHASE3 | Hypogonadism | COMPLETED | NCT01709331 |
| Placebo | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT01611883 |
| Ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT01611883 |
| Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01566149 |
| Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01566149 |
| Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01566149 |
| Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01566149 |
| Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing) | Other | Phase PHASE4 | Contraception | COMPLETED | NCT01490190 |
| Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing) | Other | Phase PHASE4 | Contraception | COMPLETED | NCT01490190 |
| mometasone furoate | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01165424 |
| mometasone furoate | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01165424 |
| Mometasone Furoate | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00687531 |
| Estradiol (E2) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Ethinyl estradiol (EE) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Etonogestrel (ENG) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Nomegestrol acetate (NOMAC) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Estradiol (E2) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Ethinyl estradiol (EE) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Etonogestrel (ENG) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Nomegestrol acetate (NOMAC) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Estradiol (E2) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Ethinyl estradiol (EE) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Etonogestrel (ENG) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Nomegestrol acetate (NOMAC) | Other | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Ibuprofen | Other | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| Placebo | Other | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| Etonogestrel containing contraceptive vaginal ring (ENG-CVR) | Other | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR) | Other | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| Ibuprofen | Other | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| Placebo | Other | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| Etonogestrel containing contraceptive vaginal ring (ENG-CVR) | Other | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR) | Other | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01244828 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01244828 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01142596 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01142596 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01142596 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01142596 |
| Placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01135134 |
| Mometasone furoate | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01135134 |
| Placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01135134 |
| Mometasone furoate | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01135134 |
| mometasone furoate nasal spray | Other | Phase PHASE4 | Adenoids | COMPLETED | NCT01098071 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00755794 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00755794 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00755794 |
| atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00157924 |
| simvastatin (+) ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00157924 |
| atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00157924 |
| simvastatin (+) ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00157924 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01857063 |
| Montelukast | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01857063 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01857063 |
| Montelukast | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01857063 |
| Placebo Dry Powder Inhaler (DPI) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Placebo Metered Dose Inhaler (MDI) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Placebo Dry Powder Inhaler (DPI) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Placebo Metered Dose Inhaler (MDI) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| hCG Bolus injection | Other | Phase PHASE2 | Ovulation Induction | TERMINATED | NCT00697255 |
| human Chorion Gonadotropin (hCG) | Other | Phase PHASE2 | Ovulation Induction | TERMINATED | NCT00697255 |
| recombinant Follicle Stimulating Hormone (recFSH) | Other | Phase PHASE2 | Ovulation Induction | TERMINATED | NCT00697255 |
| corifollitropin alfa | Other | Phase PHASE2 | Ovulation Induction | TERMINATED | NCT00697255 |
| Placebo | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01918033 |
| Desloratadine 5 mg | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01918033 |
| Placebo | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01918033 |
| Desloratadine 5 mg | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01918033 |
| Desloratadine 5 mg | Other | Phase PHASE3 | Eczema | COMPLETED | NCT01916980 |
| Desloratadine 5 mg | Other | Phase PHASE3 | Eczema | COMPLETED | NCT01916980 |
| Placebo | Other | Phase PHASE3 | Urticaria | COMPLETED | NCT01916967 |
| Desloratadine | Other | Phase PHASE3 | Urticaria | COMPLETED | NCT01916967 |
| Montelukast Chewable Tablets (CT) | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01852812 |
| Montelukast Oral Granules (OG) | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01852812 |
| Montelukast Chewable Tablets (CT) | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01852812 |
| Montelukast Oral Granules (OG) | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01852812 |
| Montelukast Chewable Tablets (CT) | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01852812 |
| Montelukast Oral Granules (OG) | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01852812 |
| Placebo Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Placebo Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Placebo Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Olanzapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Placebo Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Asenapine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Part II- Placebo to naproxen 500 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II - Placebo to etoricoxib 90 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II- Placebo to etoricoxib 60 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - Placebo to etoricoxib 90 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - Placebo to etoricoxib 60 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II- naproxen 1000 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II- etoricoxib 90 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II- etoricoxib 60 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - Placebo to naproxen 500 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I- naproxen 1000 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - etoricoxib 90 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - etoricoxib 60 mg | Other | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Placebo to Etoricoxib 90 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Placebo to Etoricoxib 60 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Etoricoxib 90 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Etoricoxib 60 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Placebo to Etoricoxib 90 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Placebo to Etoricoxib 60 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Etoricoxib 90 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Etoricoxib 60 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Placebo to Etoricoxib 90 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Placebo to Etoricoxib 60 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Etoricoxib 90 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Etoricoxib 60 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Placebo | Other | Phase PHASE3 | Bipolar 1 Disorder | COMPLETED | NCT00764478 |
| Asenapine | Other | Phase PHASE3 | Bipolar 1 Disorder | COMPLETED | NCT00764478 |
| Placebo | Other | Phase PHASE3 | Bipolar 1 Disorder | COMPLETED | NCT00764478 |
| Asenapine | Other | Phase PHASE3 | Bipolar 1 Disorder | COMPLETED | NCT00764478 |
| losartan potassium | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00756938 |
| losartan potassium | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00756938 |
| open-label recFSH | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| placebo-corifollitropin alfa | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| placebo-recFSH (follitropin alfa) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| progesterone | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| human chorion gonadatropin (hCG) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| gonadatropin releasing hormone (GnRH) antagonist (ganirelix) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| recFSH (follitropin beta) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| corifollitropin alfa (Org 36286) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| open-label recFSH | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| placebo-corifollitropin alfa | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| placebo-recFSH (follitropin alfa) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| progesterone | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| human chorion gonadatropin (hCG) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| gonadatropin releasing hormone (GnRH) antagonist (ganirelix) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| recFSH (follitropin beta) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| corifollitropin alfa (Org 36286) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| Progesterone | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| (rec)hCG | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| GnRH antagonist | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| FSH | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| Corifollitropin alfa | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| Progesterone | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| (rec)hCG | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| GnRH antagonist | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| FSH | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| Corifollitropin alfa | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696878 |
| Placebo for Losartan/HCTZ | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT00447603 |
| Placebo for Losartan | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT00447603 |
| losartan potassium | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT00447603 |
| hydrochlorothiazide (+) losartan potassium | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT00447603 |
| Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| Placebo for simvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| ezetimibe/simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| Placebo for simvastatin 40 mg | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| ezetimibe/simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| Comparator: placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00101439 |
| ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00101439 |
| DRSP 3 mg + EE 30 µg | Other | Phase PHASE3 | Contraception | COMPLETED | NCT01277211 |
| ENG 120 µg + EE 15 µg intravaginal ring | Other | Phase PHASE3 | Contraception | COMPLETED | NCT01277211 |
| Rescue medication | Drug | Phase PHASE3 | Bipolar Disorder, Pediatric | COMPLETED | NCT01244815 |
| Placebo to match asenapine | Other | Phase PHASE3 | Bipolar Disorder, Pediatric | COMPLETED | NCT01244815 |
| asenapine | Other | Phase PHASE3 | Bipolar Disorder, Pediatric | COMPLETED | NCT01244815 |
| Rescue medication | Drug | Phase PHASE3 | Bipolar Disorder, Pediatric | COMPLETED | NCT01244815 |
| Placebo to match asenapine | Other | Phase PHASE3 | Bipolar Disorder, Pediatric | COMPLETED | NCT01244815 |
| asenapine | Other | Phase PHASE3 | Bipolar Disorder, Pediatric | COMPLETED | NCT01244815 |
| recFSH (follitropin beta) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01146418 |
| Corifollitropin alfa | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01146418 |
| recFSH (follitropin beta) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01146418 |
| Corifollitropin alfa | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01146418 |
| recFSH (follitropin beta) | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01146418 |
| Corifollitropin alfa | Other | Phase PHASE3 | Infertility | COMPLETED | NCT01146418 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01098110 |
| Asenapine 10 mg | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01098110 |
| Asenapine 5 mg | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01098110 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01098110 |
| Asenapine 10 mg | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01098110 |
| Asenapine 5 mg | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01098110 |
| Progesterone | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| hCG | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Ganirelix | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| RecFSH / Follitropin beta (Days 8 to hCG) | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Placebo RecFSH / follitropin beta | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Placebo Corifollitropin alfa | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| RecFSH / Follitropin beta (Days 1 to 7) | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Corifollitropin alfa | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Progesterone | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| hCG | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Ganirelix | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| RecFSH / Follitropin beta (Days 8 to hCG) | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Placebo RecFSH / follitropin beta | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Placebo Corifollitropin alfa | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| RecFSH / Follitropin beta (Days 1 to 7) | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Corifollitropin alfa | Other | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 50 mg 4% DMSO | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Placebo | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 163 mg 4% DMSO gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 150 mg 4% PG Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 150 mg 4% DMSO Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 75 mg 4% PG Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 75 mg 4% DMSO Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 50 mg 4% DMSO | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Placebo | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 163 mg 4% DMSO gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 150 mg 4% PG Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 150 mg 4% DMSO Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 75 mg 4% PG Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 75 mg 4% DMSO Gel | Other | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| MK0217/Duration of Treatment : 12 Months | Drug | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00480766 |
| MK0217/Duration of Treatment : 12 Months | Drug | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00480766 |
| MK0217/Duration of Treatment : 12 Months | Drug | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00480766 |
| alendronate | Other | Phase PHASE3 | Paget's Disease of Bone | COMPLETED | NCT00480662 |
| alendronate | Other | Phase PHASE3 | Paget's Disease of Bone | COMPLETED | NCT00480662 |
| Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00395408 |
| MK0476, montelukast sodium / Duration of Treatment : 56 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00395408 |
| Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00395408 |
| MK0476, montelukast sodium / Duration of Treatment : 56 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00395408 |
| MK-0476, montelukast sodium | Other | Phase PHASE2 | Bronchiolitis | COMPLETED | NCT00394069 |
| MK-0476, montelukast sodium | Other | Phase PHASE2 | Bronchiolitis | COMPLETED | NCT00394069 |
| MK-0476, montelukast sodium | Other | Phase PHASE2 | Bronchiolitis | COMPLETED | NCT00394069 |
| Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00389740 |
| MK0217, /Duration of Treatment : 12 Months | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00389740 |
| Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00389740 |
| MK0217, /Duration of Treatment : 12 Months | Drug | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00389740 |
| Comparator: placebo | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00140881 |
| MK0476; montelukast sodium | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00140881 |
| Comparator: placebo | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00140881 |
| MK0476; montelukast sodium | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00140881 |
| Comparator: placebo / Duration of Treatment - 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111722 |
| MK0462, rizatriptan benzoate / Duration of Treatment -1day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111722 |
| Comparator: placebo / Duration of Treatment - 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111722 |
| MK0462, rizatriptan benzoate / Duration of Treatment -1day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111722 |
| Comparator: placebo / Duration of Treatment - 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111709 |
| MK0462, rizatriptan benzoate / Duration of Treatment -1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111709 |
| Comparator: placebo / Duration of Treatment - 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111709 |
| MK0462, rizatriptan benzoate / Duration of Treatment -1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111709 |
| Comparator: placebo / Duration of Treatment - 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111709 |
| MK0462, rizatriptan benzoate / Duration of Treatment -1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00111709 |
| Comparator: placebo / Duration of Treatment: 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00095004 |
| MK0462, rizatriptan benzoate / Duration of Treatment: 1day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00095004 |
| Comparator: placebo / Duration of Treatment: 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00095004 |
| MK0462, rizatriptan benzoate / Duration of Treatment: 1day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00095004 |
| Comparator: placebo / Duration of Treatment: 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00095004 |
| MK0462, rizatriptan benzoate / Duration of Treatment: 1day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00095004 |
| Comparator: placebo / Duration of Treatment: 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00092963 |
| MK0462, rizatriptan benzoate / Duration of Treatment: 1day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00092963 |
| Comparator: placebo / Duration of Treatment: 1 day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00092963 |
| MK0462, rizatriptan benzoate / Duration of Treatment: 1day | Drug | Phase PHASE3 | Migraine | COMPLETED | NCT00092963 |
| Comparator: placebo | Other | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00092105 |
| MK0476, montelukast sodium | Other | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00092105 |
| Comparator: placebo | Other | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00092105 |
| MK0476, montelukast sodium | Other | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00092105 |
| Placebo to budesonide inhaler | Other | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Placebo to montelukast chewable tablets | Other | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Budesonide inhaler | Other | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Montelukast chewable tablets | Other | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Placebo to budesonide inhaler | Other | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Placebo to montelukast chewable tablets | Other | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Budesonide inhaler | Other | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Montelukast chewable tablets | Other | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks | Drug | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00092066 |
| MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks | Drug | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00092066 |
| MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks | Drug | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00092066 |
| Comparator: risedronate / Duration of Intervention: 12 mo | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00092040 |
| MK0217, alendronate sodium/Duration of Intervention: 12 mo | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00092040 |
| Comparator: placebo / Duration of Treatment: 6 months | Drug | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092027 |
| MK0217, alendronate sodium/Duration of Treatment: 6 months | Drug | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092027 |
| Comparator: placebo / Duration of Treatment: 6 months | Drug | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092027 |
| MK0217, alendronate sodium/Duration of Treatment: 6 months | Drug | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092027 |
| Alendronate placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Risendronate placebo | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Vitamin D | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Elemental Calcium | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Risedronate 35 mg | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Alendronate | Other | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Placebo | Other | Phase PHASE3 | Chronic Idiopathic Urticaria | COMPLETED | NCT00757562 |
| desloratadine | Other | Phase PHASE3 | Chronic Idiopathic Urticaria | COMPLETED | NCT00757562 |
| Placebo | Other | Phase PHASE3 | Chronic Idiopathic Urticaria | COMPLETED | NCT00757562 |
| desloratadine | Other | Phase PHASE3 | Chronic Idiopathic Urticaria | COMPLETED | NCT00757562 |
| Theophylline | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00756418 |
| montelukast | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00756418 |
| Theophylline | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00756418 |
| montelukast | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00756418 |
| Theophylline | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00756418 |
| montelukast | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00756418 |
| cetirizine | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00751218 |
| placebo | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00751218 |
| desloratadine | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00751218 |
| cetirizine | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00751218 |
| placebo | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00751218 |
| desloratadine | Other | Phase PHASE4 | Urticaria | COMPLETED | NCT00751218 |
| placebo | Other | Phase PHASE4 | Urticaria | TERMINATED | NCT00751166 |
| Cetirizine | Other | Phase PHASE4 | Urticaria | TERMINATED | NCT00751166 |
| Desloratadine | Other | Phase PHASE4 | Urticaria | TERMINATED | NCT00751166 |
| Placebo | Other | Phase PHASE3 | Acute Rhinosinusitis | COMPLETED | NCT00751075 |
| Amoxicillin | Other | Phase PHASE3 | Acute Rhinosinusitis | COMPLETED | NCT00751075 |
| MFNS | Other | Phase PHASE3 | Acute Rhinosinusitis | COMPLETED | NCT00751075 |
| mometasone furoate nasal spray (MFNS) | Other | Phase PHASE3 | Acute Rhinosinusitis | COMPLETED | NCT00751075 |
| Placebo | Other | Phase PHASE2 | Acute Rhinosinusitis | COMPLETED | NCT00750750 |
| Amoxicillin | Other | Phase PHASE2 | Acute Rhinosinusitis | COMPLETED | NCT00750750 |
| MFNS | Other | Phase PHASE2 | Acute Rhinosinusitis | COMPLETED | NCT00750750 |
| mometasone furoate nasal spray (MFNS) | Other | Phase PHASE2 | Acute Rhinosinusitis | COMPLETED | NCT00750750 |
| Placebo | Other | Phase PHASE2 | Acute Rhinosinusitis | COMPLETED | NCT00750750 |
| Amoxicillin | Other | Phase PHASE2 | Acute Rhinosinusitis | COMPLETED | NCT00750750 |
| MFNS | Other | Phase PHASE2 | Acute Rhinosinusitis | COMPLETED | NCT00750750 |
| mometasone furoate nasal spray (MFNS) | Other | Phase PHASE2 | Acute Rhinosinusitis | COMPLETED | NCT00750750 |
| Mometasone furoate | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00732368 |
| Placebo | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT00731185 |
| Mometasone Furoate Nasal Spray | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT00731185 |
| Placebo | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT00731185 |
| Mometasone Furoate Nasal Spray | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT00731185 |
| placebo | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00725374 |
| tibolone | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00725374 |
| placebo | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00725374 |
| tibolone | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00725374 |
| Pregnyl® | Other | Phase PHASE2 | Infertility | COMPLETED | NCT00702806 |
| Orgalutran® | Other | Phase PHASE2 | Infertility | COMPLETED | NCT00702806 |
| Puregon® | Other | Phase PHASE2 | Infertility | COMPLETED | NCT00702806 |
| Org 36286 | Other | Phase PHASE2 | Infertility | COMPLETED | NCT00702806 |
| Placebo | Other | Phase PHASE2 | Infertility | COMPLETED | NCT00702585 |
| Org 36286 | Other | Phase PHASE2 | Infertility | COMPLETED | NCT00702585 |
| Placebo | Other | Phase PHASE2 | Infertility | COMPLETED | NCT00702585 |
| Org 36286 | Other | Phase PHASE2 | Infertility | COMPLETED | NCT00702585 |
| recFSH | Other | Preclinical | Pregnancy | COMPLETED | NCT00702195 |
| Placebo | Other | Preclinical | Pregnancy | COMPLETED | NCT00702195 |
| Org 36286 (corifollitropin alfa) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702195 |
| recFSH | Other | Preclinical | Pregnancy | COMPLETED | NCT00702195 |
| Placebo | Other | Preclinical | Pregnancy | COMPLETED | NCT00702195 |
| Org 36286 (corifollitropin alfa) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702195 |
| placebo (unspecified) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00700661 |
| montelukast | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00700661 |
| placebo (unspecified) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00700661 |
| montelukast | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00700661 |
| Simvastatin | Other | Phase PHASE4 | Hypercholesterolaemia | COMPLETED | NCT00653835 |
| Ezetimibe + Simvastatin | Other | Phase PHASE4 | Hypercholesterolaemia | COMPLETED | NCT00653835 |
| Simvastatin | Other | Phase PHASE4 | Hypercholesterolaemia | COMPLETED | NCT00653835 |
| Ezetimibe + Simvastatin | Other | Phase PHASE4 | Hypercholesterolaemia | COMPLETED | NCT00653835 |
| Atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00653796 |
| Ezetimibe + Atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00653796 |
| Atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00653796 |
| Ezetimibe + Atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00653796 |
| Comparator: cyclosporine | Other | Phase PHASE1 | Cholesterol | COMPLETED | NCT00653276 |
| ezetimibe | Other | Phase PHASE1 | Cholesterol | COMPLETED | NCT00653276 |
| statins | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652847 |
| ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652847 |
| statins | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652847 |
| ezetimibe | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652847 |
| simvastatin | Other | Phase PHASE4 | Cardiovascular Disorder | COMPLETED | NCT00652717 |
| Ezetimibe | Other | Phase PHASE4 | Cardiovascular Disorder | COMPLETED | NCT00652717 |
| simvastatin | Other | Phase PHASE4 | Cardiovascular Disorder | COMPLETED | NCT00652717 |
| Ezetimibe | Other | Phase PHASE4 | Cardiovascular Disorder | COMPLETED | NCT00652717 |
| simvastatin | Other | Phase PHASE3 | Cholesterol | COMPLETED | NCT00652301 |
| Comparator: Placebo (unspecified) | Other | Phase PHASE3 | Cholesterol | COMPLETED | NCT00652301 |
| ezetimibe | Other | Phase PHASE3 | Cholesterol | COMPLETED | NCT00652301 |
| simvastatin | Other | Phase PHASE3 | Cholesterol | COMPLETED | NCT00652301 |
| Comparator: Placebo (unspecified) | Other | Phase PHASE3 | Cholesterol | COMPLETED | NCT00652301 |
| ezetimibe | Other | Phase PHASE3 | Cholesterol | COMPLETED | NCT00652301 |
| ezetimibe | Other | Phase PHASE4 | Lipid Metabolism Disorder | COMPLETED | NCT00651963 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT00651560 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT00651560 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00651391 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00651391 |
| Ezetimibe + Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00651391 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00651391 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00651391 |
| Ezetimibe + Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00651391 |
| Double Atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651378 |
| Ezetimibe + Atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651378 |
| Rosuvastatin | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651378 |
| Double Atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651378 |
| Ezetimibe + Atorvastatin | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651378 |
| Rosuvastatin | Other | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651378 |
| Placebo | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00651274 |
| Ezetimibe | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00651274 |
| Placebo | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00651274 |
| Ezetimibe | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00651274 |
| Placebo | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00651274 |
| Ezetimibe | Other | Phase PHASE4 | Atherosclerosis | COMPLETED | NCT00651274 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650819 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650819 |
| Ezetimibe + Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650819 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650819 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650819 |
| Ezetimibe + Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650819 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650819 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650819 |
| Ezetimibe + Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00650819 |
| Simvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00650663 |
| Ezetimibe + Simvastatin | Other | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00650663 |
| Follitropin beta injection | Other | Phase PHASE2 | Fertilization | COMPLETED | NCT00598208 |
| corifollitropin alfa | Other | Phase PHASE2 | Fertilization | COMPLETED | NCT00598208 |
| Follitropin beta injection | Other | Phase PHASE2 | Fertilization | COMPLETED | NCT00598208 |
| corifollitropin alfa | Other | Phase PHASE2 | Fertilization | COMPLETED | NCT00598208 |
| placebo (plus simvastatin) | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00552097 |
| ezetimibe (plus simvastatin) | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00552097 |
| placebo (plus simvastatin) | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00552097 |
| ezetimibe (plus simvastatin) | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00552097 |
| placebo (plus simvastatin) | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00552097 |
| ezetimibe (plus simvastatin) | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00552097 |
| Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks | Drug | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00551876 |
| MK0653, ezetimibe / Duration of Treatment: 30 Weeks | Drug | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00551876 |
| Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks | Drug | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00551876 |
| MK0653, ezetimibe / Duration of Treatment: 30 Weeks | Drug | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00551876 |
| Comparator: simvastatin / Duration of Treatment: 27 Weeks | Drug | Phase PHASE3 | Coronary Disease | COMPLETED | NCT00551447 |
| MK0733, simvastatin / Duration of Treatment: 27 Weeks | Drug | Phase PHASE3 | Coronary Disease | COMPLETED | NCT00551447 |
| MK0653, ezetimibe / Duration of Treatment: 27 Weeks | Drug | Phase PHASE3 | Coronary Disease | COMPLETED | NCT00551447 |
| Comparator: simvastatin / Duration of Treatment: 27 Weeks | Drug | Phase PHASE3 | Coronary Disease | COMPLETED | NCT00551447 |
| MK0733, simvastatin / Duration of Treatment: 27 Weeks | Drug | Phase PHASE3 | Coronary Disease | COMPLETED | NCT00551447 |
| MK0653, ezetimibe / Duration of Treatment: 27 Weeks | Drug | Phase PHASE3 | Coronary Disease | COMPLETED | NCT00551447 |
| Comparator: Fluticasone / Duration of Treatment: 6 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00545324 |
| MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00545324 |
| Comparator: Fluticasone / Duration of Treatment: 6 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00545324 |
| MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00545324 |
| Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00542087 |
| MK0663, etoricoxib / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00542087 |
| Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00542087 |
| MK0663, etoricoxib / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00542087 |
| Comparator: atorvastatin / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00541697 |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00541697 |
| Comparator: atorvastatin / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00541697 |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00541697 |
| Comparator : atenolol /Duration of Treatment : 16 Weeks | Drug | Phase PHASE3 | Hypertension | COMPLETED | NCT00541684 |
| MK0954, /Duration of Treatment : 16 Weeks | Drug | Phase PHASE3 | Hypertension | COMPLETED | NCT00541684 |
| Comparator : atenolol /Duration of Treatment : 16 Weeks | Drug | Phase PHASE3 | Hypertension | COMPLETED | NCT00541684 |
| MK0954, /Duration of Treatment : 16 Weeks | Drug | Phase PHASE3 | Hypertension | COMPLETED | NCT00541684 |
| Comparator : fluticasone propionate / Duration of Treatment: 1 Year | Drug | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00489346 |
| MK0476, montelukast sodium / Duration of Treatment: 1 Year | Drug | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00489346 |
| Comparator : fluticasone propionate / Duration of Treatment: 1 Year | Drug | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00489346 |
| MK0476, montelukast sodium / Duration of Treatment: 1 Year | Drug | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00489346 |
| Comparator : fluticasone propionate / Duration of Treatment: 1 Year | Drug | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00489346 |
| MK0476, montelukast sodium / Duration of Treatment: 1 Year | Drug | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00489346 |
| Comparator : ramipril /Duration of Treatment : 8 Weeks | Drug | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00480805 |
| MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks | Drug | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00480805 |
| Comparator : ramipril /Duration of Treatment : 8 Weeks | Drug | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00480805 |
| MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks | Drug | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00480805 |
| Comparator : ramipril /Duration of Treatment : 8 Weeks | Drug | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00480805 |
| MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks | Drug | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00480805 |
| MK0653, ezetimibe / Duration of Treatment: 4 Weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00457275 |
| MK0653, ezetimibe / Duration of Treatment: 4 Weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00457275 |
| MK0954, losartan potassium / Duration of Treatment - 12 weeks | Drug | Phase PHASE3 | Hypertension | TERMINATED | NCT00449111 |
| MK0954, losartan potassium / Duration of Treatment - 12 weeks | Drug | Phase PHASE3 | Hypertension | TERMINATED | NCT00449111 |
| MK0954, losartan potassium / Duration of Treatment - 12 weeks | Drug | Phase PHASE3 | Hypertension | TERMINATED | NCT00449111 |
| Comparator: placebo / Duration of Treatment: 2 Weeks | Drug | Phase PHASE2 | Rhinitis Allergic | COMPLETED | NCT00446186 |
| MK0476, montelukast sodium / Duration of Treatment: 2 Weeks | Drug | Phase PHASE2 | Rhinitis Allergic | COMPLETED | NCT00446186 |
| Comparator: ketotifen / Duration of Treatment: 4 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00446056 |
| MK0476, montelukast sodium / Duration of Treatment: 4 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00446056 |
| Comparator: ketotifen / Duration of Treatment: 4 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00446056 |
| MK0476, montelukast sodium / Duration of Treatment: 4 Weeks | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT00446056 |
| MK0476, montelukast sodium / Duration of Treatment: 8 Weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00445107 |
| MK0476, montelukast sodium / Duration of Treatment: 8 Weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00445107 |
| raloxifen | Other | Phase PHASE4 | Osteopenia | COMPLETED | NCT00431431 |
| tibolone | Other | Phase PHASE4 | Osteopenia | COMPLETED | NCT00431431 |
| raloxifen | Other | Phase PHASE4 | Osteopenia | COMPLETED | NCT00431431 |
| tibolone | Other | Phase PHASE4 | Osteopenia | COMPLETED | NCT00431431 |
| Loratadine/montelukast combination | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00423995 |
| Loratadine/montelukast combination | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00423995 |
| MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks | Drug | Phase PHASE3 | Hypertension | COMPLETED | NCT00400218 |
| MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks | Drug | Phase PHASE3 | Hypertension | COMPLETED | NCT00400218 |
| losartan potassium (+) hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00398541 |
| losartan potassium (+) hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00398541 |
| MK0733, simvastatin / Duration of Treatment: 12 Weeks | Drug | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00398294 |
| MK0733, simvastatin / Duration of Treatment: 12 Weeks | Drug | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00398294 |
| MK0476, montelukast sodium / Duration of Treatment: 12 Weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00398151 |
| MK0476, montelukast sodium / Duration of Treatment: 12 Weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00398151 |
| Comparator: atorvastatin / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Cardiovascular Diseases | TERMINATED | NCT00395603 |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Cardiovascular Diseases | TERMINATED | NCT00395603 |
| Comparator: atorvastatin / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Cardiovascular Diseases | TERMINATED | NCT00395603 |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks | Drug | Phase PHASE3 | Cardiovascular Diseases | TERMINATED | NCT00395603 |
| MK0476, Montelukast Sodium /Duration of Treatment : 14 Days | Drug | Phase PHASE2 | Bronchiolitis | COMPLETED | NCT00394160 |
| Comparator: placebo / Duration of Treatment: 48 weeks | Drug | Phase PHASE3 | Benign Prostatic Hyperplasia | COMPLETED | NCT00127179 |
| MK0906, finasteride / Duration of Treatment: 48 weeks | Drug | Phase PHASE3 | Benign Prostatic Hyperplasia | COMPLETED | NCT00127179 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00110435 |
| Duration of Treatment: 4 wk placebo run in then 6 wk active | Drug | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00110435 |
| MK0653A, ezetimibe (+) simvastatin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00110435 |
| ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hyperlipidemia | COMPLETED | NCT00093899 |
| placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00092989 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00092989 |
| placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00092989 |
| montelukast sodium | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00092989 |
| Comparator: placebo | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092898 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092898 |
| Comparator: placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00092885 |
| MK0476, montelukast sodium | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00092885 |
| Comparator: placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00092885 |
| MK0476, montelukast sodium | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00092885 |
| Comparator: ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia, Familial | TERMINATED | NCT00092833 |
| Comparator: ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia, Familial | TERMINATED | NCT00092833 |
| Comparator: ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia, Familial | TERMINATED | NCT00092833 |
| Comparator: placebo | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092820 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092820 |
| Comparator: placebo | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092820 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092820 |
| Comparator: placebo | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092820 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092820 |
| Comparator: placebo | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092807 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092807 |
| Comparator: placebo | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092807 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092807 |
| Comparator: celecoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092781 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092781 |
| Comparator: celecoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092781 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092781 |
| Comparator: celecoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092768 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092768 |
| Comparator: celecoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092768 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092768 |
| Comparators: ibuprofen and placebo | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092755 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092755 |
| Comparators: ibuprofen and placebo | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092755 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092755 |
| Comparator: naproxen sodium | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT00092729 |
| Comparator: placebo (unspecified) | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT00092729 |
| etoricoxib (MK0663) | Other | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT00092729 |
| Comparator: atorvastatin / Duration of Treatment: 28 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092716 |
| MK0653, ezetimibe / Duration of Treatment: 28 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092716 |
| Comparator: atorvastatin / Duration of Treatment: 28 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092716 |
| MK0653, ezetimibe / Duration of Treatment: 28 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092716 |
| Comparator: atorvastatin / Duration of Treatment: 28 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092716 |
| MK0653, ezetimibe / Duration of Treatment: 28 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092716 |
| Comparator: Diclofenac sodium | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092703 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092703 |
| Comparator: Diclofenac sodium | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092703 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092703 |
| Comparator: Diclofenac sodium | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092703 |
| MK0663, etoricoxib | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092703 |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092664 |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092664 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092638 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092638 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092638 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092638 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092625 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092625 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092625 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092625 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092625 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092625 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092612 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092612 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092612 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092612 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092599 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092599 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092599 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092599 |
| Comparator: ezetimibe, placebo | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092599 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092599 |
| Comparator: statins | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092586 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092586 |
| Comparator: statins | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092586 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092586 |
| Comparator: fenofibrate monotherapy | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092573 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092573 |
| Comparator: fenofibrate monotherapy | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092573 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092573 |
| Comparator: fenofibrate monotherapy | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092573 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092573 |
| Comparator: fenofibrate monotherapy | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092560 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092560 |
| Comparator: fenofibrate monotherapy | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092560 |
| MK0653, ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092560 |
| Comparator: simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092157 |
| MK0733, simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092157 |
| Comparator: simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092157 |
| MK0733, simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092157 |
| Comparator: placebo / Duration of Treatment: 4 weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00092144 |
| MK0476, montelukast sodium / Duration of Treatment: 4 weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00092144 |
| Comparator: placebo / Duration of Treatment: 4 weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00092144 |
| MK0476, montelukast sodium / Duration of Treatment: 4 weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00092144 |
| Comparator: placebo / Duration of Treatment: 4 weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00092144 |
| MK0476, montelukast sodium / Duration of Treatment: 4 weeks | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT00092144 |
| Comparator: Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090298 |
| MK0653A, ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090298 |
| Comparator: Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090298 |
| MK0653A, ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090298 |
| Duration of Treatment: 6 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090168 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090168 |
| MK0653A , ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090168 |
| Duration of Treatment: 6 weeks | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090168 |
| Comparator: atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090168 |
| MK0653A , ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090168 |
| Comparator: placebo | Other | Phase PHASE3 | Bronchiolitis | COMPLETED | NCT00076973 |
| montelukast sodium | Other | Phase PHASE3 | Bronchiolitis | COMPLETED | NCT00076973 |
| Comparators: simvastatin and ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092651 |
| MK0653A, ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092651 |
| Comparators: simvastatin and ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092651 |
| MK0653A, ezetimibe (+) simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092651 |
| Standard of care for treatment of osteoarthritis (OA) of knee(s) | Drug | Preclinical | Osteoarthritis | COMPLETED | NCT01294696 |
| Standard of care for treatment of osteoarthritis (OA) of knee(s) | Drug | Preclinical | Osteoarthritis | COMPLETED | NCT01294696 |
| Standard of care for treatment of osteoarthritis (OA) of knee(s) | Drug | Preclinical | Osteoarthritis | COMPLETED | NCT01294696 |
| Placebo | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01673620 |
| Montelukast 10 mg/loratadine 10 mg | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01673620 |
| Placebo | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01673620 |
| Montelukast 10 mg/loratadine 10 mg | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01673620 |
| Human chorionic gonadotprophin (hCG). | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Recombinant follicle stimulating hormone (recFSH) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Triptorelin | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Corifollitropin alpha (MK-8962, Org 36286) 150 ug | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Corifollitropin alpha (MK-8962, Org 36286) 100 ug | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Human chorionic gonadotprophin (hCG). | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Recombinant follicle stimulating hormone (recFSH) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Triptorelin | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Corifollitropin alpha (MK-8962, Org 36286) 150 ug | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Corifollitropin alpha (MK-8962, Org 36286) 100 ug | Other | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| hCG Bolus injection | Other | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| human Chorion Gonadotropin (hCG) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| recombinant Follicle Stimulating Hormone (recFSH) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| corifollitropin alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| hCG Bolus injection | Other | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| human Chorion Gonadotropin (hCG) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| recombinant Follicle Stimulating Hormone (recFSH) | Other | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| corifollitropin alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| Progesterone | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| hCG | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| Ganirelix | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| 200 IU RecFSH/Follitropin beta (Days 8 to hCG) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| Placebo for RecFSH/Follitropin beta | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| Placebo for Corifollitropin Alfa | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| 200 IU RecFSH/Follitropin beta (Days 1 to 7) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| 150 µg Corifollitropin Alfa | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| Progesterone | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| hCG | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| Ganirelix | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| 200 IU RecFSH/Follitropin beta (Days 8 to hCG) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| Placebo for RecFSH/Follitropin beta | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| Placebo for Corifollitropin Alfa | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| 200 IU RecFSH/Follitropin beta (Days 1 to 7) | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| 150 µg Corifollitropin Alfa | Other | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| Progesterone | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| FSH | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| (rec)hCG | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| GnRH antagonist | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| Corifollitropin alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| Progesterone | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| FSH | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| (rec)hCG | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| GnRH antagonist | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| Corifollitropin alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| Albuterol/Salbutamol | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Placebo | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Mometasone | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Albuterol/Salbutamol | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Placebo | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Mometasone | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Albuterol/Salbutamol | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Placebo | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Mometasone | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Progesterone | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| hCG | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Ganirelix | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| 200 IU RecFSH/Follitropin beta (Days 8 to hCG) | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Placebo for RecFSH/Follitropin beta | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Placebo for Corifollitropin Alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| 200 IU RecFSH/Follitropin beta (Days 1 to 7) | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Corifollitropin Alfa 150 μg | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Progesterone | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| hCG | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Ganirelix | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| 200 IU RecFSH/Follitropin beta (Days 8 to hCG) | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Placebo for RecFSH/Follitropin beta | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Placebo for Corifollitropin Alfa | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| 200 IU RecFSH/Follitropin beta (Days 1 to 7) | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Corifollitropin Alfa 150 μg | Other | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Placebo | Other | Phase PHASE4 | Breakthrough Bleeding | COMPLETED | NCT04047875 |
| Norethisterone 10mg/day | Other | Phase PHASE4 | Breakthrough Bleeding | COMPLETED | NCT04047875 |
| Follitropin beta injection 300 IU | Other | Phase PHASE1 | Ovarian Function Insufficiency | COMPLETED | NCT05330130 |
| Follitropin beta injection 150 IU | Other | Phase PHASE1 | Ovarian Function Insufficiency | COMPLETED | NCT05330130 |
| Follitropin beta injection 300 IU | Other | Phase PHASE1 | Ovarian Function Insufficiency | COMPLETED | NCT05330130 |
| Follitropin beta injection 150 IU | Other | Phase PHASE1 | Ovarian Function Insufficiency | COMPLETED | NCT05330130 |
| No intervention being administered | Other | Preclinical | Chronic Conditions, Multiple | COMPLETED | NCT05000489 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| OG-6219 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| OG-6219 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| E6005 ointment (vehicle) | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01461941 |
| E6005 | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01461941 |
| E6005 ointment (vehicle) | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01461941 |
| E6005 | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01461941 |
| E6005 ointment (vehicle) | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01461941 |
| E6005 | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01461941 |
| E6005 0.2% | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT02094235 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT02094235 |
| E6005 0.05% | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT02094235 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT01179880 |
| E6005 | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT01179880 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT01179880 |
| E6005 | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT01179880 |
| FLOT | Other | Phase PHASE2 | Esophagogastric Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05504720 |
| Trastuzumab | Other | Phase PHASE2 | Esophagogastric Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05504720 |
| Pembrolizumab | Other | Phase PHASE2 | Esophagogastric Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05504720 |
| VTAMA (tapinarof) cream, 1% | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT05789576 |
| VTAMA (tapinarof) cream, 1% | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT05789576 |
| VTAMA (tapinarof) cream, 1% | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT05789576 |
| VTAMA® (tapinarof) Cream 1% | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT05680740 |
| Vehicle Cream | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03983980 |
| Tapinarof | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03983980 |
| Vehicle Cream | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03983980 |
| Tapinarof | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03983980 |
| Vehicle Cream | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03956355 |
| Tapinarof | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03956355 |
| Vehicle Cream | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03956355 |
| Tapinarof | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT03956355 |
| Tapinarof cream, 1% | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT04042103 |
| Tapinarof cream, 1% | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT04042103 |
| tapinarof cream, 1% | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT04053387 |
| tapinarof cream, 1% | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT04053387 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05142774 |
| Etonogestrel 68mg implant | Other | Phase EARLY_PHASE1 | Menstrual Symptoms | SUSPENDED | NCT06775626 |
| Implanon NXT® subdermal implant | Other | Phase EARLY_PHASE1 | Menstrual Symptoms | SUSPENDED | NCT06775626 |
| vehicle cream | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05032859 |
| tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05032859 |
| Vehicle cream | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05014568 |
| tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05014568 |
| Vehicle cream | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05014568 |
| tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05014568 |
| Vehicle cream | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05014568 |
| tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05014568 |
| Tapinarof cream, 1% | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05186805 |
| Lipitor 40 mg or 80 mg | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT05761444 |
| Atozet 10/40 mg or 10/80 mg | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT05761444 |
| Lipitor 40 mg or 80 mg | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT05761444 |
| Atozet 10/40 mg or 10/80 mg | Other | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT05761444 |
| NOMAC-E2 COC | Other | Phase PHASE3 | Contraception | TERMINATED | NCT05264506 |
| NOMAC-E2 COC | Other | Phase PHASE3 | Contraception | TERMINATED | NCT05264506 |
| Cerazette® | Other | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| Gonapeptyl® | Other | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| Orgalutran® | Other | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| Puregon® | Other | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| Elonva® | Other | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| Radiopaque Etonogestrel (ENG) Implant | Other | Phase PHASE3 | Contraception | COMPLETED | NCT04626596 |
| Radiopaque Etonogestrel (ENG) Implant | Other | Phase PHASE3 | Contraception | COMPLETED | NCT04626596 |
| Radiopaque Etonogestrel (ENG) Implant | Other | Phase PHASE3 | Contraception | COMPLETED | NCT04626596 |
| 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger | Other | Phase PHASE3 | Fertility | COMPLETED | NCT06134479 |
| 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5 | Other | Phase PHASE3 | Fertility | COMPLETED | NCT06134479 |
| Tapinarof | Other | Phase PHASE2 | Palmoplantar Keratoderma | RECRUITING | NCT06561321 |
| Tapinarof | Other | Phase PHASE2 | Palmoplantar Keratoderma | RECRUITING | NCT06561321 |
| Tapinarof | Other | Phase PHASE2 | Palmoplantar Keratoderma | RECRUITING | NCT06561321 |
| Multiload-cu 375® | Other | Phase PHASE2 | Contraception | COMPLETED | NCT00967746 |
| Etonogestrel-releasing IUS | Other | Phase PHASE2 | Contraception | COMPLETED | NCT00967746 |
| Placebo | Other | Phase PHASE2 | Benign Prostatic Hyperplasia (BPH) | TERMINATED | NCT00651807 |
| etonogestrel | Other | Phase PHASE2 | Benign Prostatic Hyperplasia (BPH) | TERMINATED | NCT00651807 |
| Placebo | Other | Phase PHASE2 | Benign Prostatic Hyperplasia (BPH) | TERMINATED | NCT00651807 |
| etonogestrel | Other | Phase PHASE2 | Benign Prostatic Hyperplasia (BPH) | TERMINATED | NCT00651807 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| tapinarof cream, 1% | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05172726 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof cream, 1% | Other | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| tapinarof cream, 1% | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05172726 |
| Etonogestrel 68mg implant | DRUG | Phase EARLY_PHASE1 | Menstrual Symptoms | SUSPENDED | NCT06775626 |
| Implanon NXT® subdermal implant | DEVICE | Phase EARLY_PHASE1 | Menstrual Symptoms | SUSPENDED | NCT06775626 |
| Etonogestrel implant | DRUG | Preclinical | Endometrial Hyperplasia Without Atypia | NOT_YET_RECRUITING | NCT06378489 |
| Cerazette® | DRUG | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| Gonapeptyl® | DRUG | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| Elonva® | DRUG | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger | DRUG | Phase PHASE3 | Fertility | COMPLETED | NCT06134479 |
| 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5 | DRUG | Phase PHASE3 | Fertility | COMPLETED | NCT06134479 |
| VTAMA (tapinarof) cream, 1% | DRUG | Phase PHASE4 | Psoriasis | COMPLETED | NCT05789576 |
| Lipitor 40 mg or 80 mg | DRUG | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT05761444 |
| Atozet 10/40 mg or 10/80 mg | DRUG | Phase PHASE4 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT05761444 |
| VTAMA® (tapinarof) Cream 1% | DRUG | Phase PHASE4 | Psoriasis | COMPLETED | NCT05680740 |
| double cleavage-stage or single blastocyst stage embryos transfer | PROCEDURE | Approved | Infertility, Female | UNKNOWN | NCT05632731 |
| OG-6219 | DRUG | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| SB5 (Adalimumab Biosimilar) | DRUG | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT05510063 |
| Humira (Adalimumab) | DRUG | Phase PHASE4 | Plaque Psoriasis | COMPLETED | NCT05510063 |
| Follitropin beta injection 300 IU | DRUG | Phase PHASE1 | Ovarian Function Insufficiency | COMPLETED | NCT05330130 |
| Follitropin beta injection 150 IU | DRUG | Phase PHASE1 | Ovarian Function Insufficiency | COMPLETED | NCT05330130 |
| NOMAC-E2 COC | DRUG | Phase PHASE3 | Contraception | TERMINATED | NCT05264506 |
| 150 mcg levonorgestrel/30 mcg ethinyl estradiol | DRUG | Preclinical | Contraception | UNKNOWN | NCT05116371 |
| vehicle cream | DRUG | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05032859 |
| Vehicle cream | DRUG | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT05014568 |
| Complete Clinical Interaction | OTHER | Preclinical | Healthcare Disparities | ENROLLING_BY_INVITATION | NCT05013710 |
| No intervention being administered | OTHER | Preclinical | Chronic Conditions, Multiple | COMPLETED | NCT05000489 |
| tapinarof cream, 1% | DRUG | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05172726 |
| Norethisterone 10mg/day | DRUG | Phase PHASE4 | Breakthrough Bleeding | COMPLETED | NCT04047875 |
| Tapinarof cream, 1% | DRUG | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Vehicle Cream | DRUG | Phase PHASE3 | Atopic Dermatitis | RECRUITING | NCT07265479 |
| Tapinarof | DRUG | Phase PHASE2 | Palmoplantar Keratoderma | RECRUITING | NCT06561321 |
| Simivastatin | DRUG | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT03882905 |
| Atovastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03882892 |
| Fluticasone propionate placebo | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Mometasone furoate placebo | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Chlorpheniramine maleate syrup | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Beclomethasone dipropionate nasal spray | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Placebo for Atorvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867318 |
| Atorvastatin 80 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Loratadine | DRUG | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Beclomethasone Dipropionate (BDP) | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT03855189 |
| Mometasone Furoate (MF) | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT03855189 |
| Placebo for atorvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03768427 |
| Placebo for FDC EZ/Ator | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03768427 |
| Prednisone/Prednisolone | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| Albuterol/Salbutamol PRN | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF MDI 100 mcg BID | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF/F MDI 100/10 mcg BID | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| MF MDI 100 mcg BID (Open Label) | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT02741271 |
| Placebo for Rosuvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| Placebo for Ezetimibe | DRUG | Phase PHASE3 | Familial Hypercholesterolemia | COMPLETED | NCT03884452 |
| Rosuvastatin 2.5 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02741245 |
| ENG 125 μg + E2 300 μg vaginal ring (MK-8342B) | DRUG | Phase PHASE3 | Dysmenorrhea | TERMINATED | NCT02668822 |
| Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring | DRUG | Phase PHASE3 | Moderate to Severe Primary Dysmenorrhea | TERMINATED | NCT02668783 |
| LNG-EE 150 μg/30 μg COC | DRUG | Phase PHASE3 | Contraception | TERMINATED | NCT02616146 |
| Diet control/Daily Exercise | BEHAVIORAL | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02550288 |
| Placebo for Atorvastatin 10 mg capsule | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02550288 |
| Placebo for Ezetimibe 10 mg tablet | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02550288 |
| ENG-E2 125 μg/300 μg vaginal ring | DRUG | Phase PHASE3 | Contraception | TERMINATED | NCT02616146 |
| EZ 10 mg/Atorva 10 mg FDC | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02460159 |
| EZ 10 mg/Atorva 20 mg FDC | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02460159 |
| Single-use, non-sterile applicator | DEVICE | Phase PHASE3 | Contraception: Optional Applicator for Insertion of Vaginal Ring | COMPLETED | NCT02275546 |
| Placebo vaginal ring | DRUG | Phase PHASE3 | Dysmenorrhea | TERMINATED | NCT02668822 |
| E6005 0.2% | DRUG | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT02094235 |
| E6005 0.05% | DRUG | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT02094235 |
| Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel | DRUG | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 50 mg 4% DMSO | DRUG | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 163 mg 4% DMSO gel | DRUG | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 150 mg 4% PG Gel | DRUG | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 150 mg 4% DMSO Gel | DRUG | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 75 mg 4% PG Gel | DRUG | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Etoricoxib 75 mg 4% DMSO Gel | DRUG | Phase PHASE1 | Osteoarthritis Pain | COMPLETED | NCT01980940 |
| Montelukast Chewable Tablets (CT) | DRUG | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01852812 |
| Montelukast Oral Granules (OG) | DRUG | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01852812 |
| Estradiol (E2) | DRUG | Phase PHASE3 | Contraception | WITHDRAWN | NCT01723579 |
| Ethinyl estradiol (EE) | DRUG | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Etonogestrel (ENG) | DRUG | Phase PHASE2 | Contraception | COMPLETED | NCT01709318 |
| Nomegestrol acetate (NOMAC) | DRUG | Phase PHASE3 | Contraception | WITHDRAWN | NCT01723579 |
| Montelukast 10 mg/loratadine 10 mg | DRUG | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01673620 |
| Etonogestrel containing contraceptive vaginal ring (ENG-CVR) | DRUG | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR) | DRUG | Phase PHASE2 | Dysmenorrhea | COMPLETED | NCT01670656 |
| ferrous fumarate | DRUG | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| ethinylestradiol (EE) | DRUG | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| NETA-EE | DRUG | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| Placebo Olanzapine | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Placebo Asenapine | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Rescue medication: Prednisone/Prednisolone | DRUG | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Rescue medication: short-acting beta-2 agonist (SABA) MDI | DRUG | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| Montelukast tablets 5 mg (4 mg for children 5 years of age) | DRUG | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| BDP hydrofluoroalkane (HFA) 80 mcg | DRUG | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F MDI 100/5 mcg | DRUG | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F MDI 50/5 mcg | DRUG | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| MF/F Metered Dose Inhaler (MDI) 25/5 mcg | DRUG | Phase PHASE2 | Asthma | WITHDRAWN | NCT01615874 |
| human Chorionic Gonadotropin (hCG) | DRUG | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| MK-8962 | DRUG | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| Other Statin | DRUG | Phase PHASE4 | Dyslipidemia | WITHDRAWN | NCT01587235 |
| Ezetimibe/simvastatin | DRUG | Phase PHASE4 | Dyslipidemia | WITHDRAWN | NCT01587235 |
| celecoxib | DRUG | Preclinical | Osteoarthritis | COMPLETED | NCT01572675 |
| etorocoxib | DRUG | Preclinical | Osteoarthritis | COMPLETED | NCT01572675 |
| Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01566149 |
| Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT01566149 |
| Celecoxib 200 mg | DRUG | Phase PHASE3 | Osteoarthritis of the Knee | COMPLETED | NCT01554163 |
| Etoricoxib 30 mg | DRUG | Phase PHASE3 | Osteoarthritis of the Knee | COMPLETED | NCT01554163 |
| Placebo Dry Powder Inhaler (DPI) | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Placebo Metered Dose Inhaler (MDI) | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01502371 |
| Zotepine | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Sertindole | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Amisulpride | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Clozapine | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Lurasidone | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Paliperidone | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Iloperidone | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Ziprasidone | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Risperidone | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Quetiapine | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Aripiprazole | DRUG | Preclinical | Bipolar Disorder | COMPLETED | NCT01498770 |
| Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing) | DRUG | Phase PHASE4 | Contraception | COMPLETED | NCT01490190 |
| Prednisone/prednisolone | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Albuterol 90 mcg /salbutamol 100 mcg HFA MDI | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate MDI 200 mcg | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate MDI 100 mcg | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate/Formoterol MDI 200/5 mcg | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Mometasone Furoate/Formoterol MDI 100/5 mcg | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT01471340 |
| Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg | DRUG | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Placebo to ibuprofen | DRUG | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Placebo to etoricoxib | DRUG | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT01462370 |
| Ibuprofen | DRUG | Phase PHASE3 | Dysmenorrhea | TERMINATED | NCT02668822 |
| E6005 ointment (vehicle) | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01461941 |
| MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet | DRUG | Phase PHASE3 | Osteoporosis | COMPLETED | NCT01437111 |
| Hypolipemics | DRUG | Preclinical | Dyslipidemia | COMPLETED | NCT01436253 |
| Lifestyle Changes | BEHAVIORAL | Preclinical | Dyslipidemia | COMPLETED | NCT01436253 |
| Losartan 50 mg / HCTZ 12.5 mg | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT01431508 |
| Placebo for etoricoxib | DRUG | Phase PHASE4 | Osteoarthritis | WITHDRAWN | NCT01429168 |
| Placebo for MFNS | DRUG | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT01386125 |
| Placebo to ezetimibe/atorvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Placebo to ezetimibe | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Placebo to atorvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Ezetimibe/atorvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01370603 |
| Calcitriol | DRUG | Phase PHASE4 | Osteoporosis, Postmenopausal | COMPLETED | NCT01350934 |
| alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus) | DRUG | Phase PHASE4 | Osteoporosis, Postmenopausal | COMPLETED | NCT01350934 |
| Phase 3 NOMAC-E2 "Batch B" | DRUG | Phase PHASE1 | Healthy Postmenopausal Females | COMPLETED | NCT01345786 |
| Phase 3 NOMAC-E2 "Batch A" | DRUG | Phase PHASE1 | Healthy Postmenopausal Females | COMPLETED | NCT01345786 |
| Commercial NOMAC-E2 | DRUG | Phase PHASE1 | Healthy Postmenopausal Females | COMPLETED | NCT01345786 |
| Test Meal | OTHER | Approved | Dyslipidemia | COMPLETED | NCT01333436 |
| nsNSAIDs | DRUG | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| Other COX-2 inhibitor | DRUG | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| Placebo to losartan 50 mg | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| Placebo to losartan 100 mg | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| Losartan | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| Placebo to MK-954H | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| Placebo to MK-0954A | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| MK-954H | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT01307033 |
| MK-0954A | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT01307046 |
| Orgalutran | DRUG | Preclinical | Fertilization in Vitro | COMPLETED | NCT01304511 |
| Standard of care for treatment of osteoarthritis (OA) of knee(s) | DRUG | Preclinical | Osteoarthritis | COMPLETED | NCT01294696 |
| Standard Care | DRUG | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT01286207 |
| Rizatriptan 10 mg | DRUG | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT01286207 |
| Rizatriptan 5 mg | DRUG | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT01286207 |
| Placebo to match amlodipine | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Amlodipine camsylate | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Placebo to match losartan/amlodipine tablets | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| Losartan (+) amlodipine | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT01277822 |
| DRSP 3 mg + EE 30 µg | DRUG | Phase PHASE3 | Contraception | COMPLETED | NCT01277211 |
| ENG 120 µg + EE 15 µg intravaginal ring | DRUG | Phase PHASE3 | Contraception | COMPLETED | NCT01277211 |
| Mometasone Furoate DPI | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Placebo MDI without spacer | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Placebo MDI with spacer | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Formoterol Fumarate DPI | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT01258803 |
| Rescue medication | DRUG | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT01349907 |
| Placebo to match asenapine | DRUG | Phase PHASE3 | Bipolar Disorder, Pediatric | COMPLETED | NCT01244815 |
| Ezetimibe/atorvastatin 10mg/80mg FDC | DRUG | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Atorvastatin 80mg | DRUG | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Atorvastatin 10mg | DRUG | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Ezetimibe/atorvastatin 10mg/10mg FDC | DRUG | Phase PHASE1 | Hyperlipidemia | COMPLETED | NCT01236430 |
| Part II- Placebo to naproxen 500 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II - Placebo to etoricoxib 90 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II- Placebo to etoricoxib 60 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - Placebo to etoricoxib 90 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - Placebo to etoricoxib 60 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II- naproxen 1000 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II- etoricoxib 90 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part II- etoricoxib 60 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - Placebo to naproxen 500 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I- naproxen 1000 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - etoricoxib 90 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Part I - etoricoxib 60 mg | DRUG | Phase PHASE3 | Spondylitis, Ankylosing | COMPLETED | NCT01208207 |
| Placebo to Etoricoxib 90 mg | DRUG | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Placebo to Etoricoxib 60 mg | DRUG | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Etoricoxib 60 mg | DRUG | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Asenapine 2.5 mg | DRUG | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01206517 |
| asenapine 5.0 mg | DRUG | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190254 |
| asenapine 2.5 mg | DRUG | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190254 |
| E6005 | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01461941 |
| ezetimibe 10 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01154036 |
| Placebo for recFSH | DRUG | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| Placebo for SCH 900962 | DRUG | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| RecFSH / follitropin beta | BIOLOGICAL | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| SCH 900962 / Corifollitropin alfa / Org 36286 | BIOLOGICAL | Phase PHASE3 | Infertility | COMPLETED | NCT01144416 |
| Asenapine 1x15mg followed by 3x5mg | DRUG | Phase PHASE2 | Schizophrenia | COMPLETED | NCT01101464 |
| Asenapine 3x5mg followed by 1x15mg | DRUG | Phase PHASE2 | Schizophrenia | COMPLETED | NCT01101464 |
| Asenapine 10 mg | DRUG | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01206517 |
| Asenapine 5 mg | DRUG | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01206517 |
| No anti-inflammatory treatment | OTHER | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Other Non-selective NSAIDs | DRUG | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Other Cox-2 inhibitors | DRUG | Preclinical | Ankylosing Spondylitis | COMPLETED | NCT01077843 |
| Etoricoxib | DRUG | Preclinical | Osteoarthritis | COMPLETED | NCT01685424 |
| Raloxifene | DRUG | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Risedronate | DRUG | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Ibandronate | DRUG | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Etidronate | DRUG | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| FOSAMAX PLUS D | DRUG | Preclinical | Osteoporosis | COMPLETED | NCT01065779 |
| FOSAMAX PLUS | DRUG | Preclinical | Osteoporosis | COMPLETED | NCT01065779 |
| Nuvaring ™ (etonorgestrel/ethinylestradiol) | DRUG | Phase PHASE4 | Contraception | COMPLETED | NCT01044056 |
| norelgestrominum and ethinylestradiol patch oral contraceptive patch | DRUG | Phase PHASE4 | Contraception | COMPLETED | NCT01044056 |
| Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets | DRUG | Phase PHASE4 | Contraception | COMPLETED | NCT01044056 |
| amlodipine/losartan | DRUG | Preclinical | Hypertension | COMPLETED | NCT01041807 |
| Placebo metered-dose inhaler BID | DRUG | Phase PHASE3 | Asthma | WITHDRAWN | NCT01026870 |
| SCH 32088 mometasone furoate (MF) metered-dose inhaler | DRUG | Phase PHASE3 | Asthma | WITHDRAWN | NCT01026870 |
| Ethinylestradiol + Desogestrel | DRUG | Preclinical | Contraception | COMPLETED | NCT01005056 |
| Comparator: cetirizine | DRUG | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00974571 |
| Multiload-cu 375® | DEVICE | Phase PHASE2 | Contraception | COMPLETED | NCT00967746 |
| Etonogestrel-releasing IUS | DRUG | Phase PHASE2 | Contraception | COMPLETED | NCT00967746 |
| Comparator: montelukast/loratadine | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: loratadine | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| hydrochlorothiazide (HCTZ) | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT00953680 |
| losartan potassium (+) hydrochlorothiazide (HCTZ) | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT00953680 |
| Comparator: losartan + ISMN | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: isosorbide mononitrate (ISMN) | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT00943852 |
| Comparator: Usual Care | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00943397 |
| Follitropin beta | DRUG | Preclinical | Anovulation | COMPLETED | NCT00920634 |
| placebo tablet | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| Placebo inhaler | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| beclomethasone | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00911547 |
| Vytorin (R) (Ezetimibe + Simvastatin) | DRUG | Preclinical | Hypercholesterolemia | COMPLETED | NCT00909389 |
| Comparator: sumatriptan | DRUG | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00898677 |
| rizatriptan benzoate (MK0462) | DRUG | Phase PHASE3 | Migraine Headache | COMPLETED | NCT00897949 |
| Comparator: Sumatriptan | DRUG | Phase PHASE3 | Acute Migraine | COMPLETED | NCT00894556 |
| rizatriptan | DRUG | Phase PHASE3 | Migraine, Acute | COMPLETED | NCT01001234 |
| Asenapine WHITE UNFLAVORED (Treatment C) | DRUG | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine RED raspberry flavor (Treatment B) | DRUG | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| Asenapine WHITE raspberry flavor (Treatment A) | DRUG | Phase PHASE2 | Psychosis | COMPLETED | NCT00878462 |
| atorvastatin 10 mg or simvastatin 20 mg | DRUG | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| simvastatin 40 mg or atorvastatin 20 mg | DRUG | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| Oxycodone | DRUG | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Morphine | DRUG | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Matching Placebo for Ibuprofen | DRUG | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Matching Placebo for Etoricoxib 90 mg | DRUG | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Matching Placebo for Etoricoxib 120 mg | DRUG | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Ibuprofen 600 mg | DRUG | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Etoricoxib 120 mg | DRUG | Phase PHASE3 | Pain, Postoperative | COMPLETED | NCT00820027 |
| Etoricoxib 90 mg | DRUG | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01208181 |
| Normal saline | DRUG | Phase PHASE2 | Valvular Stenosis | COMPLETED | NCT00819377 |
| Milrinone | DRUG | Phase PHASE2 | Valvular Stenosis | COMPLETED | NCT00819377 |
| MF | DEVICE | Phase PHASE3 | Asthma | COMPLETED | NCT00817817 |
| Placebo for Oxybutynin 2.5 mg | DRUG | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Placebo for Desloratadine 2.5 mg | DRUG | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Oxybutynin 2.5 mg | DRUG | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| Desloratadine 2.5 mg | DRUG | Phase PHASE2 | Post-nasal Drip | COMPLETED | NCT00816972 |
| rizatriptan benzoate | DRUG | Phase PHASE3 | Acute Migraine With or Without Aura in Adolescents | COMPLETED | NCT01004263 |
| Comparator: alendronate | DRUG | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00806416 |
| alendronate sodium+vitamin D combination | DRUG | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00803790 |
| Desloratadine 5 mg (Clarinex) | DRUG | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794846 |
| Cetirizine (Zyrtec) | DRUG | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794846 |
| Desloratadine (Clarinex) | DRUG | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00794794 |
| desloratadine 5 mg | DRUG | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794768 |
| etoricoxib (MK0663) 90 mg | DRUG | Phase PHASE3 | Acute Pain Following a Total Abdominal Hysterectomy | COMPLETED | NCT00788710 |
| etoricoxib (MK0663) 120 mg | DRUG | Phase PHASE3 | Acute Pain Following a Total Abdominal Hysterectomy | COMPLETED | NCT00788710 |
| fluticasone nasal spray | DRUG | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00817050 |
| Comparator: rosuvastatin 20 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 10 mg + ezetimibe 10 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 10 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Comparator: rosuvastatin 5 mg + ezetimibe 10 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00783263 |
| Placebo for FP | DRUG | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Placebo for MF | DRUG | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| fexofenadine | DRUG | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00794768 |
| Desloratadine 5 mg | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT02320396 |
| atorvastatin 20 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00782184 |
| atorvastatin 40 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00782184 |
| ezetimibe/simvastatin 10/40 | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00782184 |
| NOMAC-E2 placebo | DRUG | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| Moxifloxacin placebo | DRUG | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| NOMAC-E2 (Org 10486-0 + Org 2317) | DRUG | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| Moxifloxacin | DRUG | Phase PHASE1 | Contraception | COMPLETED | NCT00779532 |
| Zyrtec® (cetirizine) | DRUG | Phase PHASE4 | Allergies | COMPLETED | NCT00780403 |
| Marvelon | DRUG | Phase PHASE4 | Infertility | COMPLETED | NCT00778999 |
| Fluticasone | DRUG | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00783224 |
| Desloratadine Syrup | DRUG | Preclinical | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00761527 |
| Theophylline | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00756418 |
| Low Salt Diet | BEHAVIORAL | Phase PHASE3 | Hypertension | COMPLETED | NCT00739674 |
| losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB]) | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT00739674 |
| GnRH agonist | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00724789 |
| INEGY | DRUG | Preclinical | Primary Hypercholesterolemia | COMPLETED | NCT00724477 |
| statin | DRUG | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705081 |
| Desloratadine (assigned by investigator as part of normal practice) | DRUG | Preclinical | Rhinitis | COMPLETED | NCT00704769 |
| Ezetimibe + other lipid-lowering medication(s) | DRUG | Preclinical | Hypercholesterolemia | COMPLETED | NCT00705211 |
| Comparator: montelukast | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| Comparator: mometasone | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT00666679 |
| Niaspan | DRUG | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00652431 |
| Vytorin | DRUG | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00652431 |
| Vytorin + Niaspan | DRUG | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00652431 |
| Double Statin (simvastatin, atorvastatin, or pravastatin) | DRUG | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin) | DRUG | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652327 |
| etonogestrel | DRUG | Phase PHASE2 | Benign Prostatic Hyperplasia (BPH) | TERMINATED | NCT00651807 |
| placebo nasal spray | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03861559 |
| mometasone furoate nasal spray | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03861559 |
| Comparator: Fluticasone / Duration of Treatment: 6 Weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00545324 |
| MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00545324 |
| 20-mg Desloratadine | DRUG | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| 10-mg Desloratadine | DRUG | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| Atorvastatin 40 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Ezetimibe 10 mg/simvastatin 40 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Atorvastatin 20 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Ezetimibe 10 mg/simvastatin 20 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00535405 |
| Comparator: Comparator: placebo (unspecified) | DRUG | Phase PHASE4 | Exercise-induced Bronchoconstriction (EIB) | COMPLETED | NCT00534976 |
| Comparator: montelukast sodium | DRUG | Phase PHASE4 | Exercise-induced Bronchoconstriction (EIB) | COMPLETED | NCT00534976 |
| Comparator: rizatriptan benzoate | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT00516737 |
| If bleeding does not remove ring | OTHER | Approved | Breakthrough Bleeding | COMPLETED | NCT00475553 |
| remove ring if bleeding or spotting occurs more than 5 days | OTHER | Approved | Breakthrough Bleeding | COMPLETED | NCT00475553 |
| mometasone furoate | DRUG | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01165424 |
| Comparator : placebo (unspecified) /Duration of Treatment : 5 Years | DRUG | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398931 |
| MK0217, alendronate sodium / Duration of Treatment : 5 Years | DRUG | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398931 |
| Comparator : calcium carbonate /Duration of Treatment : 2 Years | DRUG | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398606 |
| MK0217, alendronate sodium / Duration of Treatment : 2 Years | DRUG | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00398606 |
| MK0733, simvastatin / Duration of Treatment: 12 Weeks | DRUG | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00398294 |
| Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks | DRUG | Phase PHASE3 | HDL Cholesterol | COMPLETED | NCT00389896 |
| MK0733 / Duration of Treatment: 18 Weeks | DRUG | Phase PHASE3 | HDL Cholesterol | COMPLETED | NCT00389896 |
| Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months | DRUG | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00389740 |
| MK0217, /Duration of Treatment : 12 Months | DRUG | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00389740 |
| MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days | DRUG | Phase PHASE4 | Pain | COMPLETED | NCT00380627 |
| Fluticasone/Salmeterol 500/50 mcg BID | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| Fluticasone/Salmeterol 250/50 mcg BID | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| mometasone furoate combination MDI 400/10 mcg BID | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| mometasone furoate combination MDI 200/10 mcg BID | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00379288 |
| vaginal ring | DEVICE | Approved | Pregnancy | COMPLETED | NCT00357526 |
| OCPs | DRUG | Approved | Pregnancy | COMPLETED | NCT00357526 |
| Placebo / Duration of Treatment: mean 3.4 years | DRUG | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT00308347 |
| MK0954, losartan / Duration of Treatment: mean 3.4 years | DRUG | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT00308347 |
| losartan / Duration of Treatment: 6 weeks | DRUG | Phase PHASE3 | Mild to Severe Hypertension | COMPLETED | NCT00307060 |
| MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks | DRUG | Phase PHASE3 | Mild to Severe Hypertension | COMPLETED | NCT00307060 |
| Comparator: losartan +/- HCTZ | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT00289887 |
| ethinyl estradiol/norelgestromin transdermal contraceptive | DRUG | Phase PHASE4 | Contraception | COMPLETED | NCT00269620 |
| ethinyl estradiol/etonogestrel vaginal ring | DRUG | Phase PHASE4 | Contraception | COMPLETED | NCT00269620 |
| Placebo or Ibuprofen / Duration of Treatment 12 Weeks | DRUG | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00269191 |
| MK0663, etoricoxib / Duration of Treatment 12 Weeks | DRUG | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00269191 |
| Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks | DRUG | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00242489 |
| MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks) | DRUG | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00242489 |
| MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks | DRUG | Phase PHASE4 | Essential Hypertension | COMPLETED | NCT00157963 |
| Comparator: theophylline ER/Duration of Treatment: 16 weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00157937 |
| Comparator: simvastatin / Duration of Treatment: 12 weeks | DRUG | Phase PHASE3 | Hypercholerolemia | COMPLETED | NCT00157911 |
| MK0653; ezetimibe / Duration of Treatment: 12 weeks | DRUG | Phase PHASE3 | Hypercholerolemia | COMPLETED | NCT00157911 |
| Asenapine - Double Blind | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00150176 |
| Placebo - Double Blind | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00150176 |
| Asenapine - Open Label | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00150176 |
| Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days | DRUG | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| MK0663; etoricoxib / Duration of Treatment: 5 Days | DRUG | Phase PHASE4 | Acute Gout | COMPLETED | NCT00142558 |
| Comparator: pranlukast | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00127647 |
| Comparator: placebo / Duration of Treatment: 48 weeks | DRUG | Phase PHASE3 | Benign Prostatic Hyperplasia | COMPLETED | NCT00127179 |
| MK0906, finasteride / Duration of Treatment: 48 weeks | DRUG | Phase PHASE3 | Benign Prostatic Hyperplasia | COMPLETED | NCT00127179 |
| Salmeterol matching placebo | DRUG | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Montelukast matching placebo | DRUG | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| Salmeterol xinafoate | DRUG | Phase PHASE3 | Exercise Induced Asthma | COMPLETED | NCT00127166 |
| cetirizine | DRUG | Phase PHASE4 | Urticaria | COMPLETED | NCT00751218 |
| Cetirizine | DRUG | Phase PHASE4 | Urticaria | TERMINATED | NCT00751166 |
| Amoxicillin | DRUG | Phase PHASE3 | Acute Rhinosinusitis | COMPLETED | NCT00751075 |
| MFNS | DRUG | Phase PHASE3 | Acute Rhinosinusitis | COMPLETED | NCT00751075 |
| mometasone furoate nasal spray (MFNS) | DRUG | Phase PHASE3 | Acute Rhinosinusitis | COMPLETED | NCT00751075 |
| CE/MPA | DRUG | Phase PHASE3 | Postmenopausal Women | COMPLETED | NCT00745108 |
| Tibolone 2.5 mg | DRUG | Phase PHASE3 | Postmenopausal Women | COMPLETED | NCT00745108 |
| Mometasone furoate | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Comparator: Alendronate sodium (Fosamax) | DRUG | Phase PHASE4 | Osteoporosis Postmenopausal | COMPLETED | NCT00729651 |
| Matching placebo nasal spray | DRUG | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00733005 |
| Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate | DRUG | Preclinical | Dyslipidemia | COMPLETED | NCT00726856 |
| triptorelin | DRUG | Phase PHASE3 | Controlled Ovarian Stimulation | COMPLETED | NCT00725491 |
| ganirelix | DRUG | Phase PHASE3 | Controlled Ovarian Stimulation | COMPLETED | NCT00725491 |
| etonogestrel implant (Implanon) | DRUG | Phase PHASE4 | Contraception | COMPLETED | NCT00725413 |
| Desloratadine | DRUG | Phase PHASE3 | Urticaria | COMPLETED | NCT01916967 |
| Statin | DRUG | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT03882905 |
| nomegestrol acetate and estradiol | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00711607 |
| Corifollitropin Alfa 150 μg | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| gonadatropin releasing hormone (GnRH) antagonist (ganirelix) | DRUG | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| corifollitropin alfa (Org 36286) | DRUG | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| Pregnyl® | DRUG | Phase PHASE2 | Infertility | COMPLETED | NCT00702806 |
| Orgalutran® | DRUG | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| Puregon® | DRUG | Phase PHASE4 | Ovarian Stimulation | RECRUITING | NCT06175832 |
| open-label recFSH (follitropin beta) | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| placebo-recFSH (follitropin beta) | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| human chorion gonadotropin (hCG) | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| recFSH (follitropin beta) | BIOLOGICAL | Phase PHASE3 | Infertility | COMPLETED | NCT01146418 |
| open-label recFSH | BIOLOGICAL | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| placebo-corifollitropin alfa | DRUG | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| placebo-recFSH (follitropin alfa) | DRUG | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| progesterone | BIOLOGICAL | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| human chorion gonadatropin (hCG) | DRUG | Phase PHASE3 | Infertility | COMPLETED | NCT00702845 |
| gonadatropin releasing hormone (GnRH) antagonist ganirelix | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00702624 |
| recFSH (follitropin alfa) | BIOLOGICAL | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702546 |
| Human chorionic gonadotprophin (hCG). | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Recombinant follicle stimulating hormone (recFSH) | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Triptorelin | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Corifollitropin alpha (MK-8962, Org 36286) 150 ug | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| Corifollitropin alpha (MK-8962, Org 36286) 100 ug | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00702520 |
| hCG Bolus injection | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| human Chorion Gonadotropin (hCG) | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| recombinant Follicle Stimulating Hormone (recFSH) | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702338 |
| 200 IU RecFSH/Follitropin beta (Days 8 to hCG) | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Placebo for RecFSH/Follitropin beta | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| Placebo for Corifollitropin Alfa | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| 200 IU RecFSH/Follitropin beta (Days 1 to 7) | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00703014 |
| 150 µg Corifollitropin Alfa | DRUG | Preclinical | In Vitro Fertilization | COMPLETED | NCT00702273 |
| FSH | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| (rec)hCG | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| GnRH antagonist | BIOLOGICAL | Preclinical | Pregnancy | COMPLETED | NCT00702234 |
| recFSH | DRUG | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| Org 36286 (corifollitropin alfa) | DRUG | Phase PHASE2 | In Vitro Fertilization | COMPLETED | NCT00702351 |
| placebo (unspecified) | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00700661 |
| Placebo and Ketamine | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00700076 |
| Ketamine and Org 25935 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00700076 |
| Progesterone | DRUG | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| hCG | DRUG | Phase PHASE3 | Hypogonadotropic Hypogonadism | COMPLETED | NCT03019575 |
| RecFSH / Follitropin beta (Days 8 to hCG) | BIOLOGICAL | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Placebo RecFSH / follitropin beta | DRUG | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Placebo Corifollitropin alfa | DRUG | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| RecFSH / Follitropin beta (Days 1 to 7) | BIOLOGICAL | Phase PHASE3 | In Vitro Fertilization | COMPLETED | NCT00696800 |
| Corifollitropin alfa | DRUG | Phase PHASE3 | Hypogonadotropic Hypogonadism | COMPLETED | NCT03019575 |
| Comparator: acetaminophen + codeine | DRUG | Phase PHASE3 | Postoperative Dental Pain | COMPLETED | NCT00694369 |
| Comparator: ibuprofen | DRUG | Phase PHASE3 | Postoperative Dental Pain | COMPLETED | NCT00694369 |
| Comparator: etoricoxib | DRUG | Phase PHASE1 | Pain | COMPLETED | NCT00945035 |
| Referred-Care Model | OTHER | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00692913 |
| FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol) | DRUG | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00692913 |
| Mometasone Furoate | DRUG | Phase PHASE4 | Asthma | TERMINATED | NCT00687531 |
| Standard administration of protamine | DRUG | Approved | Bleeding | COMPLETED | NCT00684450 |
| Titration protamine | PROCEDURE | Approved | Bleeding | COMPLETED | NCT00684450 |
| Cream (betamethasone diproprionate) | DRUG | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate and gentamicin) | DRUG | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate) | DRUG | Phase PHASE4 | Dermatitis, Atopic | TERMINATED | NCT00671528 |
| pitavastatin | DRUG | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00653913 |
| SCH 58235 | DRUG | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00653913 |
| Comparator: cyclosporine | DRUG | Phase PHASE1 | Cholesterol | COMPLETED | NCT00653276 |
| statins | DRUG | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652847 |
| Placebo (Unspecified) | DRUG | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00652444 |
| Double Atorvastatin | DRUG | Phase PHASE4 | Hypercholesterolemia | TERMINATED | NCT00651378 |
| Rosuvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT02748057 |
| Ezetimibe + Rosuvastatin | DRUG | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT00651144 |
| Atorvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Ezetimibe + Atorvastatin | DRUG | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00653796 |
| Simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| Ezetimibe + Simvastatin | DRUG | Phase PHASE4 | Hypercholesterolaemia | COMPLETED | NCT00653835 |
| Lyndiol® | DRUG | Phase PHASE1 | Infertility | COMPLETED | NCT00647933 |
| Org 36286 | DRUG | Preclinical | Pregnancy | COMPLETED | NCT00702988 |
| alendronate sodium (+) cholecalciferol | DRUG | Phase PHASE1 | Osteoporosis | COMPLETED | NCT00806416 |
| MF MDI 200 mcg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| MF DPI 200 mcg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| mometasone furoate/formoterol 400/10 mcg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| mometasone furoate/formoterol 200/10 mcg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| mometasone furoate/formoterol 100/10 mcg | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT00635882 |
| NuvaRing | DRUG | Approved | Pharmacokinetics | COMPLETED | NCT00710606 |
| Ortho Tri-cyclen Lo | DRUG | Phase PHASE4 | Birth Control Compliance | COMPLETED | NCT00635570 |
| Implanon (etonogestrel implant) | DRUG | Phase PHASE3 | Contraception | COMPLETED | NCT00620464 |
| Radiopaque Implanon | DRUG | Phase PHASE3 | Contraception | COMPLETED | NCT00620464 |
| Radiopaque Etonogestrel Implant | DRUG | Phase PHASE3 | Contraception | COMPLETED | NCT00620035 |
| Rizatriptan 10 mg Placebo | DRUG | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| Rizatriptan 5 mg Placebo | DRUG | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| rizatriptan benzoate (10 mg) | DRUG | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| rizatriptan benzoate (5 mg) | DRUG | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00604812 |
| SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ) | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00604500 |
| Mometasone furoate nasal spray (MFNS) | DRUG | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| Follitropin beta injection | DRUG | Phase PHASE2 | Fertilization | COMPLETED | NCT00598208 |
| corifollitropin alfa | DRUG | Preclinical | Infertility, Female | COMPLETED | NCT01408615 |
| Enalapril Maleate | DRUG | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Placebo (Losartan) | OTHER | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Comparator: Placebo (amlodipine besylate) | OTHER | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Comparator: amlodipine besylate | DRUG | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Comparator: Placebo (Losartan) | OTHER | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| Losartan Potassium | DRUG | Phase PHASE3 | Proteinuria | COMPLETED | NCT00568178 |
| oxymetazoline nasal spray (OXY) twice daily | DRUG | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00552110 |
| mometasone furoate nasal spray (MFNS) once daily | DRUG | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00552110 |
| OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY) | DRUG | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00552110 |
| placebo (plus simvastatin) | DRUG | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00552097 |
| ezetimibe (plus simvastatin) | DRUG | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00552097 |
| Mometasone Furoate nasal spray | DRUG | Phase PHASE3 | Adenoids Hypertrophy | COMPLETED | NCT00552032 |
| Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00551876 |
| MK0653, ezetimibe / Duration of Treatment: 30 Weeks | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00551876 |
| Comparator: simvastatin / Duration of Treatment: 27 Weeks | DRUG | Phase PHASE3 | Coronary Disease | COMPLETED | NCT00551447 |
| MK0733, simvastatin / Duration of Treatment: 27 Weeks | DRUG | Phase PHASE3 | Coronary Disease | COMPLETED | NCT00551447 |
| MK0653, ezetimibe / Duration of Treatment: 27 Weeks | DRUG | Phase PHASE3 | Coronary Disease | COMPLETED | NCT00551447 |
| Comparator: Valsartan (+) Hydrochlorothiazide | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT00546754 |
| losartan potassium (+) hydrochlorothiazide | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT00546754 |
| Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks | DRUG | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00542087 |
| MK0663, etoricoxib / Duration of Treatment: 6 Weeks | DRUG | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00542087 |
| Comparator : atenolol /Duration of Treatment : 16 Weeks | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT00541684 |
| MK0954, /Duration of Treatment : 16 Weeks | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT00541684 |
| Placebo to fluticasone | DRUG | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Fluticasone propionate | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03882047 |
| Placebo to montelukast | DRUG | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Montelukast sodium | DRUG | Phase PHASE3 | Asthma, Bronchial | WITHDRAWN | NCT00540839 |
| Mometasone furoate dry powder inhaler | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00521599 |
| Levonorgestrel and Ethinyl Estradiol | DRUG | Phase PHASE3 | Contraception | COMPLETED | NCT00511355 |
| LNG-EE | DRUG | Phase PHASE3 | Contraception | COMPLETED | NCT00511342 |
| Comparator: carvedilol (+) hydrochlorothiazide | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| Comparator: losartan (+) hydrochlorothiazide (HCTZ) | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| Comparator: carvedilol | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT00496834 |
| usual administration of exogenous recombinant FSH | DRUG | Preclinical | Anovulation | COMPLETED | NCT00492882 |
| Mometasone Furoate Nasal Spray | DRUG | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00817050 |
| Comparator : fluticasone propionate / Duration of Treatment: 1 Year | DRUG | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00489346 |
| MK0476, montelukast sodium / Duration of Treatment: 1 Year | DRUG | Phase PHASE3 | Asthma, Bronchial | COMPLETED | NCT00489346 |
| Comparator : ramipril /Duration of Treatment : 8 Weeks | DRUG | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00480805 |
| MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks | DRUG | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00480805 |
| MK0217/Duration of Treatment : 12 Months | DRUG | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00480766 |
| alendronate | DRUG | Phase PHASE3 | Paget's Disease of Bone | COMPLETED | NCT00480662 |
| Comparator : rosuvastatin calcium | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00479713 |
| Ganirelix | DRUG | Phase PHASE3 | Infertility | WITHDRAWN | NCT01599494 |
| MK0653, ezetimibe / Duration of Treatment: 4 Weeks | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00457275 |
| MK0954, losartan potassium / Duration of Treatment - 12 weeks | DRUG | Phase PHASE3 | Hypertension | TERMINATED | NCT00449111 |
| Placebo for Losartan/HCTZ | DRUG | Phase PHASE3 | Hypertension | TERMINATED | NCT00447603 |
| Placebo for Losartan | DRUG | Phase PHASE3 | Hypertension | TERMINATED | NCT00447603 |
| hydrochlorothiazide (+) losartan potassium | DRUG | Phase PHASE3 | Hypertension | TERMINATED | NCT00447603 |
| Comparator: placebo / Duration of Treatment: 2 Weeks | DRUG | Phase PHASE2 | Rhinitis Allergic | COMPLETED | NCT00446186 |
| MK0476, montelukast sodium / Duration of Treatment: 2 Weeks | DRUG | Phase PHASE2 | Rhinitis Allergic | COMPLETED | NCT00446186 |
| Comparator: ketotifen / Duration of Treatment: 4 Weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00446056 |
| MK0476, montelukast sodium / Duration of Treatment: 4 Weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00446056 |
| MK0476, montelukast sodium / Duration of Treatment: 8 Weeks | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00445107 |
| simvastatin (+) ezetimibe | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00496730 |
| inhaled corticosteroid | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00442559 |
| Placebo for Asmanex twisthaler | OTHER | Phase PHASE4 | Asthma | TERMINATED | NCT00442351 |
| Asmanex twisthaler | DRUG | Phase PHASE4 | Asthma | TERMINATED | NCT00442351 |
| aminophylline hydrate | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00442338 |
| Budesonide DPI | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00442117 |
| raloxifen | DRUG | Phase PHASE4 | Osteopenia | COMPLETED | NCT00431431 |
| low-dose estradiol/noresterone | DRUG | Phase PHASE4 | Menopause | COMPLETED | NCT00431093 |
| Fluticasone propionate/salmeterol (F/SC) DPI | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00424008 |
| Mometasone furoate/formoterol (MF/F) MDI | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00424008 |
| Loratadine/montelukast combination | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00423995 |
| simvastatin 40 mg | DRUG | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00423579 |
| Ezetimibe/Simvastatin 10/20 mg | DRUG | Phase PHASE4 | Hypercholesterolemia | COMPLETED | NCT00423579 |
| Simvastatin Placebo | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00423488 |
| Ezetimibe Placebo | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00423488 |
| Simvastatin 20 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00423488 |
| Ezetimibe 10 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Matching Placebo nasal spray plus antibiotic | DRUG | Phase PHASE3 | Sinusitis | TERMINATED | NCT00423176 |
| MFNS and antibiotic | DRUG | Phase PHASE3 | Sinusitis | TERMINATED | NCT00423176 |
| Placebo (unspecified) | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00418834 |
| ezetimibe and atorvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00418834 |
| Ezetimibe with Simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00413972 |
| estradiol-norethisterone | DRUG | Phase PHASE3 | Sexual Dysfunction | COMPLETED | NCT00413764 |
| tibolone | DRUG | Phase PHASE3 | Postmenopausal Women | COMPLETED | NCT00745108 |
| DRSP-EE | DRUG | Phase PHASE3 | Contraception | COMPLETED | NCT00511433 |
| NOMAC-E2 | DRUG | Phase PHASE3 | Contraception | TERMINATED | NCT01656434 |
| Comparator: atorvastatin calcium | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00409773 |
| Placebo tablet | DRUG | Phase PHASE3 | Rhinitis, Allergic | COMPLETED | NCT03855228 |
| 5-mg Desloratadine | DRUG | Phase PHASE4 | Chronic Idiopathic Urticaria | COMPLETED | NCT00536380 |
| etonogestrel with testosterone undecanoate | DRUG | Phase PHASE2 | Contraception | COMPLETED | NCT00403793 |
| MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT00400218 |
| MK0476, montelukast sodium / Duration of Treatment: 12 Weeks | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00398151 |
| Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | DRUG | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT00396175 |
| MK0906, finasteride / Duration of Treatment : 48 Weeks | DRUG | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT00396175 |
| Comparator: atorvastatin / Duration of Treatment: 6 Weeks | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00541697 |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00541697 |
| MK0653, ezetimibe / Duration of Treatment: 6 Weeks | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00395473 |
| Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00395408 |
| MK0476, montelukast sodium / Duration of Treatment : 56 Weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00395408 |
| montelukast | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00756418 |
| fluticasone propionate hydrofluoroalkane (HFA) | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00394355 |
| mometasone furoate dry powder inhaler | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00442117 |
| MK0476, Montelukast Sodium /Duration of Treatment : 14 Days | DRUG | Phase PHASE2 | Bronchiolitis | COMPLETED | NCT00394160 |
| MK-0476, montelukast sodium | DRUG | Phase PHASE2 | Bronchiolitis | COMPLETED | NCT00394069 |
| Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks | DRUG | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393354 |
| MK0663, Etoricoxib / Duration of Treatment : 12 Weeks | DRUG | Phase PHASE3 | Recurrent Low Back Pain | COMPLETED | NCT00393354 |
| Mirtazapine Treatment | DRUG | Phase PHASE2 | Depression | COMPLETED | NCT00385437 |
| Driving Simulator Testing | BEHAVIORAL | Phase PHASE2 | Depression | COMPLETED | NCT00385437 |
| Formoterol Fumarate 10 mcg | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00383552 |
| Mometasone Furoate MDI (MF MDI) | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00383552 |
| Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00383552 |
| Formoterol MDI | DRUG | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00383721 |
| formoterol fumarate 10 mcg | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00383240 |
| Mometasone furoate MDI (MF MDI) 200 mcg | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00383240 |
| mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00383240 |
| Mometasone furoate MDI (MF MDI) | DRUG | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00383721 |
| Mometasone furoate/formoterol (MF/F) combination | DRUG | Phase PHASE3 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT00383721 |
| MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00380705 |
| Placebo nasal spray | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Mometasone furoate nasal spray | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT03879772 |
| Levocetirizine placebo capsule | DRUG | Phase PHASE4 | Hypersensitivity | COMPLETED | NCT00359138 |
| Desloratadine placebo tablet | DRUG | Phase PHASE4 | Hypersensitivity | COMPLETED | NCT00359138 |
| levocetirizine | DRUG | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT00789152 |
| Mometasone Furoate Nasal Spray (MFNS) | DRUG | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT01386125 |
| Leuprolide acetate | DRUG | Phase PHASE4 | Ovarian Hyperstimulation Syndrome | COMPLETED | NCT00349258 |
| Comparator : atenolol /Duration of Treatment : 5 Years | DRUG | Phase PHASE3 | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | COMPLETED | NCT00338260 |
| MK0954, /Duration of Treatment : 5 Years | DRUG | Phase PHASE3 | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | COMPLETED | NCT00338260 |
| Comparator: Placebo (unspecified) | DRUG | Phase PHASE3 | Cholesterol | COMPLETED | NCT00652301 |
| Duration of Treatment: 3 months | DRUG | Phase PHASE3 | Hypercholesterolaemia | COMPLETED | NCT00328523 |
| MK-0653, ezetimibe | DRUG | Phase PHASE3 | Hypercholesterolaemia | COMPLETED | NCT00328523 |
| loratadine; montelukast | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00319995 |
| Atorvastatin 10 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03867110 |
| Ezetimibe | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT03885921 |
| desloratadine | DRUG | Phase PHASE3 | Dermatitis, Atopic | COMPLETED | NCT00817076 |
| Estradiol + Medroxy Progesterone Acetate | DRUG | Phase PHASE4 | Postmenopause | COMPLETED | NCT00294463 |
| Estradiol | DRUG | Phase PHASE4 | Postmenopause | COMPLETED | NCT00294463 |
| Tibolone | DRUG | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00519857 |
| Comparator: fluticasone | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00284856 |
| Comparator: Placebo. | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| pseudoephedrine | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00276016 |
| phenylephrine | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00276016 |
| Comparator: Placebo to niacin (ER) | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: ezetimibe and simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: ezetimibe/simvastatin and niacin (ER) | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: Placebo to Niacin (ER) | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: ezetimibe (+) simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: niacin (ER) tablet | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: Placebo to ezetimibe/simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: ezetimibe/simvastatin + niacin (ER) | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00271817 |
| Comparator: diclofenac | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00264147 |
| etoricoxib | DRUG | Preclinical | Spondylarthropathies; Spondylitis, Ankylosing | COMPLETED | NCT01327638 |
| Duration of Treatment: Z-Phase, 2 years. | DRUG | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours | DRUG | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Comparator: A-Phase: low molecular weight heparin, unfractionated heparin | DRUG | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years | DRUG | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| A-Phase: tirofiban; Z-Phase simvastatin | DRUG | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT00251576 |
| Comparator: Rizatriptan | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT00250458 |
| Comparator: Placebo (salmeterol) | DRUG | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Placebo (montelukast) | DRUG | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Comparator: Salmeterol | DRUG | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Testosterone undecanoate | DRUG | Phase PHASE2 | Coronary Heart Disease | COMPLETED | NCT00239590 |
| Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| Placebo for simvastatin 40 mg | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| ezetimibe/simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00202878 |
| atorvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01154036 |
| olanzapine | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00265343 |
| Placebo arm | OTHER | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156104 |
| Haloperidol | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00156104 |
| asenapine | DRUG | Phase PHASE3 | Bipolar Disorder, Pediatric | COMPLETED | NCT01244815 |
| Olanzapine | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Asenapine | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01617187 |
| Comparator: amlodipine / Duration of Treatment: 20 weeks | DRUG | Phase PHASE4 | Renal Disorder | COMPLETED | NCT00140985 |
| MK0954, losartan potassium/Duration of Treatment: 20 weeks | DRUG | Phase PHASE4 | Renal Disorder | COMPLETED | NCT00140985 |
| Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks | DRUG | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT00140972 |
| MK0663; etoricoxib / Duration of Treatment:4 Weeks | DRUG | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT00140972 |
| Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT00140959 |
| MK0954, losartan potassium/Duration of Treatment: 18 weeks | DRUG | Phase PHASE4 | Hypertension | COMPLETED | NCT00140959 |
| Comparator: placebo / Duration of Treatment: 16 weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00140946 |
| MK0476; montelukast sodium/Duration of Treatment: 16 weeks | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00157937 |
| losartan potassium | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT00953680 |
| MK0476; montelukast sodium | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT00140881 |
| Sex steroid analysis | PROCEDURE | Preclinical | Transsexualism | COMPLETED | NCT00135148 |
| Filling out a questionnaire on libido and possible partner relationship | PROCEDURE | Preclinical | Transsexualism | COMPLETED | NCT00135148 |
| Comparator: rosuvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT01154036 |
| Comparator: pravastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: lovastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| Comparator: fluvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| MK0653A (ezetimibe [+] simvastatin) | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| simvastatin | DRUG | Phase PHASE4 | Systemic Lupus Erythematosus | TERMINATED | NCT00739050 |
| ezetimibe with simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00413972 |
| testosterone undecanoate | DRUG | Phase PHASE3 | Malnutrition | UNKNOWN | NCT00117000 |
| MK0462, rizatriptan benzoate / Duration of Treatment -1day | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT00111722 |
| Comparator: placebo / Duration of Treatment - 1 day | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT00111722 |
| MK0462, rizatriptan benzoate / Duration of Treatment -1 day | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT00111709 |
| Duration of Treatment: 4 wk placebo run in then 6 wk active | DRUG | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00110435 |
| ezetimibe | DRUG | Phase PHASE3 | Primary Hypercholesterolemia | COMPLETED | NCT00867165 |
| placebo | DRUG | Phase PHASE3 | Schizophrenia, Paranoid | COMPLETED | NCT01190254 |
| Comparator: placebo / Duration of Treatment: 1 day | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT00095004 |
| MK0462, rizatriptan benzoate / Duration of Treatment: 1day | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT00095004 |
| Comparator: ezetimibe | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00276458 |
| Comparator: celecoxib | DRUG | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092781 |
| Comparators: ibuprofen and placebo | DRUG | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00092755 |
| Comparator: naproxen sodium | DRUG | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT00092729 |
| Comparator: placebo (unspecified) | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT00666679 |
| etoricoxib (MK0663) | DRUG | Phase PHASE3 | Dysmenorrhea | COMPLETED | NCT00092729 |
| Comparator: atorvastatin / Duration of Treatment: 28 weeks | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092716 |
| MK0653, ezetimibe / Duration of Treatment: 28 weeks | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092716 |
| Comparator: Diclofenac sodium | DRUG | Phase PHASE3 | Rheumatoid Arthritis,Osteoarthritis | COMPLETED | NCT00250445 |
| MK0663, etoricoxib | DRUG | Phase PHASE3 | Rheumatoid Arthritis,Osteoarthritis | COMPLETED | NCT00250445 |
| ezetimibe (+) simvastatin | DRUG | Phase PHASE3 | Cardiovascular Disorder | COMPLETED | NCT00862251 |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092664 |
| Comparators: simvastatin and ezetimibe | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092651 |
| Comparator: ezetimibe, placebo | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092638 |
| Comparator: statins | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092586 |
| Comparator: fenofibrate monotherapy | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092573 |
| MK0653, ezetimibe | DRUG | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00092898 |
| Comparator: placebo, losartan, hydrochlorothiazide | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT00092209 |
| MK0954A, hydrochlorothiazide (+) losartan potassium | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT00092209 |
| Comparator: simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00132717 |
| MK0733, simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00092157 |
| Comparator: placebo / Duration of Treatment: 4 weeks | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00092144 |
| MK0476, montelukast sodium / Duration of Treatment: 4 weeks | DRUG | Phase PHASE3 | Asthma | COMPLETED | NCT00092144 |
| Montelukast | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01857063 |
| MK0476, montelukast sodium | DRUG | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00092885 |
| Placebo to budesonide inhaler | DRUG | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Placebo to montelukast chewable tablets | DRUG | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Budesonide inhaler | DRUG | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| Montelukast chewable tablets | DRUG | Phase PHASE4 | Asthma, Bronchial | COMPLETED | NCT00092092 |
| MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks | DRUG | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00092066 |
| ibandronate | DRUG | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092053 |
| Comparator: risedronate / Duration of Intervention: 12 mo | DRUG | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00092040 |
| MK0217, alendronate sodium/Duration of Intervention: 12 mo | DRUG | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT00092040 |
| Comparator: placebo / Duration of Treatment: 6 months | DRUG | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092027 |
| MK0217, alendronate sodium/Duration of Treatment: 6 months | DRUG | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092027 |
| Alendronate placebo | DRUG | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Risendronate placebo | DRUG | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Risedronate 35 mg | DRUG | Phase PHASE3 | Postmenopausal Osteoporosis | COMPLETED | NCT00092014 |
| Alendronate | DRUG | Preclinical | Esophageal Cancer | COMPLETED | NCT01077817 |
| Comparator: Rosuvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090298 |
| MK0653A, ezetimibe (+) simvastatin | DRUG | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00110435 |
| Losartan 150 mg | DRUG | Phase PHASE3 | Heart Failure | COMPLETED | NCT00090259 |
| Losartan 50 mg | DRUG | Phase PHASE3 | Heart Failure | COMPLETED | NCT00090259 |
| Comparator: diclofenac / Duration of Treatment: 4 weeks | DRUG | Phase PHASE4 | Chronic Low Back Pain | COMPLETED | NCT00090181 |
| MK0663, etoricoxib / Duration of Treatment: 4 weeks | DRUG | Phase PHASE2 | Bone Neoplasms | WITHDRAWN | NCT00095017 |
| Duration of Treatment: 6 weeks | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090168 |
| Comparator: atorvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00496730 |
| MK0653A , ezetimibe (+) simvastatin | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00090168 |
| Comparator: Placebo | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00972738 |
| Comparator: Montelukast | DRUG | Phase PHASE3 | Asthma, Exercise-Induced | COMPLETED | NCT00245570 |
| Eptifibatide (Integrilin) | DRUG | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00089895 |
| Comparator: placebo | DRUG | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT00979901 |
| montelukast sodium | DRUG | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT00974571 |
| Albuterol/Salbutamol | DRUG | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00070707 |
| Placebo | DRUG | Phase PHASE2 | Endometriosis | COMPLETED | NCT05560646 |
| Mometasone | DRUG | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00783237 |
Total products: 3195